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Abstract 
Immune dysregulation due to infection, inflammation or compromises to immune and 
molecular mechanisms can have detrimental effects on normal physiological 
functions. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a 
disorder of unknown mechanism where diagnosis is often delayed and evidence-based 
effective treatments are lacking. CFS/ME is characterised by severe fatigue, flu-like 
symptoms, pain and cognitive disturbances. To date a mechanism explaining the 
relationship between these symptoms and the physiological irregularities presented by 
patients remains obscure. As such, CFS/ME patients spend a considerable amount of 
money on health service cost in pursuit of the most effective treatment to alleviate 
their symptoms. An important initiative towards better management of CFS/ME is the 
development of accurate diagnosis. The principal aim of this research is to identify 
feasible biomarkers that can be used in effective diagnosis of CFS/ME. This research 
examines the status of lymphocytes in CFS/ME with a specific focus on their cellular 
function including apoptosis, protein secretion, receptor expression and gene 
expression. It is hypothesized that irregularities in these cellular processes contribute 
to the mechanism of CFS/ME and thus may form a suite of diagnostic markers for 
assessing CFS/ME patients.  
 
Participants for the study comprised 95 CFS/ME patients and 50 non-fatigued 
controls at baseline. Data for 50 CFS/ME and 27 non-fatigued controls was available 
for the follow up study at 6 and 12 months. Participants were aged between 25-65 
years. The criteria for inclusion were based on the Centre for Disease Prevention and 
Control (CDC) 1994 clinical diagnostic criteria. Whole blood was collected from each 
participant at baseline, at 6 months and at 12 months. Flow cytometric protocols were 
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employed in examining measures of cytotoxic activity in CD8
+
T and Natural Killer 
(NK) cells, levels of CD56
bright
CD16
negative 
NK cells CD56
dim
CD16
positive 
NK 
phenotypes, CD4
+
T helper cytokine secretion and levels of Foxp3 and vasoactive 
neuropeptide receptor (VPACR2). The expression pattern of cytotoxic related genes 
including granzyme A (GZMA), granzyme K (GZMK), perforin (PRF1) and 
interferon-gamma (IFN-G) and the expression of microRNA (miRNA) molecules in 
NK and CD8
+
T cells were investigated.  
 
At baseline, compared to the non-fatigued controls, CFS/ME patients exhibited 
significant decreases in cytotoxic activity of NK and CD8
+
T cells, levels of 
CD56
bright
CD16
negative 
NK cells and repression of IFN-G, GZMA and GZMK gene 
expression. At the same time, significant increases in cytokines, IL-10, IFN-γ and 
TNF-α, FOXP3, VPACR2 and PRF1expression were noticed in the CFS/ME patients 
compared to controls. At 6 months follow up, significant reductions in NK activity, 
CD56
bright
CD16
negative
 NK cells, IL-10 and IL-17A were observed in the CFS/ME 
patients compared to the non-fatigued controls. At 12 months, in contrast to the non-
fatigued controls, CFS/ME patients continued to demonstrate significant decreases in 
NK activity and significant increases in only IL-2. Assessment of miRNA expression 
revealed a significant down-regulation of a number of miRNAs in CFS/ME patients in 
comparison to the non-fatigued controls, specifically, miR-21, miR-146a, miR-223, 
miR-17-5p, miR-103, miR-106, miR-10a, miR-191 and miR-152 were significantly 
down-regulated mainly in the CFS/ME patients in comparison to the controls.  
 
In conclusion, the results from this study have elucidated the extent of decreases in 
cytotoxic activity in CFS/ME. In addition, this study has identified unique immune 
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related processes and molecules that are compromised in CFS/ME patients. These 
novel parameters may have important implications in the development of biomarkers 
for CFS/ME. Moreover the consistent decrease in cytotoxic activity and NK 
phenotypes over the 12 month period strongly supports their usefulness as biomarkers 
for diagnosing CFS/ME. These biomarkers if implemented in the clinical setting 
could potentially assist in improving diagnosis and demonstrating a clear 
pathomechanism for CFS/ME. Eventually, this may result in the development of 
better therapeutic and treatment strategies for managing CFS/ME.  
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1.1. Overview of Chronic Fatigue Syndrome 
Chronic Fatigue Syndrome (CFS) also known as Myalgic Encephalomyelitis (ME) is 
an unexplained multi-symptom debilitating disorder with multi-factorial 
heterogeneous characteristics that undermine efficient development of a 
comprehensive mechanism to explain this disorder (Masuda et al., 1994). Currently, 
the method of diagnosis is based on individuals demonstrating prevailing symptoms 
of severe fatigue, neurological disturbances and physical impairments enduring for 
more than six months (Fukuda et al. 1994). The prevalence rate of CFS/ME is 
between 0.2-2.6% (Grinde, 2008) with a higher prevalence in females compared to 
males at a ratio of 6:1 (Devanur & Kerr, 2006). In 2002, the Royal Australian College 
of Physicians reported that 25% of Australians who visit the general practitioner with 
fatigue are diagnosed with CFS/ME, hence, the prevalence rate of CFS/ME in 
Australia is 0.4% (Jason, 1999; Jason et al., 2008; Reynolds et al., 2004).  
 
Significant economic and social losses incurred by patients in pursuit of the best 
therapy to manage their disorder can include direct and indirect costs. Direct costs 
refer to medical, ambulatory and hospital expenses, prescription medications, over-
the-counter medications, and medical laboratory testing and indirect costs include 
transportation costs, work productivity losses, disability reimbursements, lower 
quality of life, social isolation, loss of leisure, services provided by family members, 
friends, or other informal care providers (Jason et al.,2008). At an estimated 
prevalence rate of 0.4% in Australia, the economic and social cost to society would be 
exceptionally high, emphasizing substantial decreases in overall economic 
contribution from this group due to this disorder. Using data extrapolated from 
indirect and direct costs incurred by a United States (US) CFS/ME population, the 
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annual cost associated with treatment and management of CFS/ME in Australia is 
estimated to be approximately AU$379 million per annum (assuming a 0.4% 
prevalence rate in Australia and a direct cost of US$ 5,509 (AU$5,176) per patient) 
(Jason et al., 2008).  
 
The diagnostic criteria for CFS/ME are not uniform and there currently exists four 
separate guidelines/definitions, the Australian, British, Canadian and the Centre for 
Disease Prevention and Control (CDC 1994) criteria (Carruthers et al., 2003, Fukuda 
et al., 1994, Lloyd et al., 1990, Sharpe et al., 1991). The most widely used guidelines 
for research purposes are the CDC 1994 criteria which describes CFS/ME as a novel 
onset of lingering relentless fatigue for over a period of at least 6 months, where four 
of the following symptoms (i) impaired short term memory or concentration, (ii) sore 
throat, (iii) tender cervical or axillary lymph nodes, (iv) muscle pain, (v) multijoint 
pain with no indication of swelling or redness, (vi) severe headaches, (vii) 
unrefreshing sleep and (viii) postexertional malaise must be experienced by the 
patient (Fukuda et al. 1994). Exclusion criteria for this definition consist of 
indications of psychiatric disorders such as melancholic depression, substance abuse, 
bipolar disorder, psychosis and eating disorders (Fukuda et al. 1994). In contrast, 
mental fatigue, psychosis, organic brain disorder and neuropsychiatric symptoms are 
incorporated in the other three definitions (Wyller 2007). Psychosis and organic brain 
diseases are indicative of a psychiatric disorder and are therefore not included in the 
CDC 1994 definition (Wyller 2007). Although, these definitions assist health 
professionals in diagnosing CFS/ME, they are not definitive as assessment is based on 
self-report from patients. Therefore, discrepancies can occur during diagnosis 
increasing the possibility of misdiagnosing CFS/ME as purely psychological. The 
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CDC 1994 case definition minimises these errors as it is more robust and is constantly 
being evaluated to ensure that the definition is appropriate and effective in isolating 
CFS/ME cases from other patients (Reeves et al. 2003; Jones et al. 2007). However, 
recently, the Canadian definition has been found to be a better assessment tool when 
compared with the CDC1994 case definition as it provides a more structured format 
of assessing patient illness and symptoms with focus specificity in physiological 
systems known to be compromised in CFS/ME (Caruthers et al., 2003). 
 
CFS/ME is a multi-system disorder that may result in impaired physiological 
homeostasis associated with imbalances in endocrine, immune, muscular, central and 
autonomic nervous system (Klimas and Koneru, 2007, Maes et al., 2006, Fulle et al., 
2003, Di Giorgio et al., 2005, Cleare, 2003, Goertzel et al., 2006). Previously, 
CFS/ME was thought to have a psychological origin where depression was the 
prevailing cause for the symptoms patients described (Wessely and Powell, 1989). To 
date despite the vast research in CFS/ME, a singular causal agent for CFS/ME has not 
yet been identified, and infections originating from viral antigens may be a component 
of the disease mechanism. Additionally, currently there are no definitive biomarkers 
established for assessing CFS/ME as diagnosis is based on the previously described 
definitions. Whether CFS/ME occurs as a consequence of either post or pre-infectious 
episodes, toxins and other related factors remains to be determined although post or 
pre-infectious episodes may occur in some patients with CFS/ME. Immune 
deterioration appears to be a hallmark of CFS/ME and there is now compelling 
evidence to support this proposition. In particular, cell numbers, function and proteins 
implicated in the immune response to pathogens and inflammation may be defective 
in these patients. Immune cells that have been investigated in association with 
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CFS/ME include neutrophils, T (Cluster of Differentiation (CD) 4
+
 and CD8
+
T) cells, 
B cells and Natural Killer (NK) cells. Results on the total numbers of these 
lymphocytes in CFS/ME are most often inconsistent, nonetheless, NK cell activity is 
consistently noted to be severely decreased in CFS/ME patients while expression 
levels of genes related to immune function are also abnormally expressed in some 
CFS/ME individuals, suggesting that the changes in immune response may develop 
from cellular and molecular changes in immune cells and proteins. Deficiencies in 
these immune factors prompt inflammatory symptoms (Dantzer et al., 2008) and this 
may present in the form of fatigue, pain, severe headaches and swollen lymph nodes 
as occurs in CFS/ME.  
 
As CFS/ME is a multi-system disorder, neuroendocrine and neuroimmune 
interactions and molecular patterns may be compromised. These changes may involve 
novel immune regulators including vasoactive neuropeptide (VNs) and the recently 
discovered small non-protein coding molecules known as microRNAs (miRNAs). 
These VNs are important neuroimmune regulators with expressions and receptors on 
immune cells in the periphery and central nervous system (CNS). They have 
neuroprotective effects as they prevent CNS insults, restore immune balance and act 
as anti-inflammatory mediators. Deficiencies in these peptides have been associated 
with a number of autoimmune conditions. Similarly an association between miRNAs 
and disease pathology and immune function exists (Liston et al., 2010b). As these 
parameters have not been investigated in CFS/ME, it is important to examine the link 
between these markers and CFS/ME as it further expands and may have the potential 
to assist in understanding the immunomodulation profile in CFS/ME. Additionally, 
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changes in gene expression in CFS/ME can affect immune, neurological, metabolic 
and important transcriptional processes.  
 
This research attempts to fill the ambiguities in the current knowledge on CFS/ME 
such as (i) to determine the specific role of immune cells that have not being 
previously measured in CFS/ME, (ii) to investigate the relationship between immune 
function and disease progression overtime, (iii) to assess the contribution of novel 
molecules VNs, FOXP3 and miRNAs to the immune profile of CFS/ME individuals 
and (iv) to identify potential biomarkers for CFS/ME. 
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1.2. Immunological Parameters 
The following sections review the immune system with specific focus on T and 
Natural Killer (NK) lymphocytes. A review of the extent of research on these cells in 
CFS/ME is also provided.  
 
The immune system comprises a wide array of cells and proteins widely distributed 
throughout the human body and involve many physiological functions including 
neurological, endocrine, cardiovascular and gastrointestinal systems. Generally, the 
immune system is subdivided into the innate and adaptive systems. Immunological 
molecules are widespread throughout the human body. Hence, these components are 
intertwined with other systems to sustain optimal physiological homeostasis. 
Therefore, perturbations in any part of the immune process affect the outcome of 
other physiological systems and alter the homeostatic control.   
 
The innate immune system is the primary defence mechanism that reacts to initial 
stages of infection, inflammation or other inflammatory insults. The adaptive immune 
system comes into play where the actions of the innate immune system are 
insufficient to effectively remove the infection or inflammatory insult and a more 
specific response is required. Cells of the innate immune system include neutrophils, 
macrophages, dendritic cells, NK cells, eosinophils and basophils, while those in the 
adaptive immune system are largely comprised of T and B cells, the latter of which 
produce antibodies. These cells are important during inflammatory episodes as they 
produce either anti- or pro-inflammatory mediators as well as antibodies to thwart 
pathogenesis and excessive inflammation. Dendritic cells, macrophages, neutrophils 
and NK cells eliminate pathogens either through phagocytosis (macrophages and 
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neutrophils) or cytotoxic activity. They also secrete cytokines and chemokines that 
induce inflammation, recruit, and activate adaptive immune cells (B and T 
lymphocytes) and present peptide fragments of the pathogen to T lymphocytes. Once 
activated the adaptive immune cells secrete antibodies (B cells) that help eradicate 
pathogens and retain memory of the pathogen, repair tissues, induce apoptosis of the 
infected cells and release cytokines that either enhance or dampen the inflammatory 
response.  
 
During infection or inflammation, innate immune cells are firstly recruited to sites of 
pathogen infiltration or inflammation where they either phagocytose (macrophages 
and neutrophils) or induce apoptosis (NK lymphocytes) of cells infected by the 
pathogen and release proteins known as cytokines or chemokines that induce 
inflammation. To promote effective pathogen clearance, the cells of the innate 
immune system activate T and B cells via presentation of pathogen peptide fragments 
to the T lymphocytes or secrete cytokines that activate these cells (Figure 1). 
Activated T lymphocytes induce further pathogen lysis, secrete additional cytokines 
that further stimulate B and T lymphocytes to create memory and enhance further 
inflammation. T lymphocytes are thus important regulators of these immune reactions 
and restore immunological stability (Hoebe et al., 2004). Failure to effectively 
eliminate pathogens or restore immune balance can affect physiological homeostasis 
and potentially present a symptom profile similar to CFS/ME. 
 
The main cells of interest to this study are the NK and T lymphocytes and their 
cytokines. The exact role of these cells in the immune system is discussed in the 
following sections. Several factors such as neuropeptides and gene expression 
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enhance the ability of immune cells, such as T lymphocytes to successfully regulate 
immune response and homeostasis. Compromises to their functions have been shown 
to significantly alter anti- and pro-inflammatory actions of T lymphocytes in various 
diseases which share similar symptoms to CFS/ME (Moldofsky, 1995, Whistler et al., 
2009). The activities of VNs and small non-coding RNA molecules in the immune 
function are also discussed. 
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Figure 1: The components of the immune system. The immune system is made up of the innate and adaptive components, bidirectional 
communication between these components via the release of cytokines, chemokines and antibodies activate immune cells to respond to 
pathogens, maintain tolerance and regulate inflammatory reactions. Copyright Ekua Weba Brenu  
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1.2.1. T Lymphocytes 
T lymphocytes are important components of immunological function and are most 
often explored in immune related disorders such as CFS/ME. T lymphocytes are 
generally involved in adaptive immune responses against antigens released during 
pathogen invasion or inflammation and are recruited via the release of soluble 
proteins from cells of the innate immune system, dendritic cells, macrophages and 
neutrophils. They characteristically express surface protein CD3. There are two major 
types of T lymphocytes described, CD3
+
CD4
+
 and CD3
+
CD8
+
. CD3
+
CD4
+
 and 
CD3
+
CD8
+
 have receptors that recognise and selectively bind to peptides known as 
major histocompatibility complex (MHC), specifically MHC class II and MHC class I 
respectively (Mazza and Malissen, 2007). 
 
CD3
+
CD4
+
T lymphocytes are helper cells and are further classified into T helper (Th) 
cells 1, Th2, Th17 and regulatory T lymphocytes (Treg). CD3
+
CD8
+
T lymphocytes 
can be further classified in to CD8
+
CD11b
+
 (suppressor activity) and CD8
+
CD11b
-
 
(cytotoxic activity) (Reddy and Grieco, 1991). Immature and mature T lymphocytes 
express a variety of co-stimulatory receptors at different stages of immune defence 
against infection. A number of these receptors have been shown to be differentially 
expressed in CFS/ME patients (Table 1). For example CD28 is required for the 
propagation of T lymphocytes and cytokines during an immune response to infections  
(Boise et al., 1995). In the occurrence of an infection, antigen presenting cells (APC) 
such as dendritic cells and cytokines bind with high affinity to CD28 on the naïve T 
lymphocytes, activating the T lymphocyte. The T lymphocyte encounters the antigen 
and retains a representation of its receptor thus becoming memory T lymphocyte. 
CD45RO
+
 and CD45RA
+
 represent the naïve or memory component of the T 
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lymphocytes respectively (de Jong et al., 1991, Hamann et al., 1996, Sohen et al., 
1990). Memory T lymphocytes, CD45RA, and other T lymphocyte surface markers, 
tend to be significantly low in some cases of CFS/ME. This can have severe 
consequences on overall immune function as the vast majority of the T lymphocyte 
repertoire is imperative for physiological homeostasis. 
 
1.2.1.1. CD4+ T helper Lymphocytes 
Naïve CD4
+
T lymphocytes differentiation into subtypes is dependent on signals 
received during initial antigen interactions. Figure 2 describes the immune factors 
released by these cells and also molecules implicated in their differentiation from 
naïve CD4
+
T lymphocytes into the different subtypes. CD4
+
 T cells can be 
categorised into Th1, Th2, Th17 and Tregs (Figure 3) where Th1 and Th17 
predominantly promote inflammation while Th2 inhibit inflammation. Tregs are 
suppressors of autoimmune reaction and autoreactive T lymphocytes that alter 
immune homeostasis. The mechanism of action of these cells occurs via the secretion 
and expression of soluble proteins and receptors for these proteins and include 
cytokines, chemokines and their receptors (Mosmann and Coffman, 1989). Immune 
perturbations affecting physiological functions similar to those exhibited by CFS/ME 
patients may occur where there is either an excessive or inadequate production of 
these cytokines. Importantly, shifts in cytokine profiles have been noticed in CFS/ME 
where there is a preferential shift towards either a Th1 or Th2 cytokine profile. A 
governing Th1 and Th17 immune response is thought to be associated with 
autoimmune diseases such as Rheumatoid Arthritis and Multiple Sclerosis (Singh et 
al., 2007, Drulovic et al., 2009). An overwhelming Th2 mediated immune response 
triggers most systemic and allergic disorders (Nevala et al., 2009). 
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Figure 2: Differentiation of CD4
+
 T helper cells. CD4
+
T lymphocytes expansion into 
various subsets generates four distinct populations of CD4
+
T lymphocytes in the 
presence of different transcription factors and molecules necessary for their 
differentiation. These cells secrete cytokines that assist in maintaining immune 
homeostasis (Zhu and Paul, 2008). 
 
Among the different subsets of T cells, Th1 cells are the main producers of IFN-γ, IL-
2 and lymphotoxin α (LTα) (Rook et al. 1997; Hanson et al. 2001). These cells are 
important in ensuring efficient anti-inflammatory activity during infiltration of the 
intracellular environment by mycobacteria particles. IFN-γ stimulates macrophages to 
phagocytise microbial pathogens while the production of IL-2 is paramount for the 
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formation of memory CD4
+
 and CD8
+
 T lymphocytes. This assists in successful 
detection and elimination of mycobacterial, viral and tumour antigens should they 
reappear (Williams et al., 2006, Yamane et al., 2005). Equivocal levels of IL-2 and 
IFN-γ have been reported in CFS/ME (Patarca et al., 1994, Linde et al., 1992, Lloyd 
et al., 1992, Peakman et al., 1997, Gold et al., 1990) and this may explain the 
occurrence of persistent infections and heightened inflammation. Where pathogens 
are not adequately cleared due to a lack of CD4
+
 and CD8
+
 T lymphocytes memory 
formation against pathogenic antigens or an increase in IFN-γ pro-inflammatory 
reactions tissue damage occurs and may encourage autoimmune related immune 
response in these patients. 
 
Conversely Th2 is an anti-inflammatory mediator secreting cytokines IL-4, IL-9, IL-
10, IL-13 and IL-25 (Swain et al., 1990, Longphre et al., 1999, Wynn, 2003, Urban et 
al., 1998, Fort et al., 2001). Induction of these cytokines is necessary for protecting 
against extracellular pathogenesis which includes parasites (Mosmann and Coffman, 
1989, Paul and Seder, 1994). Immune responses to allergic reactions involves IL-5, 
IL-9, while IL-4 and IL-10 modulate inflammatory reactions (Le Gros et al., 1990, 
Longphre et al., 1999, Wynn, 2003, Urban et al., 1998, Fort et al., 2001). Hence, 
discrepancies in Th2 immune related responses in CFS/ME patients may affect the 
differentiation of both Th2 and Th1 cells, as cytokines, IL-2 and IL-4, produced by 
these cells are necessary for their survival (Zhu et al., 2006, Jankovic et al., 2000, Min 
et al., 2004, Finkelman et al., 2000, Zhu et al., 2002). This can have severe 
consequences on the ability of the body to respond to extracellular pathogens and 
restore balance after an inflammatory episode. 
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Th17 cells are secretors of pro-inflammatory IL-17 (IL-17A and IL-17F), IL-21, IL-
22 and TNF-α and direct the production of pro-inflammatory chemokines CCL2, 
CCL3 and CCL20 (Paust et al., 2009, Pene et al., 2008). These chemokines stimulate 
the migration of monocytes and T lymphocytes (Paust et al., 2009, Pene et al., 2008). 
Th17 induces the generation of antimicrobial peptides, facilitates neutrophil migration 
to sites of infection and secretes an array of pro-inflammatory cytokines and 
chemokines (Weaver et al., 2007, Fossiez et al., 1996, Liang et al., 2006, Ouyang et 
al., 2008). Similarities between Th1 and Th17 can be attributed to the finding that 
both Th17 cells and Th1 cells increase the production of pro-inflammatory cytokine 
IFN-γ (Bending et al., 2009). Currently, data regarding Th17 cells in CFS/ME are 
insufficient, however, elevated levels of cytokines, TGF-β and IL-6, required for 
Th17 differentiation (Bettelli et al. 2006; Zhou et al. 2007) have been reported in 
CFS/ME patients (Chao et al., 1991, Chao et al., 1990, Bennett et al., 1997). An 
increase in TGF-β and IL-6 may favour Th17 production. Antigenic modifications of 
the Th17 cells may cause neuropathic pain, systemic intestinal inflammation and the 
production of anti-apoptotic molecules (Kleinschek et al., 2009, Hou et al., 2009, 
Koenders et al., 2005, Lubberts et al., 2005). Interestingly, in CFS/ME patients many 
viral antigens have been observed. These antigens may modify the activities of Th17 
cells (Hofstetter et al., 2009) and promote severe fatigue and other CFS/ME like 
episodes. 
 
The fourth types of T cells are the Tregs. Tregs are classified as either natural or 
adaptive. Natural Tregs make up 5-10% of all CD4
+
T lymphocytes (Sakaguchi, 
2005). An important attribute of Tregs is the expression of the forkhead/winged helix 
transcription factor (FOXP3), a member of the FOXP subfamily of transcriptional 
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repressors and activators (Fontenot et al., 2003, Hori et al., 2003). FOXP3 suppresses 
IL-2 and IFN-γ thus modulating the amount of pro-inflammatory factors in circulation 
(Bettelli et al., 2005, Bettelli and Kuchroo, 2005, Wu et al., 2006b). This protects 
against elevated production of autoreactive T lymphocytes, Tregs and inflammation 
through the joint action of enzymes, adenosine diphosphate hydrolysing enzyme 
CD39 and ecto-5‟-nucleotidase CD73 (Deaglio et al., 2007) and cyclic adenosine 
monophosphate (cAMP) (Bopp et al., 2007). Natural Tregs secrete IL-10 and TGF-β 
(Tang and Bluestone, 2006). TGF-β has a role in the delineation of Th17 cells 
whereas IL-10 reduces Th1 directed pro-inflammatory responses (Bettelli et al., 
2006). Dysfunctional CD4
+
CD25
+
Treg is a distinct contributory factor to many 
autoimmune diseases (Shevach, 2002, Sakaguchi et al., 2001) and a similar 
presentation may occur in CFS/ME. The other types of Tregs are the adaptive Tregs 
which secrete anti-inflammatory cytokines IL-5, IL-10, TGF-β and IFN-γ (Roncarolo 
et al., 2001, Roncarolo et al., 2006, Weiner, 2001, Faria and Weiner, 2006). 
Interestingly, these cytokines are required for the generation of some CD4
+
T cell 
subsets, regulation of naïve T lymphocytes and the prevention of autoimmune 
reactions (Sundstedt et al., 2003, Oida et al., 2003, O'Garra and Barrat, 2003). 
Collectively, these immune related processes assist in preserving homeostasis.  
 
Currently, a clear profile of CD4
+
T cell subtypes and their cytokine secretion in 
CFS/ME has not yet been demonstrated. The tremendous contribution of these cells to 
inflammatory pathways, suggest the need for further investigations to clarify their role 
in the mechanism of CFS/ME pathogenesis as this can assist in both diagnosing and 
treating this disorder.  
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1.2.1.2. CD8+ T Lymphocytes 
CD8
+
T lymphocytes are the second subset of T lymphocytes that are necessary for the 
control of both chronic and intracellular infections. They express MHCI and are 
derived from multi-potent T lymphocytes and are able to either remain in stasis or 
differentiate in to cytotoxic, suppressor and memory CD8
+
T lymphocytes. As such 
CD8+T cells can be sub grouped into four major subsets (Figure 4), including Tc1, 
Tc2, Tc17 and CD8
+
Treg cells (Huber et al., 2009, Xystrakis et al., 2004). Antigen 
specific memory CD8
+
T lymphocytes are more prominent in the periphery and 
constantly survey the peripheral environment for secondary infection (Kaech and 
Wherry, 2007) thus guarding against re-infection. CD8
+
T lymphocytes are highly 
cytotoxic and secrete antiviral proteins (Grayson et al., 2001, Luckey et al., 2006, 
Bachmann et al., 2006). Cytotoxic CD8
+
T lymphocytes are the focus of this project. 
These lymphocytes are more differentiated in comparison to the other CD8
+
T cells 
thus they express high quantities of granzymes, perforin, cytokines and chemokine 
receptors (Peixoto et al., 2007). 
 
CD8
+
T lymphocytes differentiate into CD8
+
CD25
+
T lymphocytes (CD8
+
Tregs) in the 
presence of exclusive APCs, tumour and viral antigens that alter co-stimulatory 
molecules (Alatrakchi et al., 2007, Jarnicki et al., 2006, Myers et al., 2005). They are 
important in preserving sites of immune privilege and homeostatic balance in immune 
response. They can either initiate suppression through direct killing (cytotoxic) or 
stimulate the production of immunosuppressive cytokines such as TGF-β and IL-10 
(Niederkorn, 2008). However, their actions are largely effective in the presence of 
IFN-γ, thus in most cases, the CD8+Tregs are only functionally effective after IFN-γ 
activation (Niederkorn, 2008). The idea of lowered or deteriorating immune function 
in CFS/ME that allows recurrent infections and an inability to clear old and/or new 
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infections may be due to a lowered number of memory and suppressive CD8
+
 T 
lymphocytes. Thus cell phenotyping may be a better method of determining the type 
of cells that are compromised in CFS/ME patients if any.  Additionally, as NK 
cytotoxic activity is reduced in CFS/ME, CD8
+
T cell activity may also be reduced and 
this requires more confirmatory studies. 
 
Figure 3: Differentiation of CD8
+
 T cell. CD8
+
T cells can be subdivided into these 
phenotypes depending on the cytokines and other co-stimulatory molecules present. 
These cells interact with viral infected and transformed cells using the peptide MHCI 
peptide recognition pathways. This induces various cytotoxic and immunosuppressive 
pathways ensuring complete clearance of pathogens and maintenance of immune 
homeostasis.  
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1.2.1.3. T Lymphocyte in Chronic Fatigue Syndrome 
To date over 20 studies have investigated immune function in CFS/ME, the 
parameters most often examined are viral antigens, inflammatory signals, cytokine 
levels, NK function and lymphocyte numbers (Table 1). The results from these studies 
with respect to T lymphocytes are however inconsistent, as variations in the number 
of these cells and their surface markers in peripheral blood circulation occur in the 
CFS/ME population in comparison to the controls where participants have either 
identical or equivocal numbers in the overall quantity of T lymphocytes and their 
subsets.   
 
Immunological assessments of antibody positive and negative Epstein Barr Virus 
(EBV) CFS/ME patients have identified similarities in the levels of T lymphocytes in 
both CFS/ME patients and controls (Jones, 1988, Jones et al., 1988). However, only 
one patient demonstrated a significant change in T lymphocytes (Jones, 1988). 
CFS/ME patients demonstrate similarities in levels of activated, naïve and memory 
CD4
+
T and CD8
+
T lymphocytes to that of healthy individuals (Visser et al., 1998). T 
lymphocyte counts remain constant despite symptom severity and disease persistence 
(Landay et al., 1991, Tirelli et al., 1994).  
 
Contrary to these studies, CFS/ME patients may have reduced T lymphocytes 
particularly the CD4
+
T and CD8
+
T lymphocytes with diminished response of T 
lymphocytes during delayed hypersensitivity (Lloyd et al., 1989). In some cases the 
levels of CD4
+
T lymphocytes were similar to controls while CD8
+
T lymphocytes had 
a propensity to increase among the CFS/ME patients. However, CFS/ME patients 
with an incidence of EBV infections may demonstrate high levels of CD4
+
T 
lymphocytes with unaltered CD8
+
T lymphocytes and an increase in overall T cell 
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suppression (Straus et al., 1985). Hence, it is likely that although the CD8
+
T 
lymphocytes remained similar to that of healthy controls the prevalence of suppressor 
CD8
+
T lymphocytes was much higher in the CFS/ME group. These findings could 
suggest a relationship between CD8
+
T lymphocytes suppressor function and CFS/ME, 
however, the activities of subtypes of CD8
+
T and CD4
+
T lymphocytes were not 
indicated in this study.
 
Additionally, lymphocytes subsets may differ between 
CFS/ME patients and healthy individuals according to the mode of onset of illness, 
that is, either sudden or gradual (Hanson et al., 2001). Both patients with gradual and 
sudden onset of CFS/ME exhibit decreases in the percentage of total T lymphocytes 
and CD8
+
T lymphocytes nevertheless CD4
+
T lymphocytes are elevated (Hanson et 
al., 2001).  Significantly higher levels of antiviral antibodies such as human herpes 
virus-6 (HHPV-6), EBV-EA and Coxsackie‟s B4 virus (CB4) are prevalent in some 
cases of CFS/ME regardless of the symptom severity (Landay et al., 1991). This may 
indicate an inability of the CD8
+
T and NK lymphocytes to effectively clear viral 
antigens permitting increases in viral loads. 
 
These studies have highlighted the profile of T lymphocytes in CFS/ME, however, the 
constraint with these studies relates to the lack of measurements for T cell functions. 
Changes in T cell number are not necessarily a reflection of the function of these cells 
especially in a disorder such as CFS/ME where the exact cause is not known. 
Additionally, it is important to know the precise subsets of CD4
+
T and CD8
+
T 
lymphocytes that are reduced. Similarities may exist between the overall counts of 
these cells in both healthy and CFS/ME patients. It is likely that in CFS/ME patients 
some subsets of these cells may be more or less prevalent than others. This project 
provides an insightful view of the function and subsets of T lymphocytes in CFS/ME, 
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with specific focus on CD4
+
T lymphocytes and CD8
+
T lymphocytes. In this study, 
CD4
+
T cell studies are concerned with their cytokine profiles while CD8
+
T cell 
investigations are centred on cytotoxic activity. Although, NK cell studies have 
indicated significant decreases in NK function in CFS/ME patients, as CFS/ME is 
heterogeneous and multifactorial with inconsistencies in immune parameters, further 
investigative studies are required to assess the function of CD8
+
T lymphocytes in a 
novel CFS/ME cohort as both NK and CD8
+
T cells perform some parallel immune 
functions. 
 
1.2.2. Natural Killer Lymphocytes 
NK lymphocytes are the cytotoxic cells of the innate immune system. These cells 
mature in the bone marrow from CD34
+
 hematopoietic progenitor cells (Farag et al. 
2002). They represent 10-18% of the total lymphocyte population in both lymphoid 
and non-lymphoid tissues (Caligiuri 2008). Their primary functions are to eliminate 
foreign pathogens and tumours, activate other immune cells and preferentially provide 
an adequate supply of cytokines to the immune system (Caligiuri 2008; Vivier et al. 
2008). These cells express CD56 and CD16 receptor molecules on their cell surfaces 
(Fan et al. 2008). CD16 is also known as the fragment crystallisation gamma receptor 
III (FcγRIII) (Farag et al. 2002). FcγRIII is required for the initiation of antibody 
dependent cytotoxic activity in NK lymphocytes (Vivier et al. 2008). The two main 
subtypes of NK lymphocytes are CD56
dim
CD16
positive
 and CD56
bright
CD16
negative
 NK 
lymphocytes (Farag et al. 2002). The name CD56
bright
CD16
negative
 NK depicts high 
levels of CD56 (neural cell adhesion molecule (NCAM)) molecules and low levels of 
CD16 (Fc γ receptor III for lysis) receptors on the cell surface of these cells (Fan et al. 
2008). CD56
bright
CD16
negative 
NK lymphocytes are primarily responsible for producing 
cytokines, TNF-β, IFN-γ, IL-10, TNF-α and granulocyte macrophage colony-
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stimulating factor (GM-CSF) (Caligiuri 2008). CD56
dim
CD16
positive
 NK lymphocytes 
can be distinguished from CD56
bright
CD16
negative
 NK lymphocytes by the presence of 
low levels of the adhesion molecule, CD56, but high levels of CD16 (Caligiuri 2008). 
Increased expression of FcγRIII/CD16 enhances target killing via ADCC when the 
FcγRIII/CD16 recognises and binds targets activating death receptor pathways (Vivier 
et al. 2008). These particular NK lymphocytes with a high density of CD16 contain 
increasing amounts of lytic granules perforin and granzymes, necessary for ADCC 
and natural cytotoxicity (Bryceson et al. 2006).   
 
 
 
        A 
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Figure 4: The profile of NK lymphocyte subsets. The two main types of NK cells are 
morphologically and functionally distinct cells. The CD56
bright
CD16
negative
 (A) NK 
lymphocyte secretes less granule containing lytic molecules, are less cytotoxic and 
express different NK receptors. They are high cytokine producers. 
CD56
dim
CD16
positive
 NK lymphocyte (B) secretes less cytokines. However, they are 
more cytotoxic express more NK receptors and granules containing lytic molecules 
(Cooper et al., 2001).  
 
1.2.3. Cytotoxic Activity 
NK lymphocytes and CD8
+
T lymphocytes exert their effector function via granule-
dependent cytotoxic activity (Chowdhury and Lieberman, 2008, Russell and Ley, 
2002). In the granule-dependent pathway, granules containing perforin, proteases and 
granzymes (include Granzyme (GZM) A, B, H, K and M) are released in to the target 
cell (Figure 5) where they induce death or apoptosis (Ashton-Rickardt, 2005, Bots and 
Medema, 2006, Lieberman, 2003). During viral infection or tumour growth receptors 
on the surfaces of cytotoxic cells CD8
+
T and NK lymphocytes are activated when 
cytokines and adhesion molecules attach to these receptors (Makrigiannis & Anderson 
 49 | P a g e  
 
2003; Cerwenka & Lanier 2001). Activation of these receptors stimulates signal 
transduction molecules, intracellular signalling, tyrosine phosphorylation and the 
release of cytokines and granules containing granzymes and perforin into the plasma 
membrane of the target cell (Cerwenka & Lanier 2001). The exact role of perforin in 
the mechanism of cytolysis remains unknown however there are suggestions that 
perforin sabotages the plasma membrane to allow endocytosis and release of the 
contents of the cytotoxic granules into the cytoplasm (Catalfamo and Henkart, 2003, 
Pipkin and Lieberman, 2007). They may also direct the granzymes into the 
endosomes and subvert the endosome, thus facilitating the movement of granzymes to 
appropriate organelles and the nucleus of target cells where they induce apoptosis 
(Voskoboinik et al., 2006, Voskoboinik and Trapani, 2006, Scott et al., 2008).  
 
Granzymes act via a number of mechanisms to induce cell death in the target cell. 
Granzyme K (GZMK) has been observed to activate the release of reactive oxygen 
species (MacDonald et al., 1999), degrade mitochondria, induce single stranded nicks 
in the DNA, caspase-independent nuclear fragmentation and nuclear condensation 
(Zhao et al., 2007). GZMB, a serine protease, acts via a caspase-dependent apoptosis 
pathway (Sutton et al., 2003) while GZMA, GZMH, and GZMM act independently of 
caspase activation (Johnson et al., 2003, Kelly et al., 2004, MacDonald et al., 1999). 
GZMA activates slow apoptosis by inducing single stranded DNA nicks in the 
nucleus (Warren & Smyth 1999; Cullen & Martin 2008). Gram B activates the 
caspase pathway by acting on the mitochondria to release cytochrome C and BCL-2 
(Warren & Smyth 1999; Cullen & Martin 2008). BCL-2 suppresses the activation 
BAX and BAK, thus preventing apoptosis, while cytochrome C induces an 
apoptosome formation (Warren & Smyth 1999; Cullen & Martin 2008). The death 
promoters and apoptosome stimulate caspase resulting in eventual death of the target 
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cells. Other death receptor pathways exist involving CD95 (Fas), TNF or TRAIL. NK 
and CD8
+
 T lymphocytes are highly equipped to maintain homeostasis in the immune 
systems and a deficiency in their function can have severe consequences on immune 
response to pathogens. These mechanisms are illustrated in Figure 5. These important 
attributes of NK cell function suggests that they are a necessary component of 
immune function and breaches in this mechanism can affect viral clearance following 
infection or memory creation that facilitates rapid anti-viral activity upon subsequent 
exposure.   
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Figure 5: The mechanism of cytotoxic activity of NK and CD8
+
T lymphocytes. Recruitment of NK and CD8
+
T lymphocytes to sight of 
infection or tumour growth results in the release of granules containing granzymes and perforin and induction of apoptosis. Apoptosis is 
stimulated by the binding of granzymes to organelles of the viral infected or tumour cell (Lieberman, 2003). 
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1.2.3.1. Natural Killer Lymphocytes in CFS/ME 
NK lymphocytes are the primary lytic agents that eliminate viral infected cells, hence, 
their deterioration in terms of function may evoke immune compromised situations. 
NK lytic activity, also referred to as cytotoxic activity, has been examined in CFS/ME 
where most often decreases in NK activity have been observed to be a characteristic 
of CFS/ME (Klimas et al. 1990; Ojo-Amaise et al 1994; Barker et al. 1994; Brenu et 
al., 2010).  
 
CFS/ME patients with abnormal serological levels of EBV demonstrate a 65% 
reduction in NK cell cytotoxicity compared to the controls (Klimas et al. 1990, Ojo-
Amaise et al 1994) suggesting a possible association between NK lysis and viral 
infections. However, decreases in NK cell activity in CFS/ME patients may occur 
without viral antigens compared to healthy controls (Barker et al. 1994) although, in 
some cases the presence of viral antigens was not measured (Brenu et al., 2010; 
Maher et al. 2005; Fletcher et al. 2010). Hence, it is difficult to draw conclusions on 
the role of viral antigens in NK activity. When NK cell function in CFS/ME is 
compared to patients with Acquired Immune Deficiency Syndrome (AIDS) and 
healthy subjects, CFS/ME patients had a higher killing rate of the target cells 
compared to the AIDS patients though they were considerably reduced when 
evaluated against the healthy controls (See et al. 1997). In contrast, CFS/ME patients 
demonstrate lower NK activity in comparison to fatigue-non-CFS/ME and healthy 
individuals (Masuda et al. 1994).  
 
These studies indicate substantial deficiencies in the cytotoxic activity of NK 
lymphocytes in CFS/ME, however, the prevalence of incompetent NK lymphocytes 
are not as severe as in diseases such as AIDS. AIDS is an established disorder where a 
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mechanism for the disease pathogenesis is known while CFS/ME remains an 
unexplained phenomenon. Nonetheless, NK cell lytic deficiencies possibly occur from 
paucities in lytic proteins, perforin and granzymes, in CFS/ME patients (Maher et al., 
2005; Saiki et al., 2008). For example, a two-fold decrease in perforin and granzymes 
in CFS/ME patients compared to healthy subjects (Saiki et al., 2008) can reduce lysis 
capabilities of NK lymphocytes. Moreover changes in NK cell phenotypes, 
CD56
dim
CD16
positive
 NK lymphocytes and CD56
bright
CD16
negative
 NK have been 
associated with some cases of CFS/ME (Brenu et al., 2010, Maher et al., 2005, 
Robertson et al., 2005, Tirelli et al., 1994). Abnormalities in NK cell phenotype can 
affect soluble protein production required to ensure successful pathogen lysis. For 
instance, a decline in CD56
dim
CD16
positive
 NK lymphocytes suggests ineffective 
cytotoxic activity while an increase or decrease in CD56
bright
CD16
negative
 NK 
lymphocytes causes an increase in inflammation or a decrease in lymphocyte 
activation and effector function. Further studies are therefore required to confirm 
these inept NK lymphocytes in CFS/ME patients. Remarkably, longitudinal 
assessment of NK phenotypes and NK activity has not been performed, this study 
therefore assesses these attributes of NK lymphocytes in CFS/ME patients over a long 
period of time. 
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Table 1: A summary of studies investigating immune function in CFS/ME and their 
findings 
T lymphocytes  NK lymphocytes 
CD 
molecules 
Authors 
↓CD4+ T 
lymphocytes 
↓ CD8+ T 
  Lloyd et al. 1989 
↑CD4+T 
↨CD8+T  
  Straus et al. 1985 
↨Total T cell   Jones et al., 1988 
↨CD4+T  
↓Suppressor CD4+ 
↓CD45RA+ T 
lymphocytes 
↑NK lymphocytes 
↓NK activity 
↑CD20+ 
↑CD21+ 
↑CD2+ 
Klimas et al., 1990 
↓CD8+T   ↓CD38+ Landay et al. 1991 
↑T suppressors   (Kato et al., 1992) 
 ↓NK  
↓CD56dimCD16positive 
↑CD56brightCD16negative 
 Tirelli et al., 1994 
 ↓NK activity  Ojo-Amaize et al., 
1994 
Pathological T 
lymphocytes 
  Hilgers and Frank, 
1994 
↨Total T cell 
↓CD8+CD11b+  
↨CD16+ 
↨CD56+NK 
↓NK cell activity 
↑CD38+ 
↑CD28+  
Barker et al., 1994 
 ↓NK  
↓CD56dimCD16positive 
↓CD56brightCD16negative 
↓NK activity 
 Masuda et al., 1994 
 ↨ NK activity  Mawle et al., 1997 
↓Total T cell   Vedhara et al. 1997 
↓CD8+ T-cell ↓NK activity ↓CD5+  
↓CD11a+ 
See et al., 1998 
↨T proliferation   Visser 1998 
↓Total T cell    Kavelaars et al., 
2000 
↓CD8+ T 
↑CD4+T 
 ↓CD34+ Hanson et al., 2001 
 ↓CD56+ NK  Racciatti et al., 2004 
↑CD8+ T  
↓Naïve T cells 
  Nijs et al., 2003 
 ↓CD56+  Stewart et al., 2003 
 55 | P a g e  
 
↓CD4+ and CD8+T 
↑CD4+/CD8+ ratio  
↓CD56+NK  Racciatti et al., 2004 
 ↓NK activity  Maher et al. 2005 
 ↓NK activity  Robertson et al., 
2005 
↓Early T cell 
activation 
 ↓CD69 Maes et al., 2005 
  ↓CD69+ Mihaylova et al., 
2007 
 ↓NK activity  Siegel et al., 2006 
 ↓CD56brightCD16negative 
↓NK activity 
 (Brenu et al., 2010) 
↑ refers to significant increase while ↓ refers to a significant decrease and ↨ refers to no changes 
when CFS/ME patients are compared with healthy individuals. 
 
1.2.4. Soluble Proteins 
Immune cells express CD molecules on their cell surfaces which are important during 
differentiation, priming of T lymphocytes during antigen presenting cells (APC) 
presentation and elimination of pathogens. T lymphocytes express receptors for 
surface markers, cytokines and chemokines and also secrete some of these markers. 
Deficiencies or defects in these markers may have severe consequences on 
physiological function.  
 
Cytokines are important determinants of all immune related responses including 
cytotoxic function, phagocytosis, allergies, immunosuppression, antigen presentation, 
humoral and cellular mediated immunity. They are responsible for growth, 
differentiation and activation of immune cells. The classification of these markers can 
be confined to the ability to induce anti-inflammatory or pro-inflammatory immune 
responses. Additionally, they can also be grouped according to their functions. 
Cytokines that are necessary for antigen presentation cell (APCs) are produced 
following binding of ligand to the pattern recognition receptors on the surface of 
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APCs. This interaction generates the production of TNF, IL-1, IL-6, IL-8, IL-12, IL-
15, IL-18 and IL-23. Importantly, cytokines also contribute to effective cytotoxic 
activity and this is necessary to eliminate viral infections. Cytokines such as IFN-α 
inhibit viral growth and therefore have antiviral qualities. Other cytokines that may be 
useful for cytotoxic activity also include IL-1. The proliferation and differentiation of 
NK and cytotoxic T cells is in part modulated by IL-7 while INF-γ, IL-17, IL-21 and 
IL-2 are responsible for cell mediated immunity involving T cells (Commins et al. 
2010). Chemokines are chemotactic molecules that primarily induce the migration of 
immune cells to sites of immune compromise or immune insults. In the adaptive 
immune system they are responsible for the generation of haematopoiesis, lymphocyte 
trafficking and immune homeostasis (Borish et al., 2003). 
 
Paucities in cytokine quantity are likely to have negative consequences on cytotoxic 
function, humoral immunity and cellular mediated immunity. Additionally, skewness 
in the cytokine distribution either towards a dominant anti-inflammatory or pro-
inflammatory state may activate autoimmune or systemic inflammation respectively 
(Elenkov et al., 2005). 
 
1.2.4.1. CD Molecules and Cytokines in CFS/ME 
In CFS/ME levels of soluble proteins are inconsistent across studies. High levels of 
inter-cellular adhesion molecule (ICAM)-1 and CD4
+
T lymphocyte function-
associated antigen (LFA)-1 on the surfaces of CD4
+
T lymphocytes may be observed 
in CFS/ME individuals (Gupta and Vayuvegula, 1991). In CFS/ME, patients with less 
severe symptoms exhibit higher increases in surface markers such as CD11b
-
, CD38
+
 
and HLA-DR on CD8
+
T lymphocytes (Landay et al., 1991). However, compared to 
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healthy individuals, some CFS/ME patients regardless of their symptom severity may 
display significantly higher levels of CD38
+
 and HLA-DR on their CD8
+
T 
lymphocytes (Landay et al., 1991). Alterations in these molecules may occur as a 
consequence of significantly high levels of antiviral antibodies such as HHPV-6, 
EBV-EA and CB4 virus in the circulation of CFS/ME patients. This is indicative of 
potential decrease in pathogen lysis and recurring viral infection. Similarly, reductions 
in CD11b
+
 (Barker et al., 1994, Swanink et al., 1996) with increasing levels of CD38
+
 
and CD28
+
 markers have been noticed on CD8
+
T lymphocytes in some CFS/ME 
patients (Barker et al., 1994). Equivalent expression of other surface molecules 
CD38
+
, CD45RO, HLA-DR on CD8
+
 T lymphocytes and CD4
+
 T lymphocytes are 
present in some CFS/ME patients and healthy participants (Hassan et al., 1998). 
CD28
+
 is heterogeneously expressed on CD8
+
T lymphocytes in CFS/ME, it may be 
reduced (Hassan et al., 1998) or elevated (Barker et al., 1994) in comparison to 
healthy individuals. This highlights the heterogeneity associated with CFS/ME and 
implicates an imbalance in inflammatory markers in CFS/ME, however more studies 
are required to investigate if these changes depict CFS/ME as an autoimmune (high 
levels of Th1) or systemic (predominant Th2) disorder or whether patients express 
attributes of both. 
 
Similarly, grouping of CFS/ME patients into two populations using both 1988 and the 
1994 CDC definitions yields comparable results with respect to levels of surface 
molecules (CD8
+
CD38
+
, CD8
+
HLA-DR
+
, CD8
+
CD11b, CD8
+
CD28
+
, 
CD4
+
CD45RO
+
, CD4
+
CD45RA
+
) on both CD4
+
T and CD8
+
T lymphocytes  
(Natelson et al., 1998). Surprisingly, the levels of surface markers were akin to 
patients with Multiple Sclerosis and depression (Natelson et al., 1998). Conversely, 
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CFS/ME patients meeting the British criteria may show decreases in CD11b
+
 and 
CD56
+
 (Swanink et al., 1996) and increases in CD38
+
 (Peakman et al., 1997) on 
CD8
+
T lymphocytes, while levels of CD25
+
 and HLA-DR on CD4
+
 T and CD8
+
 T 
lymphocytes remain unchanged (Peakman et al., 1997).  
 
Memory (CD45RA
+
) CD4
+
T lymphocytes may also diminish in CFS/ME with an 
increase in CD8
+
HLA-DR cells (Klimas et al., 1990). A deterioration in 
CD4
+
CD45RA
+
T lymphocytes in CFS/ME may be problematic as these cells are 
important in creating memory for the CD4
+
T lymphocytes, allowing immediate action 
in response to insults and pathogens and also activating suppressor or cytotoxic 
CD8
+
T lymphocytes (Klimas et al., 1990). Accordingly, decreases in the production 
of CD4
+
CD45RA
+
T cells reduce B lymphocyte regulation. Hence, inefficient 
suppression by B lymphocytes and cytotoxic T lymphocytes may likely promote high 
levels of viral reactivation. This study however did not provide a detailed analysis of 
the B lymphocyte activity. Declining levels of CD45RA
+
T lymphocytes may be 
accompanied by an increase CD45RO
+
T lymphocytes (Hanson et al., 2001). 
Although, the specificity of T lymphocytes was not indicated in the Hanson et al., 
study it is likely that CD45RA
+
 and CD45RO
+
 measurements were inclusive of both 
CD4
+
T and CD8
+
T lymphocytes. Increases in naïve T lymphocytes without an 
increase in memory creation may incite an increase in viral load as there will be a 
limited amount of cells able to recognise and effectively lyse a recurring pathogen or 
create memory for a novel pathogen (Picker et al., 2004). 
 
Thymocytes secrete numerous amounts of soluble proteins or cytokines and 
chemokines and these can either have a pro (type 1/Th1) or anti-inflammatory (type 2/ 
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Th2) immune response (Lucey et al., 1996). Anti-inflammatory cytokines, IL-4, IL-6, 
IL-10 and IL-13, avert unwarranted inflammatory reactions of pro-inflammatory 
cytokines, and other immune modulators (Keane and Strieter, 2002). Contrarily, pro-
inflammatory cytokines, IL-1, IL-2, IL-12, TNF- and IFN- arbitrate allergic 
reactions and mobilise other cells during pathogen infiltration (Opal and DePalo, 
2000). Disequilibrium in cytokine production favouring either anti-inflammatory or 
pro-inflammatory cytokine profile may be prevalent in some CFS/ME individuals 
(Skowera et al., 2004, Swanink et al., 1996), causing changes in inflammatory 
homeostasis. Only one study has identified defective IL-17F in some cases of 
CFS/ME, and this was characterised by significantly lowered expression of Histidine-
161-Arginine in the protein composition of this cytokine. This allele is mainly 
responsible for dampening the pro-inflammatory action of this cytokine (Metzger et 
al., 2008). CFS/ME patients lacking this protein may therefore experience heightened 
levels of pro-inflammatory markers in the presence or absence of Th2 deficiencies. 
This ultimately overwhelms anti-inflammatory modulations and increases 
inflammation in the joints and other areas. Nevertheless, whether an anti- or pro-
inflammatory immune modulation is a hallmark of CFS/ME has not yet been 
determined and therefore requires additional research. Table 2 summarizes studies 
that have investigated cytokine distribution in CFS/ME. The differences in results can 
be attributed to the heterogeneous nature of the disorder. 
 
Although, the results are not consistent, they do indicate defects in the cellular 
networks of T lymphocytes in CFS/ME. Hyper or hypo expression of these markers 
coupled with shifts in Th1/Th2/Th17 cytokines affect the ability of the innate and 
adaptive immune components to collectively lyse and restore order during or after 
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pathogenesis and subsequent recurring infections. Particularly, these studies have not 
highlighted the relationship between Tregs and CFS/ME, this may be compromised in 
CFS/ME where changes in cytokines such as IL-6, IL-10 and TGF-β are either 
elevated or decreased. However, lack of Treg activities may explain the increase in 
pro-inflammatory cytokines and chemokines in some of these CFS/ME patients. 
Therefore, it is imperative to explore the role of subtypes of CD4
+
T lymphocytes with 
respect to their cytokines and transcription factors, which this study proposes to 
investigate. 
 
Table 2: Studies investigating cytokines in CFS/ME compared to non-CFS/ME 
participants. 
Cytokines Significant  
Increase in 
expression 
Significant 
Decrease in 
Expression 
No 
Change 
 
IL-1α +++  +++ Patarca et al., 1994, Linde 
et al., 1992, Lloyd et al., 
1992, Peakman et al., 
1997, Rasmussen et al., 
1994, Swanink et al., 1996 
IL-1β + + +++++ Linde et al., 1992, Morte 
et al., 1989, Patarca et al., 
1994, Peakman et al., 
1997, Rasmussen et al., 
1994, Straus et al., 1989 
sIL-1R +  + Cannon et al., 1997, 
Swanink et al., 1996 
IL-2 ++ ++ +++ Cheney et al., 1989, Gold 
et al., 1990, Kibler et al., 
1985, Linde et al., 1992, 
Patarca et al., 1994, 
Rasmussen et al., 1994, 
Straus et al., 1989 
sIL-2 +  + Linde et al., 1992, Patarca 
et al., 1994 
IL-4 +  + Visser et al., 1998 
IL-5 +   Fletcher et al., 2009 
IL-6 +++  +++++ Gupta et al., 1997, 
Buchwald et al., 1997, 
Chao et al., 1990, Chao et 
al., 1991, Linde et al., 
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1992, Lloyd et al., 1992, 
Peakman et al., 1997, See 
et al., 1997 
sIL-6R +   Patarca, 2001 
IL-8  +  Fletcher et al., 2009 
IL-10  + + Gupta et al., 1997, 
Fletcher et al., 2009 
IL-12 +   Fletcher et al., 2009 
IL-13  +  Fletcher et al., 2009 
IL-15  +  Fletcher et al., 2009 
IL-23   + Fletcher et al., 2009 
TNF-α ++ + ++ Gupta et al., 1997, Patarca 
et al., 1994, Kriegler et al., 
1988, Lloyd et al., 1992, 
Peakman et al., 1997 
TNF-β +  ++ Lloyd et al., 1992, Patarca 
et al., 1994, Peakman et 
al., 1997 
IFN-α +  ++ Linde et al., 1992, Straus 
et al., 1989, Vojdani et al., 
1997 
IFN-γ + ++ ++++ Klimas et al., 1990, Linde 
et al., 1992, Lloyd et al., 
1992, Peakman et al., 
1997, Straus et al., 1989, 
Visser et al., 1998 
TGF-β +   Bennett et al., 1997 
The symbol + represents the number of studies that have examined these cytokines and their 
corresponding result. 
 
 
1.3. Gene Expression Profile in CFS/ME 
A number of studies have investigated the molecular processes in CFS/ME. This 
section examines the findings from these gene expression studies in CFS/ME. Table 3 
provides a summary of these studies and the genes that were identified to be 
differentially expressed in CFS/ME patients in contrast with non-fatigued controls. 
The majority of these genes are involved in immune, metabolic, cellular and 
neurological functions. The following is a review of the genes that have been 
identified in relation to immune function in CFS/ME. A systematic review of all the 
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genes investigated in CFS/ME patients is beyond the scope of this research. As such 
the information provided herein is only limited to genes identified and related to 
immune function since this is the focus of this project.  
 
1.3.1. Cytokine and Chemokine Genes 
Cytokine and chemokine genes are critical for sustaining, inducing and mediating 
immune reactions including cell proliferation and activation. A number of these genes 
have been observed to be differentially expressed in CFS/ME. Among these are IL-8 
gene (IL-8), (Vernon et al. 2002) a chemokine expressed in endothelial cells that 
serves as a chemoattractant molecule for neutrophils during pathogen invasion and 
other immunological insults (Huber et al., 1991). Although neutrophil recruitment has 
not been reported to be defective in CFS/ME, deficiencies in IL-8 mRNA expression 
do occur and this has adverse consequences on inflammation (Xie, 2001, Mukaida, 
2003, Nozell et al., 2006). Secretion of end products of phagocytosis during 
neutrophil pathogen lysis, increases IL-8 chemotactics thereby causing an increase in 
the recruitment of more neutrophils to sites of infection (Sparkman and Boggaram, 
2004, Ito et al., 2004). An up regulation of IL-8 as noted in CFS/ME may be 
associated with potential declines in oxidative stress owing to the regulatory effects of 
nitric oxide and oxidative stress on IL-8 mRNA during inflammation (Sparkman and 
Boggaram, 2004, Ito et al., 2004). Neutrophil oxidative burst in CFS/ME has been 
shown to be reduced (Brenu et al., 2010). Another contributory factor to this 
alteration in expression may be related to declining NF-κB regulation (Huang et al., 
2001). NF-κB is an essential transcription factor necessary for leukocyte cytokine 
production (Artis et al., 2003, Bohuslav et al., 1998). Deficiencies in NF-κB may 
increase susceptibility to infectious agents (Artis et al., 2003, Sha et al., 1995) and 
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alter inflammatory reactions (Campbell et al., 2000, Yang et al., 1998) as observed in 
most CFS/ME cases (Fletcher et al., 2010, Broderick et al., 2010).  
 
Most cytokines are regulated and have an involvement in the Janus Kinase signal 
transducers and activators of transcription (JAK/STAT) pathways. Processes in this 
pathway involve the transcription and phosphorylation of factors including STAT5A. 
The STAT5A transcription factor is induced by cytokines IL-2, IL-4 and IL-7, and is a 
critical element in the proliferation and survival of Th2 cells (Lin and Leonard, 2000). 
Changes in this transcription factor in CFS/ME (Saiki et al., 2008) are a probable 
cause for decline in anti-inflammatory reaction/Th1 type immune response and an 
increase in pro-inflammatory mediators in the immune pathogenesis of this disorder 
(Skowera et al., 2004). STAT5 together with JAK1 mediate cytokine signalling in 
particular IFN-α, IL-2, IL-7, IL-9, IL-10, IL-13 and IL-22 signalling (Schindler et al., 
2007). An up regulation in STAT5A and JAK1 (Kerr et al., 2008b, Saiki et al., 2008) 
can significantly hinder the rate or activity of the above mentioned cytokines and their 
receptors. This has been observed in some CFS/ME patients where receptors for IL-7, 
IL-10 and IFN-α are differentially expressed (Kerr, 2008) while these same cytokines 
for example, IFN-α and IL-10, maybe either increased and decreased respectively in 
some CFS/ME cases (Gupta et al., 1997, Vojdani et al., 1997).  
 
The JAK/STAT pathways are also regulated by cytokines such as IL-6 (Kamimura et 
al., 2003, Kristiansen and Mandrup-Poulsen, 2005). Interactions between IL-6 and IL-
6R are important for modulating downstream signalling events involving JAKs and 
STATs which promote the growth of progenitor cells. Intense signalling of 
suppressors of cytokine signalling (SOCS) proteins result in exacerbation of the 
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inflammatory response and heightened inflammation (Rawlings et al., 2004, 
Kristiansen and Mandrup-Poulsen, 2005). Decreased expression of IL-6 (Light et al., 
2009), coupled with a decline in its receptor and signal transducer (IL6R and IL6ST 
genes) (Kerr, 2008) may have unfavorable outcomes on the role of IL-6 in the 
immune response and in regulating JAK1 in CFS/ME (Guschin et al., 1995). An 
immune profile where IL-6, its receptor and signal transducer are compromised, 
affects JAK1 and STAT5 signalling and alters cytokine related trans-signalization and 
inflammatory homeostasis permitting either an autoimmune or defective physiological 
function in CFS/ME.   
 
The tumour necrosis factor (TNF)-α receptor is encoded by the gene TNFRSF1A. It 
increases pro-inflammatory events via NF-κB activation that results in elevations in 
gene expression and proliferation of cytokines (Nowlan et al., 2006). TNFRSF1A is 
also involved in cellular apoptosis signalling related to the TNFR-associated factor 
(TRAF) domains (Baud and Karin, 2001). In CFS/ME, heightened cellular apoptosis 
of neutrophils has been reported (Kennedy et al., 2004, Vojdani et al., 1997, See et 
al., 1998), this possibly occurs as a consequence of changes in TNFRSF1A (Kerr et al. 
2008). Decreases in the NF-κB gene, NFKB1, correlated with a proportional decrease 
in TNFRSF1A in CFS/ME (Kerr et al., 2008) may potentially affect proliferation of 
IL-8. NFKBIZ which dampens NF-κB, has been shown to be decreased in expression 
in CFS/ME (Kerr et al. 2008). NF-κB activation involves pattern recognition 
receptors such as Toll-like receptors (TLR) (Kitamura et al., 2000, Yamazaki et al., 
2001) and other factors including TRAF3 (He et al., 2007, He et al., 2006, Hauer et 
al., 2005). It is possible to hypothesise that variations in the expression of these genes 
may have significant disadvantages on cytokine secretion and regulation in CFS/ME. 
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HIF1A represents hypoxia induced transcription factor 1 alpha (HIF1α) gene, which 
has a role in the regulation of apoptosis (Yu et al., 2004, Carmeliet and Tessier-
Lavigne, 2005, Akakura et al., 2001). It regulates phagocytosis induced by 
neutrophils and macrophages in response to the presence of microbial antigens (Nizet 
& Johnson 2009) and incidentally phagocytosis is downregulated in CFS/ME (Brenu 
et al., 2010), perchance resulting from differential expression of HIF1A. 
 
The degree of CXCR4 expression by neutrophils, monocytes and T lymphocytes is 
regulated by cAMP, IL-4, IL-6, IL-10 and reactive oxygen species, and its expression 
is essential for hematopoietic cell trafficking, differentiation, endothelial migration 
and immune proliferation in the CNS and immune systems (Moepps et al., 1997, Zou 
et al., 1998, Jazin et al., 1997). The observation of an upregulation in CXCR4 in 
CFS/ME (Kerr et al. 2008; Gow et al. 2009) relates to a change in cytokine profile 
present in some CFS/ME patients. Interestingly, most of these CXCR4 regulatory 
factors are controlled by NF-κB and VNs. VNs will be discussed in later sections. 
VNs regulate the production of cAMP and some of the anti-inflammatory cytokines, 
listed above. Perturbations in these VNs may therefore affect CXCR4 and contribute 
to altered immune profiles in some CFS/ME patients.  
 
The CD47 gene, is extensively expressed in immune and nervous system and is 
important for migration of neutrophils and chemotaxis of other cells, stimulation of T 
cells and cognitive function (Lindberg et al., 1993, Brown et al., 1990, Parkos et al., 
1996, Chang et al., 1999, Gao et al., 1996, Ticchioni et al., 1997, Waclavicek et al., 
1997). Although, differences in lymphocyte numbers remain controversial in 
CFS/ME, where some studies have reported decreases, increases or no change in 
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immune cell numbers, migration of these cells to sites of infection may be impaired 
given that IL-8, CXCR4 and CD47 are differentially expressed in CFS/ME patients 
(Kerr et al. 2008; Gow et al., 2009). 
 
The gene, TGF-β1, is an essential component of the cytokine genes, it has an 
involvement in immune response to injury, cell development and cell proliferation 
(Marie et al., 2005). TGF-β1 is a transcription factor that regulates Treg 
differentiation pathways and is also a necessary factor in the survival of Tregs (Marie 
et al., 2005). It induces apoptosis through the Fas apoptotic pathways or oxidative 
stress that inevitably cause death of the targeted cell (Sanchez-Capelo, 2005). An 
upregulation in TGF-β1 may cause an elevation in neutrophil apoptosis (Kennedy et 
al., 2005), consequently decreasing effective oxidative stress in CFS/ME (Brenu et 
al., 2010). Although, Treg function in CFS/ME patients has not being directly 
measured, it is likely that these cells may be deficient in their expression of FOXP3 
and therefore need to be studied in detail to determine if these effects at the 
transcriptome level can be translated into protein function in these cells.  
 
1.3.2. Genes Involved in Pathogen Lysis 
Cytotoxic activity of NK and CD8
+
T cells as previously mentioned occurs via a 
number of pathways including the granule dependent cytotoxic pathways. NK and 
CD8
+
T cells secrete granzymes that effectively bind to various organelles within the 
cell systematically inducing apoptosis of the target cell. Granzyme and perforin genes, 
GZMA, GZMB and PRF1, are important genes associated with activity during natural 
cytotoxic activity and antibody dependent cytotoxic activity of CD8
+
T and NK 
lymphocytes via FCRII (CD16) receptor (Lahmers et al. 2006; Madueno et al. 1993). 
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GZMA induces slow apoptosis while GZMB stimulates rapid apoptosis of the target 
cell. Diminishing mRNA levels of GZMA and GZMB in CFS/ME (Saiki et al., 2008) 
may affect efficient NK and CD8
+
T cell cytotoxicity. Not surprisingly, this is 
consistent with studies investigating NK cell activity in CFS/ME patients where most 
patients demonstrate significant declines in cytotoxic activity (Brenu et al., 2010, 
Klimas et al., 1990, Maher et al., 2005).  
 
The cathepsin gene (CTSC) is prominent in myeloid cells, polymorphonuclear 
leukocytes, alveolar macrophages and osteoclasts (Hakeda and Kumegawa, 1991, 
McGuire et al., 1997, Rao et al., 1997b). Paucity in the expression of CTSC is related 
to poor functioning in lytic proteins in particular GZMA and GZMB in cytotoxic 
lymphocytes (Pham and Ley, 1999). Thus in patients with CFS/ME uncharacteristic 
expression of CTSC may translate into low levels of GZMB and GZMA proteins 
(Maher et al. 2005; Saiki et al., 2008) and consequently resulting in suboptimal 
cytotoxic activity during infections in both the innate and adaptive immune systems. 
A decrease in these parameters may contribute to the abnormally low levels in 
cytotoxic activity of NK cells in CFS/ME patients. High rates of microbial antigens 
may persist in these patients as the immune system is not able to effectively eliminate 
these pathogens. 
 
1.3.3. Transcription factors 
Transcription factors are essential molecules for initiating the expression of genes and 
are especially important for development (Farnham, 2009). In CFS/ME, a few of these 
genes display disparities when compared to healthy individuals. A typical example is 
the early growth response protein 3 gene (EGR3), changes in this transcription factor 
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alters lymphocyte proliferation, apoptosis and inflammatory response (Yamamoto et 
al. 2005; Beinke & Ley 2004; Inoue et al. 2004). Cytotoxic pathways such as the Fas 
L and ADCC are induced by EGR3 (Matsuoka and Jeang, 2005). Altered expression 
of EGR3 reduces T cell related production of IL-2 (Safford et al., 2005). Changes in 
this gene in some CFS/ME patients (Kerr et al., 2008) may be linked to reduced 
cytotoxic activity and high levels of anti-inflammatory factors increasing pathogenesis 
and pro-inflammatory immune responses. The resultant effects include symptoms of 
fatigue, loss in memory, concentration and impaired immune function in CFS/ME as 
observed in mice deficient in this gene (Li et al., 2007a).   
 
In the innate and adaptive immune system TRAIL plays a substantial role in the 
regulation of cytotoxic activity. The presence of TRAIL on NK and CD8
+
T 
lymphocytes serves as an alternative pathway for effective cytotoxic activity against 
viral antigens (Kayagaki et al., 1999, Janssen et al., 2005). Interestingly, TRAIL has 
positive and negative effects on Th1/Th2 immune responses. TRAIL induces 
apoptosis in Th1 cells thereby inhibiting pro-inflammatory reactions while increasing 
anti-inflammatory effectors by activating Th2 differentiation (Zhang et al., 2003). 
Hence in CFS/ME, deviations in the expression of TRAIL may affect cytotoxic 
activity and cause abnormal shifts in Th1/Th2 inflammatory responses. 
 
The gene NFATC1 is the gene for nuclear factor of activated T lymphocytes. It is part 
of the NFAT family of transcription factors responsible for the regulation of genes 
encoding cytokines and cytokine receptors (Crabtree and Clipstone, 1994, Rao et al., 
1997a). NFATC1 is important for T cell proliferation, Th2 differentiation and cytokine 
production (Yoshida et al., 1998; Ranger et al., 1998). Similarly, irregularities in Th2 
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cytokine profiles in CFS/ME may ensue from perturbed expression in DEFB1 or the 
human β defensin 1 may contribute to skewed Th1 profile (Wehkamp et al., 2005). 
The involvement of DEFB1 in immunomodulation at both the innate and adaptive 
immune response, is important for dendritic cells and CD4
+
T lymphocytes 
recruitment via the CCR6 receptor (Yang et al., 1999) during infection and 
inflammation (Dommisch et al., 2005, Wehkamp et al., 2005, Sun et al., 2005). 
Animal models have revealed that dysregulation in DEFB1, increases the 
susceptibility to bacterial and viral infection (Moser et al., 2002, Morrison et al., 
2002). DEFB1 differential expression may be correlated with the observation of 
different viral antigens in serological samples from CFS/ME patients. 
 
1.3.4. Immune Regulators 
GNAS and cyclic AMP-responsive element-binding protein (CREBBP) are 
transcription factors important in the activation of cAMP in cells such as CNS related 
cells (Goodman and Smolik, 2000). Importantly, mutation in GNAS generates 
sporadic tumours (Lania et al., 2003). GNAS and CREBBP have been shown to be 
increased in CFS/ME patients (Zhang et al., 2009). As will be discussed later 
CREBBP is vital for VN conversion of ATP to cAMP via adenylate cyclase (Delgado 
and Ganea, 2001). Differential expression of CREBBP and GNAS may be detrimental 
to VN related activities that regulate immune responses in both the CNS and 
periphery, thus increasing susceptibility to infection and other pathologies (Petrij et 
al., 1995, Stevens and Bhakta, 1995). Similarly mitogen activated protein kinase 
pathways involving genes such as MAPK9 encode important signalling molecules 
known as the JNK2 protein kinase. Differential expression in this gene affects 
downstream signalling pathways that have been shown to be associated with the 
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pathogenesis of destructive insulitis (Jaeschke et al., 2005). In CFS/ME perturbations 
in these genes likely affects certain metabolic pathways contributing to severe fatigue. 
 
Similarly, CMRF35 is the gene that encodes the CD300c leukocyte surface protein 
present on macrophages (Turnbull and Colonna, 2007) and are important regulators of 
dendritic cell secretion of TNF-α and IFN-α (Ju et al., 2008). Irregularities in 
CFS/ME cytokine profiles possibly occur as a result of defects in CMRF35 which 
inadvertently disrupts anti-viral IFN-α and inflammatory TNF-α activities required for 
immune homeostasis (Sen, 2001).   
 
In summary, the perceived ramifications of these gene expression changes in immune 
related genes may contribute substantially to the disease profile of CFS/ME. 
Modifications in genes affect protein conformation during translation and 
consequently alter function. The genes discussed above have vital roles in most 
immune related activities such as inflammatory modulation, lymphocyte and cytokine 
activation, lymphocyte differentiation and proliferation and are also implicated in the 
signalling pathways of other genes especially transcription factors. A breach in the 
optimal capacity of these genes whether towards an upregulation or a down regulation 
potentially interferes with VN function, prompting either a Th1 or Th2 cytokine shift, 
decrease in cytotoxic activity, lymphocyte migration and proliferation and 
perturbations in important physiological networks.  
 
Interestingly, the consistent observation of impaired NK cytolysis in CFS/ME is 
partly due to the reduced expression of activating cytokines, perforin and granzymes. 
As previously discussed these granzymes induce apoptosis of antigens within the cell. 
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Variations in inflammatory reactions, that is, pro- and anti-inflammatory, can be 
explained by the altered levels of their corresponding cytokine genes. Most of these 
cytokines are engaged in other physiological functions hence, defects in their 
production can severely hinder other important processes. Although, most studies in 
CFS/ME have to some extent provided information on the expression of genes in 
CFS/ME patients, it is not known whether CFS/ME elicits these changes in gene 
expression pattern or vice versa. Similarly, most of the genes observed in these studies 
have not been replicated in other CFS/ME patients, and most of the time specific 
lymphocytes were not studied, it is very difficult to ascertain which specific cells are 
compromised among the CFS/ME population. It is therefore imperative for further 
studies to be carried out to determine how changes in gene expression can be related 
to the mechanism of CFS/ME and the specific cells that may be severely 
compromised in this disorder and how this relates to the disease profile. 
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Table 3: A Summary of Gene expression studies in CFS/ME 
Authors Total  number of transcripts 
found in study 
Important Genes Relevant to 
immune function 
Vernon et al., 2002 7 CMRF35, TRAIL, DEFB1, 
CTSC  
Powell et al., 2003 7 Protein kinase R 
Tumor necrosis factor alpha, 
Cathepsin C 
Kaushik et al., 
2005 
16  IL10RA, CD2BP2, GSN, 
EIF2B4, EIF4G1, ANAPC11 
Carmel et al., 2006 17 Solute carrier family 1 
membrane 6  
F-box protein 7 
Zinc finger protein 350 
T cell leukemia 1A  
Goertzel et al., 
2006a 
9 NR3C1, TPH2, COMT, 
CRHR2, CRHR1, NRC1, TH, 
POMC, 5-HTT 
Kerr et al. 2008 88 CD2BP2,CD47,CITED2,CRE
BBP,CRK,CTBP1,CXCR4,EB
I2,EIF2B4,EIF3S10,EIF4G1,E
IF4G3,GNAS,GSN,IFNAR1,I
L10RA,IL6R,IL6ST,JAK1,M
APK9,PGM2,PKN1,,PRKAR
A1A,SNAP23,SOS1,TAF11,T
CF3,TNFRSF1A,NFKB1,NHL
H1,GABAPA,ETS1,EGR1,EG
R3,IL7R, PIK3R1  
Saiki et al. 2008 9 GZMA, ATP5J2, DBI, 
COX5B, STAT5A 
Presson et al., 
2008 
299 FOXN1, PRDX3, SUCLA2, 
DCTN2, PGK1, SNURF, 
PRKCH, RYK, PPP1R14C, 
VAMP5, PRO0641, 
TMEM50A, CRNKL1, 
NPAL2, TFB2M, PBLD, 
LTV1, MED8, 
CD302(XM13557) 
Light et al., 2009 13 IL-6, IL-10, TNF-α, TLR4, 
CD14, TGF-β 
Gow et al., 2009 366 DEFA1, HBG1, CEACAM8, 
ITGA2B, HBG2, DEFA4, 
ITGB3, CD61, CXCR4, 
RPS26, ZNF294, HLA-DQA1 
Genes in bold have been examined in other studies with similar pattern of expression however, IL-
10RA was inconsistent. 
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1.4. Immune Regulators as possible markers in CFS/ME 
Immune function is regulated by proteins and other molecular products including 
novel substances which continue to be discovered. The following sections describe 
novel regulators of immune function and their potential contribution to CFS/ME 
immune mechanism in cases where they are deficient. 
 
1.4.1. MicroRNAs 
Thymocytes and other cells of the immune system are regulated by the change in gene 
expression, specifically, transcription, translation and protein formation. In relation to 
the immune systems these proteins may include cytokines, chemokines, lytic proteins 
and receptors. The synthesis of these proteins from mRNA molecules is regulated by 
many factors including microRNA (miRNA) molecules. This study examines the 
expression profiles of small non-coding molecules, miRNAs in CFS/ME patients. 
This section explores the relevance of these molecules in immune function. 
 
MicroRNAs are recently described highly conserved molecules with regulatory 
activities in multi-cellular organisms such as mammals. They are small components of 
the ribonucleoprotein particles belonging to a family of small ribonucleic acid 
molecules which have effects on diverse physiological function. MicroRNAs are 
suppressors of gene expression and affect either translational processes or the stability 
of mRNAs through the encouragement of cellular decay processes, deadenylation and 
decapping (Mishima et al., 2006, Wu et al., 2006a) process termed RNA interference 
(outlined in Figure 6). The generation of mature miRNAs from a miRNA gene occurs 
when a primary transcript (pri-miRNA) produced following transcriptional processing 
in the nucleus by RNA polymerase II. This pri-miRNA contains a hairpin stem-loop 
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structure which is served by the enzyme Drosha (RNA III enzyme) and DGCR8 
(DiGeorge critical region 8), resulting in the creation of a structure comprised of a 22 
basepair stem, 2-nucleotide 3‟ overhang and a loop, collectively this is known as the 
pre-miRNA transcript (Lee et al., 2003). The pre-miRNA transcript is transported into 
the cytoplasm where RNase  III enzyme, Dicer, cleaves the double stranded pre-
miRNA transcript into a 18- to -24 base pair product (Lee et al., 2002). The less stable 
transcript formed from the cleavage by Dicer is integrated into an RNA induced 
silencing complex (RISC) with argonaute proteins where it is further processed 
(Khvorova et al., 2003, Lee et al., 2003, Mourelatos et al., 2002, Lingel et al., 2003). 
The final product formed from this sequence of events is a miRNA-RISC complex 
(Figure 6). Suppressive effects of miRNA on gene mRNA molecules occur via the 
RISC complex which contains proteins that have the ability to cleave mRNA 
molecules and interfere with translation (Hutvagner & Zamore, 2002). The mature 
miRNA can bind complete and incomplete complementary strands of mRNA 
molecules and degrade the mRNA or inhibit translation respectively (Hutvagner and 
Zamore, 2002, Behm-Ansmant et al., 2006, Lim et al., 2005). Interactions between 
the miRNA and mRNA molecules may be potentially important for physiological 
processes.  
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Figure 6: MicroRNA biogenesis and action. A pri-miRNA is converted into a mature 
miRNA in the presence of various enzymatic processes. Mature miRNA are therefore 
able to target 3‟regions of specific genes (Inui et al., 2010). 
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Similar to mRNAs, miRNAs are regulated by transcription factors (TFs) and vice 
versa, thus it has been suggested that miRNAs together with TFs regulate the 
expression of genes (Zhou et al., 2007). Recent data have indicated their involvement 
in immune homeostasis in the adaptive and innate components of immunity and other 
related cellular processes. In the innate immune system, miRNAs such as miR-155 
enhance the maturation of macrophages and dendritic cells via the TLR receptor 
pathway, this causes heightened sensitivity in these cells to antigen presentation in 
circulation (Tili et al., 2007, O'Connell et al., 2007). MicroRNA-146 is also associated 
with the TLR pathways, which are necessary for regulating antigen recognition, 
innate-adaptive immune interactions stimulating the production of cytokines and they 
also assist in the generation of CD4
+
T helper cells thus contributing to inflammatory 
regulation (Taganov et al., 2006). CD4
+
T and CD8
+
T cell maturation into various 
subsets in the periphery are regulated by miRNAs (Wu et al., 2007a).  
 
Importantly, deficiencies in components of the miRNA such as Dicer promote a 
predominant Th1 response governed by IFN-γ with a reduction in the effects of Th2 
cells and Treg cells (Cobb et al., 2006). In contrast a predominant Th2 CD4
+
 T cell 
profile prompting systemic inflammation emanates from deficiencies in the miR-155 
(Rodriguez et al., 2007, Thai et al., 2007) while in the absence of miR-101 
autoreactive T cell mediated autoimmunity occurs (Yu et al., 2007). In CFS/ME, there 
are inconsistent data with regards to the Th1/Th2 profiles. It is likely that in the event 
that immune related miRNAs are deficient, shifts in Th1 and Th2 immune regulatory 
effectors and defects in TLR signalling may occur, and this may be related to the 
pathomechanism of CFS/ME. 
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The generation of Tregs that express FOXP3 is to some extent dependent on miRNAs 
(Kohlhaas et al., 2009). Any perturbed effects in miRNAs can influence thymic and 
peripheral derived Tregs especially in response to TGF-β stimulation on naive CD4+ 
T lymphocytes (Ha, 2011). Modulation of the effects of these molecules is essential 
for appropriate immune response to bacterial and viral invasion. MicroRNA 
molecules such as miR-181 limit the expression of phosphatases required for signal 
transduction processes that increase the ability of the T cell receptor (TCR) to 
recognise peptides released from pathogens and initiate a cascade of events that 
ensures lysis of pathogens (Li et al., 2007b). Evidently alterations in these miRNAs 
significantly promote inflammatory reactions that may be associated with CFS/ME.  
 
Additionally, miR-155 expressions are regulated by FOXP3 which is important for 
Treg responsive and the induction of IL-2 (Zheng et al., 2007, Marson et al., 2007, Lu 
et al., 2009a). A list of potential miRNA molecules that are important for immune 
function is provided in Table 4. Although, the contribution of miRNAs in the 
mechanism of CFS/ME has not been clearly outlined to date, further studies are now 
required to demonstrate or verify the role of miRNAs in CFS/ME. 
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Table 4: MicroRNAs involved in immune related activities  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNA  Function   
miR-146  Innate and adaptive immune interactions  Williams et al. 2008 
miR-150  Lymphocyte development  Zanovello 2011 
miR-17-92  Regulation of apoptosis  Nagel et al., 2009 
miR-223  Regulation and production of granulocytes  Johnnids et al., 2008 
miR-101  Autoreactive T lymphocytes  Iliopoulos et al., 2011 
miR-181  TCR signalling  Xiao et al. 2009 
miR-155  
Maturation of macrophages, dendritic 
cells, FOXP3  
Kohlhaas et al. 2009 
miR-142  Increase production of lymphocytes  Merkerova et  al., 2008 
 79 | P a g e  
 
1.4.2. Vasoactive Neuropeptides 
Vasoactive neuropeptides (VNs) are a class of peptides with diverse regulatory roles 
in almost all physiological systems. The two most important VNs, associated with a 
number of neuro-immune disorders, are vasoactive intestinal peptide (VIP) and 
pituitary adenylate cyclase activating peptide (PACAP). These VNs are widespread 
throughout the mammalian body including areas such as CNS and lymphoid organs 
and have receptors on immune cells specifically mast cells, T lymphocytes and 
granulocytes (Bellinger et al., 1996; Ganea & Delgado 2002). VIP and PACAP are 
highly expressed in the CNS and lymphoid tissues specifically in the cortex, thymus, 
spleen, lymph nodes, hypothalamus, colon, pituitary gland, neurosecretory fibres, 
gonads, adrenal, endocrine, germ cells, gastrointestinal tract, ganglia, neurons and 
muscle fibres (Arimura and Shioda, 1995, Kimura et al., 1994, Shioda et al., 1994, 
Hannibal et al., 1998, Koves et al., 1993, Bellinger et al., 1996). These peptides are 
necessary for the regulation of important physiological processes such as maintaining 
the blood brain/blood spinal barrier (BBB/BSB) (Benagiano et al., 1996), cerebellar 
development (Allais et al., 2007) and co-neurotransmitter functioning of cholinergic 
and catecholamine transmitters (Hamelink et al., 2002), inflammatory modulation 
(Delgado et al., 2003), hypoxia and nitric oxide (NO) regulation (Cohen et al., 2002, 
Larocca et al., 2007) and inhibition of apoptosis (Delgado and Ganea, 2000b).   
 
Vasoactive intestinal peptide and PACAP act through G-protein coupled receptors 
(GPCRs), VPAC1, VPAC2 and PAC1. VIP binds with high affinity to VN receptors, 
VPAC1 and VPAC2 belonging to the G-protein coupled receptor family whilst 
PACAP binds to all three receptors VPAC1, VPAC2 and PAC1(Harmar et al., 1998). 
In the periphery monocytes, macrophages, T lymphocytes and mast cells secrete VIP 
 80 | P a g e  
 
and PACAP and express receptors VPAC1, VPAC2 and PAC1 on their cell surfaces 
(Gomariz et al., 1994). VIP and PACAP adhering to their receptors (VPAC1, VPAC2 
and PAC1) activate stimulatory Gα subunit of the GPCR protein. When GDP is 
replaced by the active form GTP, the βγ subunit dissociates from the complex (Figure 
7). The GTPα complex excites adenylate cyclase (AC) to catalyse ATP to produce 
cAMP. Cyclic AMP once created binds to the regulatory protein kinase A (PKA) 
resulting in the phosphorylation of cAMP-regulatory element and binding proteins 
(CREB) phosphorylation (Ganea and Delgado, 2002, Leceta et al., 2000) and other 
signalling pathways. Considering immune function, phosphorylation of CREB 
initiates a sequence of events that either inhibit the secretion of pro-inflammatory 
molecules or activates anti-inflammatory factors (Christophe, 1993, Vaudry et al., 
2000). Thus VIP and PACAP acting through their receptors can inhibit pro-
inflammatory cytokines specifically IL-6, IL-12, TNF-α and nitric oxide (NO) 
production in macrophages and T lymphocytes (Delgado et al., 1999d, Martinez et al., 
1998, Delgado et al., 1999c).  
 
Vasoactive intestinal peptide and PACAP also control immune processes involving 
chemokine (CCL2, CCL5, CCL9, CXCL1, CXCL2, CXCL3, CXCL8, and CX3CL1) 
release, necessary for the attraction and migration of monocyte and neutrophils to 
sites of infections (Delgado et al., 2004a), activation of anti-inflammatory 
mechanisms that suppresses macrophage-related activities such as phagocytosis, 
respiratory burst, and chemotaxis, and limits lymphocyte recruitment and prevents the 
secretion of pro-inflammatory factors (Gomariz et al., 2001, Abad et al., 2005, Ganea 
and Delgado, 2002). In Th1 cells PACAP and VIP prevent the differentiation and 
proliferation of Th1 type cytokine by suppressing IL-12, a necessary component in 
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Th1 cell survival and prevalence (Murphy and Reiner, 2002). Antigen induced cell 
death (AICD) of CD4
+
 T lymphocytes occurring via Fas ligand activation is also 
prevented by VIP and PACAP (Delgado and Ganea, 2000a).  
 
An important characteristic of PACAP and VIP is their role as anti-inflammatory 
effectors. They are able to induce the generation of Th2 type cytokines and 
chemokines thereby regulating inflammation (Martinez et al., 1996, Wang et al., 
1999, Delgado et al., 1999d). This preferential selection and enhancing of Th2 type 
cytokines is a protective mechanism employed by the physiological system to prevent 
autoimmune related episodes. In this regard, PACAP and VIP interaction with CD4
+
T 
lymphocytes confers an antagonistic effect on Th1 cells through suppression of 
chemoattractant molecules CXCL10, while enhancing Th2 migration to sites of 
infection by up-regulating the release of CCL22 from innate immune cells (Jiang et 
al., 2002). CD4
+
 Th2 cells express predominantly VPAC1 and VPAC2 (Delgado et 
al., 1996) receptors, VPAC1 inhibits excessive production of pro-inflammatory 
markers from macrophages and microglia cells while VPAC2 sustains Th2 survival 
and endorses anti-inflammatory effectors (Feldmann et al., 1996). These anti-
inflammatory effectors include IL-10, IL-4, IL-5 and IL-1Ra (Delgado et al., 2004b, 
Delgado et al., 1999a, Feldmann et al., 1996). Anti-inflammatory responses are highly 
necessary to restore immune balance after an infection or inflammatory episode has 
been resolved. Inflammation due to injury or invasion by pathogens and antigens 
initiates a sequence of events that initiate the activation of TLR ligands, the release of 
pro-inflammatory molecules (chemokines and cytokines), the recognition and 
effective elimination of the pathogens. VIP and PACAP therefore act through their 
receptors to prevent persistent inflammation in the absence of injury or pathogen. VIP 
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and PACAP also contribute to Treg expansion and suppressive activities in an attempt 
to maintain homeostasis (Chorny et al., 2006). 
 
Vasoactive intestinal peptide and PACAP deficits have been recognised in 
autoimmune diseases such as Rheumatoid Arthritis (Gomariz et al., 2006). Their 
direct role in CFS/ME has not yet been determined although there are suggestions for 
compromises in their function leading to disequilibrium in the Th1/Th2 effector 
responses (Staines, 2004). As cytokine production in CFS/ME may be defective 
where either a prevailing Th1 or Th2 response may occur (Swanink et al., 1996, 
Skowera et al., 2004), it is perhaps reasonable to propose dysregulation in VNs as a 
plausible pathomechanism in CFS/ME, since they have a crucial role in the inhibition, 
release and activation of cytokines. Incidentally, CFS/ME cytokine levels are unclear 
and the heterogeneity of this disorder and techniques used in measuring may be 
responsible for these differences in results. Results supporting a Th1 immune 
dominance in CFS/ME (Rasmussen et al., 1994, Gupta et al., 1997, Patarca et al., 
1994, Lloyd et al., 1992, Swanink et al., 1996), may have a relationship with 
compromise to VIP and PACAP. This possibly affects the ability of VIP and PACAP 
to exert anti-inflammatory activities, permitting heightened inflammation in CFS/ME. 
Consequently, this may result in elevated amounts of IL-2, IL-6, IFN-γ and TNF-α 
and decreases in IL-10. A prevailing Th2 immune profile in CFS/ME (Skowera et al., 
2004, Gold et al., 1990, Visser et al., 1998, Klimas et al., 1990, Klimas et al., 2009) 
can also be attributed to changes in VN expression favouring an altered production of 
cAMP and cytokines that over-compensate the anti-inflammatory reactions and thus 
exacerbate immune reactions causing systemic insults. These severe anti-
inflammatory events may be marked by elevations in IL-4, IL-1α, IL-5 and IL-6 with 
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decreases in IL-2, IFN-γ and IL-8 (Gold et al., 1990, Visser et al., 1998, Klimas et al., 
1990, Klimas et al., 2009).  
 
In summary, positive or negative interference of inflammatory events by PACAP and 
VIP is an effective way of enforcing immune reactions of lymphocytes, cytokines, 
chemokines and their receptors and an important component for restoring balance 
after an inflammatory experience. This may be impaired in a disease like CFS/ME 
and therefore requires further investigations. These studies will further highlight 
whether CFS/ME is an autoimmune or systemic disorder and perhaps clarify the 
underlying mechanism associated with this disorder. 
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Figure 7: VIP and PACAP signalling. Binding of the VIP and PACAP to their receptors (VPAC1 and VPAC2) stimulate the binding of GTP to 
alpha and beta gamma subunits, release of the beta and gamma subunits. These evens activate adenylate cyclase to convert ATP to cAMP and 
activate the cAMP/PKA activation pathways causing either the inhibition of pro-inflammatory cytokines or the activation of anti-inflammatory 
cytokines. 
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Although, an adequate mechanism for CFS/ME has not yet been explained, CFS/ME 
possibly suggests itself in the occurrence of either environmental or physiological 
stressors. These stressors may be comorbid with e.g. infection (viral or bacterial), 
pesticide toxicity and other inflammatory instigators which alter the bidirectional 
communication that exists between the immune system and CNS. Conversely 
susceptibility to certain stressors may predispose an individual to immune compromise. 
This may then trigger changes in peptide function and cytokine secretion from the CNS 
and the peripheral immune system, either at the molecular or cellular level, in favour of 
either a predominant pro-inflammatory or an anti-inflammatory cytokine profile, and 
consequently have detrimental effects on immune cell activation and function. 
Physiological processes would be inadvertently compromised, encouraging persistent 
infections, increase in viral or bacterial load, severe fatigue, cognitive deficits and a 
pattern of symptoms observed in CFS/ME. Presently, direct assessment of CNS immune 
function is not available hence this study is primarily focused on peripheral immune 
function. 
 
Despite the number of studies examining immune activities in CFS/ME, the explicit 
function of particularly CD4
+
 and CD8
+ 
T lymphocytes is not fully known. Changes in 
T cell numbers which have been widely examined in CFS/ME patients do not provide 
adequate information on the T cell profile in these participants. Additionally peripheral 
blood investigations of cytokines in CFS/ME are not specific to cell type, hence, 
cytokine secretion by Th cells is not currently known. Studies on the cytotoxic activity 
and suppression by CD8
+
T lymphocytes and Tregs, respectively, in CFS/ME patients 
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are currently not available. To facilitate the development of a plausible pathomechanism 
that will potentially assist in the comprehension of CFS/ME, all aspects of the immune 
system must be assessed. Here, we present a study that examines cytokine secretion by 
CD4
+
T lymphocytes, cytotoxic activity and Treg expression. Notably substantial 
evidence exists to support the critical role of these VNs in inflammatory reactions in 
both CNS and peripheral blood. Defects in VNs, VIP and PACAP have adverse effects 
on Th activities. Alterations in gene expression profiles in immune markers are also 
suggestive of homeostatic imbalances in CFS/ME. However, in a disorder such as 
CFS/ME this is very speculative as other factors may be involved. This project assessed 
VIP and PACAP expression, in addition to gene expression to evaluate their 
contribution to immune cell function in CFS/ME patients.  
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The current ambiguities in CFS/ME research and lack of definitive markers for 
diagnosing this disorder suggest the need for further research. The following section 
provides the framework for a comprehensive project investigating immune function in 
CFS/ME. 
 
1.5. Hypotheses 
The null hypotheses for the project are:  
1. Quantitative assessments of cytokines released by Th1, Th2, Th17 and Tregs in 
CFS/ME patients are not statistically significantly different from the non-fatigued 
control population with no preference to either a shift in Th1 or Th2 cytokine 
profile. 
2. Treg FOXP3 expressions in CFS/ME patients are not significantly different from the 
non-fatigued control population. 
3. Assessment of CD8+T lymphocytes cytotoxic activity against tumour cells in 
CFS/ME patients will not significantly differ from non-fatigued control participants. 
4. There is no significant difference in the expression pattern of VIP and PACAP 
receptor, VPAC2, on T lymphocytes between CFS/ME and non-fatigued 
participants. 
5. The gene expression profile of CFS/ME patients with regards to NK and CD8+T 
lymphocytes is not statistically significantly different to the non-fatigued control 
participants.  
6. There are no significant differences in miRNA expression between CFS/ME and 
non-fatigued controls 
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1.6. Aims 
The primary aims of this study were to: 
1. Examine NK activity and phenotype expression in CFS/ME patients. 
2. Evaluate the protein profile of CD4+T lymphocytes in CFS/ME with specific 
focus on Th1, Th2, Th17 and Treg related proteins. 
3. Directly measure and explore cytotoxic activity of CD8+T cell in CFS/ME. 
4. Determine the role of VIP and PACAP in the immune mechanism of CFS/ME 
by examining their receptor expression on T lymphocytes. 
5. Verify the longitudinal profile of these immune parameters. 
6. Assess the expression of immune related miRNAs in the optimal function of NK 
and CD8
+
T lymphocytes in patients with CFS/ME relative to non-fatigued 
controls. 
7. Develop and establish prospective diagnostic markers for CFS/ME based on the 
results from this research that could be tested in clinical practice.  
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1.7. Significance 
This study performed a comprehensive analysis of the immune function in CFS/ME at 
the functional, molecular and protein level.  
This is the first research to:   
1. Investigate the expression of VN receptors VPAC1 and VPAC2 on lymphocytes 
in CFS/ME. This investigation illuminates the role of the neuroimmune 
interactions in CFS/ME.  
2. Determine the status of CD8+T cell cytotoxic activity in CFS/ME. 
3. Assess genes of specific lymphocytes such as CD8+T lymphocytes and NK 
lymphocytes. Presently only two studies have replicated some of the genes 
found to be differentially expressed in CFS/ME, this study decisively reproduces 
a number of these finding in these specific lymphocytes as this can potentially 
assist in the development of a mechanism for this disorder.  
4. Examine miRNA molecules related to immune function specifically NK and 
CD8
+
T cells in CFS/ME.  
5. Assess adaptive immune function with respect to T lymphocytes including 
FOXP3 expression on Tregs in CFS/ME. 
 
The results from this project have potentially served as a basis for developing a disease 
mechanism for CFS/ME. This can be translated into the generation of prospective 
diagnostic markers for detecting CFS/ME. Additionally, this may assist in reducing the 
current cost incurred by patients on management strategies to help relieve their 
symptoms. These results are likely to increase knowledge on the pathomechanism of 
CFS/ME which may serve as a basis for future investigations. 
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2. Project 
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This study was designed to thoroughly assess aspects of the immune function including 
innate and adaptive immune system in patients with CFS/ME. It was hypothesised that 
severe deterioration in multiple components of the immune system are responsible for 
the symptomatology of this disorder. Hence, this study assessed lymphocyte function, 
protein levels and genes. The project was divided into three different sections as 
described below in the following sections. The first part provides an extensive 
investigation of immune parameters at baseline, this initial study was necessary to 
establish whether the immune markers are compromised in CFS/ME. In the second part, 
the immune markers were examined over a time period to determine their stability while 
the last project was focused on miRNAs. Details of these studies are further discussed in 
the sections that follow. The specific methods used in each individual study are outlined 
in a method section within each study. 
 
2.1. Methods 
2.1.1. Participant Recruitment and Follow Up 
Recruitment for the study was achieved through the CFS/ME support groups in South 
East Queensland and Northern New South Wales. Additional recruiting strategies such 
as the media including newspaper and radio advertisement were used to recruit 
additional participants as most of the prospective participants from the support groups 
were outside the specified age range (25-65 years). Recruitment of controls was done in 
close vicinity to the collections sites and this most often included relatives and friends 
of the participants. Participants were assessed using a CFS/ME questionnaire outlined in 
the appendix. Using this method the targeted participant population was matched.Not all 
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immune parameters in the project were measured consistently over the 12 month period. 
Due to circumstances that were beyond the control of this project, not all parameters 
were examined at the baseline, 6 or 12 months. The baseline investigations included all 
parameters. However, at the 6 and 12 months only NK cytotoxic activity, NK 
phenotypes and cytokines are reported. 
 
The project was divided into three with patients assessed every six months: 1) baseline, 
2) 6 month and 3) 12 month. Prior to the baseline collection phase an information 
session was held for all interested participants. At this information session the study was 
described to qualified participants and all necessary procedures pertaining to the 
participants including consent forms, appointment scheduling and blood collection were 
outlined. This was an important component of the study as it provided an avenue for the 
patients to ask questions and convey their concerns regarding the study. This first initial 
contact with the participants was followed up with phone calls for blood collection 
appointments. After all participants had their blood collected and data analysed, a 
second follow up feedback session was held to update the patients on the progress of the 
study and also to highlight some of the findings that were stated in the ethics and 
consent forms. The mean of the overall results were presented to the patients in power 
point format. These results included full blood counts, NK phenotypes and NK 
cytotoxic activity. Similar procedures were applied to both the 6 and 12 months 
collection times. Since most of the patients and non-fatigued controls were not able to 
attend these information sessions, a weekly newsletter system was implemented and this 
contained various updates regarding scheduling times, results and progress of the study. 
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To better understand the symptoms, clinical presentation and quality of life of 
participants, a number of questionnaires were formulated. Some of the questions on the 
questionnaires were based on patient suggestions. These questionnaires also include a 
Four Dimensional Symptoms assessment criteria. Data construed from these surveys are 
currently being compiled for publication. Additionally, analysis of the medications 
administered by the CFS/ME cohort from this study has also being examined and 
submitted for publication. This study has therefore reviewed certain essential clinical 
components of CFS/ME that may be useful to health care professionals. 
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Figure 8: Criteria for Defining the Various Participant Groups. Using the CDC 1994 
case definition an inclusion and exclusion criteria was generated. The inclusion criteria 
consisted of the CFS/ME participants and non-fatigued controls. The CFS/ME 
participants were recruited via the media and the CFS/ME support groups, while the 
controls were mainly selected from the general public and spouses of the CFS/ME 
patients. The flow chart illustrates the identifiers used for each group. Those participants 
that were excluded did not meet the CFS/ME or patient criterion. 
Total participants  
N=168 
1. Symptoms of 
fatigue>6 months and 4 
or more of the following: 
Unrefreshing sleep 
Muscle pain 
 Sore throat 
 Pain in the joints 
without swelling or 
redness 
Headaches 
 Tender lymph nodes 
 Impaired concentration 
or memory 
2. Age  25-65 years 
3. Professionally 
diagnosed or 
undiagnosed 
4. Australian resident  
5. Yes/ no medication 
 
1. Aged <25 or >65 years 
2. Autoimmune disorder 
3. Smoking 
4. Pregnant/breast 
feeding 
5. Immobile 
6. Cardiovascular disease 
7. Outside SEQ or NNSW 
CFS/ME participants 
N=95 
1. No fatigue or 
4<fatigue <6 months  
2. Aged between 25-65 
years 
3. No incidence of 
anaemia 
4. No CFS/ME symptoms 
5. Australian resident  
6. Yes/No medication 
Non-fatigued Controls 
N=50 
Excluded participants 
N=53 
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2.1.2. Cell Culture 
Two cell types were used in this project these were the mouse lymphoblast-like 
mastocytoma (P815) and the human erythromyeloblastoid leukemia (K562) cell lines. 
These cells were required for the assessment of NK and CD8
+
T cell cytotoxic activity. 
These cells were grown in separate cell media supplemented with different substances. 
However fetal bovin serum (FBS) and peniciliin-streptomycin was added to each media 
prior to cell culturing. The P815 cells were grown in Dulbecco‟s Modified Eagle 
Medium (DMEM) supplemented with L-glutamine and 4.5g/L of glucose while K562 
cells were grown in Roswell Park Memorial Institute (PRMI-1640) medium 
supplemented with sodium pyruvate and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPPEs) buffer. Each cell type was cultured in an incubator at 37  containing 
5% carbon dioxide. The cells were passaged 3-4 times following which they were kept 
frozen in liquid nitrogen in a solution made up of 5% dimethyl sulfoxide (DMSO) and 
95% FBS at a concentration of 1x10
6
cells/mL. Prior to cytotoxic activity the cells were 
gently thawed in a 37  water bath and resuspended in a solution containing 50% 
complete culuter media and 50% FBS. Cells were centrifuged for 5 mins at 150 relative 
centrifugation force (rcf). The cells were then suspended in 5-10ml of complete media 
in a T25 flask and placed in the incubator until they were required.  
 
2.1.3. Participant Recruitment and Follow Up 
A volume of 10 -20mL was used for each assasy as per the procedure. The different 
isolation steps are outlines below. 
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Isolation of peripheral blood monobuclear cells PBMCs) from whole blood required 10 
mL of whole blood. This was diluted in 20mL of PBS and layered over 10mL of ficol 
Hypaque and centrifuged for 30 mins at 400rcf. Following centrifugation the solution 
was contructed into four layers. These were from top to bottoms, plasma plus PBS, 
PBMC, ficoll and packed red bloode cells. The PBMC layer was transferred into 
another tube and washsed twice first in 20mL of PBS and then in 10mL of PBS. Cells 
were counted on a hemacytometer prioto any further secondary assessment.  
 
Gene expression studies required further isolation of the PBMCs into CD8
+
T or NK 
cells using a negative isolation system. Enrichment of NK or CD8
+
T cells was 
performed using NK and CD8
+
T Cell Isolation Kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer‟s instructions. In these isolations 
biotinylated antibody cocktails were used to magnetically select non-NK or non-CD8
+
T 
cells and incubated at 8 C for 10 minutes. Anti-biotin micro-beads were added to bind 
to the biotinylated positively selected cells during a 15 minute incubation period. The 
cells were washed in PBS and resupended in PBS. The samples were then passed 
through MACS columns where unwanted cells bind to the magnet while the unlabelled 
NK or CD8
+
T cells pass through the columns and are collected for further analysis.  The 
other remaining cells labelled with the microbeads were attracted to a magnetic 
apparatus surrounding the column. NK cells and CD8+T cells were snap frozen in 
liquid nitrogen and then stored in minus 80 C freezer. 
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3. Project One: Immunological Abnormalities as Potential 
Biomarkers in Chronic Fatigue Syndrome/ Myalgic 
Encephalomyelitis 
Brenu, E.W., Ashton K.J., van Driel M, Staines, D.R, Keane, J., Ramos, S.B., Klimas, 
N.G., Marshall-Gradisnik, S.M. 2011. Potential Biomarkers for the Diagnosis of 
Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis. Journal of Translational 
Medicine. 9, 81 
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3.1. Abstract 
Background: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is 
characterised by severe prolonged fatigue, and decreases in cognition and other 
physiological functions, resulting in severe loss of quality of life, difficult clinical 
management and high costs to the health care system. To date there is no proven 
pathomechanism to satisfactorily explain this disorder. Studies have identified 
abnormalities in immune function but these data are inconsistent. We investigated the 
profile of markers of immune function (including novel markers) in CFS/ME patients. 
Methods: We included 95 CFS/ME patients and 50 healthy controls. All participants 
were assessed on natural killer (NK) and CD8
+
T cell cytotoxic activities, Th1 and Th2 
cytokine profile of CD4
+
T cells, expression of vasoactive intestinal peptide receptor 2 
(VPACR2), levels of NK phenotypes (CD56
bright
 and CD56
dim
) and regulatory T cells 
expressing FoxP3 transcription factor.  
Results: Compared to healthy individuals, CFS/ME patients displayed significant 
increases in IL-10, IFN-γ, TNF-α, CD4+CD25+ T cells, FoxP3 and VPACR2 
expression. Cytotoxic activity of NK and CD8
+
T cells and NK phenotypes, in particular 
the CD56
bright 
NK cells were significantly decreased in CFS/ME patients. Additionally 
granzyme A and granzyme K expression were reduced while expression levels of 
perforin were significantly increased in the CFS/ME population relative to the control 
population. These data suggest significant dysregulation of the immune system in 
CFS/ME patients.   
Conclusions: Our study found immunological abnormalities which may serve as 
biomarkers in CFS/ME patients with potential for an application as a diagnostic tool. 
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3.2. Introduction 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) remains a medically 
unexplained disorder despite numerous scientific investigations undertaken worldwide. 
The current worldwide prevalence rate of CFS/ME is estimated to be about 0.5% 
(Grinde, 2008) with a higher prevalence in females compared to males at a ratio of up to 
6:1 (Devanur and Kerr, 2006). The annual cost for treatment and management of 
CFS/ME in the USA is estimated to be US$319 million with a direct cost of US$7,406 
per patient (Jason et al., 2008).  
 
Generally, patients with CFS/ME experience severe fatigue, neuropsychological 
impairments, and other associated flu-like symptoms before a firm diagnosis of 
CFS/ME is made (Fukuda et al., 1994). CFS/ME has been observed to persist for more 
than six months where symptoms may decrease, remain stable or worsen six months or 
more(Jason et al., 2010). The current diagnostic strategy for health professionals is 
based on case definition, although this is not the most ideal method as it permits 
misdiagnosis. CFS/ME may share homology with certain disorders classified as fatigue 
related disorders where individuals experience fatigue and one or more of CFS/ME 
related symptoms. Further, there are no biomarkers available to affirm diagnosis thus 
complicating treatment.  
 
Population based studies have suggested a link between infections, neurological and 
neuroimmune dysfunctions and clinical manifestations of CFS/ME(Biswal et al., 2010, 
Lakhan and Kirchgessner, 2010, Lorusso et al., 2009, Natelson et al., 2005, Schutzer et 
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al., 2011). Immunity has been widely investigated in patients with CFS/ME but the 
results of these studies are inconsistent, reporting different lymphocyte cell numbers 
and cytokine distributions in patients with CFS/ME. Nonetheless, findings on 
immunoglobulins, complement markers and activation molecules in CFS/ME, may 
demonstrate an underlying infringement in immune function (Lorusso et al., 2009, 
Sorensen et al., 2009, Nijs et al., 2009). Decreased function of lymphocytes, in 
particular Natural Killer (NK) cell cytotoxic activity in CFS/ME patients compared to 
healthy controls, seems to be a consistent finding (Brenu et al., 2010, Fletcher et al., 
2010, Klimas et al., 1990, Maher et al., 2005). The functional capacity of other immune 
cells, such as T cells, and the contribution of other molecules in the pathophysiological 
mechanism of CFS/ME, remains to be determined. In particular, the role of subsets of 
CD4
+
T and the CD8
+
T cell populations has not been fully studied in CFS/ME. 
Importantly, recent data on cytokine distribution in CFS/ME patients point towards an 
increase in pro-inflammatory cytokines suggesting the presence of an underlying viral 
prevalence in these patients (Broderick et al., 2010, Kuratsune, 2007) and this can be 
detrimental to the immune inflammatory processes. 
 
It is widely known that neuropeptides regulate immunity. Relevant among these are 
vasoactive neuropeptides (VNs), specifically vasoactive intestinal peptide (VIP) and 
pituitary adenylate cyclase-activating polypeptide (PACAP). They regulate and 
suppress pro-inflammatory immune processes via the PKA/cAMP pathway (Gomariz et 
al., 2006). Their role in CFS/ME remains unknown although there are suggestions that 
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they may be implicated in observed CD4
+
T cell related activities such as cytokine 
secretion and FOXP3 expression (Staines, 2004). 
 
Immune cell numbers may not necessarily be indicative of diseased states, as stated 
previously these have been shown to be inconsistent in CFS/ME. However, the 
functional capacity of these cells during disease progression may provide a better 
understanding of the mechanism associated with unexplained disorders such as 
CFS/ME. Alternatively, this may help in identifying specific immune parameters that 
can be used as diagnostic markers for CFS/ME. The present study thus explores 
immunological abnormalities that may serve as biomarkers for diagnosing CFS/ME. 
Additionally, this is the first study to examine the role of the VNs, VIP and PACAP, 
and FOXP3 expression in CFS/ME.  
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3.3. Method 
The project having been reviewed under an Expedited Review Procedure was granted 
approval to proceed by the Bond University Human Research Ethics Committee 
(BUHREC). All participants in this present study signed an informed consent approved 
by the Bond University Human Research Ethics Committee (BUHREC). 
 
3.3.1. Participants 
All participants, both CFS/ME and non-fatigued controls were recruited from 
Queensland and New South Wales states in Australia through the CFS/ME support 
groups, newspaper and email advertisements into a prospective study as cases (CFS/ME 
patients) or non-fatigued controls (healthy volunteers). Participants were eligible if they 
were between 25 and 65 years old. Prior to inclusion all participants completed a 
consent form and a Chronic Fatigue Syndrome questionnaire based on the Centre for 
Disease Prevention and Control case definition (CDC 1994) (Fukuda et al., 1994). 
Participants previously diagnosed with autoimmune disorders, psychosis, epilepsy, heart 
disease, or who were pregnant or breastfeeding were excluded from the study (Figure 
8). 
 
3.3.2. Sample Preparation and Routine Measurements 
A volume of 25ml of blood was collected from the antecubital vein of participants into 
lithium heparinised and EDTA collection tubes between 9am and 11am. Blood samples 
were analysed within 12 hours of collection. Routine blood cell counts for red blood 
 103 | P a g e  
 
cells, lymphocytes, granulocytes and monocytes were performed using an automated 
cell counter (ACT Differential Analyzer, Beckman Coulter, Miami, FL). 
 
3.3.3. Assessment of NK Cytotoxic Activity 
The NK cells were isolated from whole blood samples using Ficoll-Hypaque (GE 
Healthcare Life Sciences; Milan, Italy) density gradient centrifugation. NK lymphocyte 
cytotoxic activity was performed as previously described (Aubry et al., 1999).  Briefly, 
isolated cells were labelled with 0.4% PKH-26 (Sigma, St Louis, MO). NK cells were 
incubated with K562 at an effector to target ratio of 25: 1, for 4 hours at 37°C in 95% 
air, 5% CO2. Apoptosis of the tumour cells was measured via FACS-Calibur flow 
cytometry using the Cell Quest Software (Becton Dickinson (BD), San Diego, CA), 
using Annexin V-FITC and 7-AAD reagent (BD Pharmingen, San Diego, CA). Percent 
lysis of K562 cells was calculated as previously described (Aubry et al., 1999).  
 
3.3.4. Assessment of CD8+T Lymphocyte Cytotoxic Activity 
Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
samples using Ficoll-Hypaque (GE Healthcare Life Sciences; Milan, Italy) density 
gradient centrifugation. CD8
+
T lymphocytes were preferentially isolated from PBMCs 
using CD8
+
T cell isolation kit (Miltenyi Biotec GmbH; Bergisch-Gladbach, Germany) 
according to the manufacturer‟s instructions. Briefly, cells were stained with a CD8+T 
cell biotin-antibody cocktail, incubated for 10 minutes and then stained with CD8
+
T cell 
microbead cocktail for 15 minutes. Cells were then passed through separation columns 
were cells of interest were collected for further analysis. Cytolysis was performed as 
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previously described using P815 cells as the target cells (White et al., 2007). In brief, 
P815 cells were stained with 0.4% PKH-26 and activated using anti-CD3 (BD 
Bioscience, San Diego, CA). The target cells were then incubated with CD8
+
T cells at 
an effector to target ratio of 25: 1, for 4 hours at 37°C in 95% air, 5% CO2. Annexin V-
FITC flow cytometry apoptosis detection was used in assessing cell death of the tumour 
cells. Percent lysis of K562 P815 cells was calculated as previously described (White et 
al., 2007).  
 
3.3.5. Gene expression in NK and CD8+T Cells 
Isolation of NK and CD8
+
T cells was done via MACS separation (Miltenyi Biotec 
GmbH; Bergisch-Gladbach, Germany) as specified by the manufacturer. Purity was 
determined on the flow cytometer using the Cell Quest software. Isolated NK cells were 
coated with PE-CD56CD16 and FITC-CD3 (BD Pharningen, San Diego, CA) 
monoclonal antibodies to determine the purity of NK cells. To establish the purity of 
CD8
+
T cells, isolated CD8
+
T cells were stained and incubated with PE-CD8 and FITC-
CD3 monoclonal antibodies (BD Pharmingen, San Diego, CA). Cells were fast frozen 
in liquid nitrogen and kept in negative 80 degrees freezing conditions for further 
assessment. Total RNA extractions were performed using the RNeasy Mini Kit (Qiagen, 
Valencia, CA) and quantified on the NanoDrop 3300 (Thermo Scientific, Wilmington, 
DE). RNA was synthesised in to cDNA using the SuperScript
TM
 III First-Strand 
synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad, CA) as specified by the 
manufacturer and stored at negative 20
 o
C for later analysis. RT-qPCR was performed 
using IQ SYBR Green Super Mix (Bio-Rad, Hercules, CA) with GAPDH as the 
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housekeeping gene. Expression levels of granzyme A, granzyme K, perforin and INF-γ 
(GZMA, GZMK, PRF1 and IFN-G) were collected and quantified using the iQCycler 
(Bio-Rad, Hercules, CA). 
 
3.3.6. Quantification of NK Phenotypes 
Distribution of NK cell phenotypes was assessed as previously described (Cooper et al., 
2001). NK lymphocytes were isolated from whole blood via negative selection using 
RosetteSep Human Natural Killer Cell Enrichment Cocktail (StemCell Technologies, 
Vancouver, BC) and, were labelled with CD56-FITC and CD16-PE monoclonal 
antibodies (BD Bioscience, San Jose, CA). 
 
3.3.7. VPACR2 Stimulation 
Whole blood samples (10mL) diluted with 1x PBS were layered over Ficoll-Hypaque 
for isolation of peripheral blood mononuclear cells. Cells were stimulated with or 
without 1µg of Lipopolysaccharide (Invitrogen, Carlsbad, CA) and cultured for 48 hours. 
Cells were stained with vasoactive intestinal peptide receptor 2 (Sigma, St Louis, MO), 
FITC-IgG (Sigma, St Louis, MO) and CD4-PE anti-mouse monoclonal antibodies and 
analysed on the flow cytometer with settings for detecting monocytes and lymphocytes 
expressing the VPACR2. Percentage of cells expressing both CD4-PE and VIP2-FITC 
were recorded from these populations to determine the levels of VPACR2 expressed on 
these cells (Sun et al., 2006). In the lymphocyte gate specific reference was made to 
CD4
+
T cells. 
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3.3.8. Cytokine Determination 
Isolated CD4
+
T cells were mitogenically stimulated with 1µg of phytohemagluttinin 
and cultured at a concentration of 1x10
6 
cells/mL for 72 hours. Following incubation, 
supernatants were removed and stored at -80
0
C for later assessment. T helper (Th)1, 
Th2 and Th17 cytokine expressions were investigated using the cytometric bead array 
kit (BD Pharmingen, San Diego, CA) (Collins et al., 1998) for determining levels of 
interleukin (IL)-2, IL-4, IL-6, IL-10, tumour necrosis factor (TNF)-α, interferon (INF)-γ 
and IL-17A. The cytokines selected for this study although not conclusive, enough were 
selected to ascertain the Th1/Th2/Th17 mechanisms in CFS patients. 
 
3.3.9. Regulatory T Cell Assessment 
Expression of FOXP3 Tregs was determined on CD4
+
CD25
+
 cells. PBMC Cells were 
stained with monoclonal antibodies FITC-CD4 and APC-CD25 (BD Pharmingen, San 
Diego, CA) following which cells were permeabilised and stained with anti-FOXP3 and 
PE-FOXP3 respectively and analysed via flow cytometery (Harmar et al., 1998). 
 
3.3.10. Statistical Analysis 
Statistical analysis was performed using SPSS software version 16.0 (SPSS Inc, 
Chicago, USA). A sample size of 59 participants per group was required to obtain 
statistically significant results with an effect size of 0.5 and a power of 85%. All data 
represented in this study are reported as means plus or minus standard error of the mean 
(±SEM). Comparative assessments among participants (that is, the CFS/ME and control 
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subjects) were performed with the analysis of variance test (ANOVA) and independent 
sample t-test. All statistically significant results had p-values less than or equal to 0.05. 
 
3.3.11. Ethical Clearance and Participant Selection 
Approval for this study was granted after review by the Bond University Human 
Research Ethics Committee (RO852A).  
 
3.4. Results 
Of the 168 participants recruited 95 met the CDC criteria for CFS/ME and 50 qualified 
as healthy controls. Twenty-three participants were rejected because they did not meet 
the inclusion criteria for CFS/ME (Figure 10) 58.2% of CFS/ME patients indicated that 
they experienced 6 or more of the symptoms listed in the CDC criteria list and 21.4% 
experienced only 4 symptoms. The baseline characteristics of the participants are 
illustrated in table 5. 
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Figure 9: Selection Process for Experimental Groups. Participants for the present 
project were grouped into CFS/ME, or non-fatigued control groups based on the CDC 
1994 case definition symptom criteria. Participants, that is, both CFS/ME and non-
fatigued controls, were comprised of both male and females selected using 
advertisements and through the CFS/ME support groups. Non-fatigued controls were 
randomly selected from the general population using newspaper and email 
advertisements. The above flow chart illustrates the process used to generate the final 
research population. 
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 Table 5: Characteristics of participants in the present study 
 
3.4.1. Lymphocyte Cytotoxic Activity 
Natural Killer and CD8
+
T (n=71) cytotoxic activity, measured as the ability of NK and 
CD8
+
T cells to effectively lyse K562 and P815 cells respectively was significantly 
decreased (p< 0.05) among the CFS/ME patients compared to the control subjects 
(Figure 10). Similarly granzyme A expression was significantly decreased in both the 
NK and CD8
+
T cells in the CFS/ME population. However, IFN-γ and granzyme K were 
decreased only in the NK cells of the CFS/ME group compared to the healthy controls 
as shown in Figure 11A and B. 
Parameters Measured CFS/ME (n=95) Controls (n=50) p-values 
Sex Female 70.5% Female 57.7%  
 Male 29.5% Male 42.3%  
Mean Age  46.47±11.7 41.9±9.6 0.11 
Height (cm) 167.47±13.2 167.9±8.9 0.16 
Weight (kg) 77.02±18.46 72.48±21.09 0.11 
White Blood Cells 5.8±1.4 6.3±1.8 0.68 
Lymphocyte (%) 38±5.7 33.6±7.9 0.03 
Monocytes (%) 5.90±1.4 5.6±2.2 0.30 
Granulocyte (%) 56.3±7.1 60.8±8.2 0.06 
Lymphocyte (x10
3
/µL) 2.3±0.8 2.03±0.6 0.24 
Monocytes (x10
3
/µL) 0.8±4.2 0.34±0.2 0.51 
Granulocyte (x10
3
/µL) 3.3±1.0 3.87±1.5 0.21 
Red Blood Cells (x10
6
/µL) 4.3±0.5 4.56±0.4 0.08 
Haemoglobin (g/L) 131.6±12.4 137.0±11.7 0.15 
Haematocrit (%) 43.8±3.3 43.68±13.0 0.89 
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Figure 10: Reduced lytic function of cytotoxic cells in CFS/ME. In vivo assessment of 
NK and CD8
+
T cell lysis (cytotoxic activity) of tumour cell lines K562 and P815 
respectively where, lytic activity is represented as percent (%) lysis on the y-axis. The 
white bars represent the non-fatigued control population while the black bars represent 
the CFS/ME cohort. *Denotes statistical significant results. Data presented as mean of 
% lysis ± SEM. 
 
 111 | P a g e  
 
 
Figure 11: mRNA Expression of Cytotoxic Molecules in NK and CD8+T Cells. 
Quantitative reverse transcriptase (RT)-PCR demonstrated the relative expression of 
granzyme A, granzyme K, perforin and IFN-g in NK (A) an dCD8+T cells (B). In NK 
and CD8+T cells expression levels of GZMA, GZMK and IFN-G were decreased in 
CFS/ME (black bars) compared to the controls (white bars). PRF1 was however 
increased in the CFS/ME group. *Denotes statistical significant results (P≤ 0.05). Data 
presented as means ± SEM. 
 
3.4.2. Altered NK Profiles in CFS/ME 
In this study NK phenotypes were classified into two, those expressing CD56
bright
CD16
-
 
and CD56
dim
CD16
+
NK cells. The number of NK cells expressing CD56
bright
CD16
-
 was 
significantly lower (p< 0.001) in the CFS/ME patients compared to the control subjects. 
However, CD56
dim
CD16
+
NK cells remained unchanged across all groups (Figure 12C). 
The raw data was converted into absolute counts (Figure 12A and B). 
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Figure 12: Distribution of NK phenotypes. NK phenotypes that were examined are 
denoted as either NK Bright (CD56
bright
CD16
-
) or NK Dim (CD56
dim
CD16
+
). (A) The 
box plots represent the raw data of the NK Bright cells in the two groups. CFS/ME 
patients were decreased in their cell numbers for this particular NK phenotype. (B) 
However, raw data of CD56
dim
CD16
+
 NK cells were examined in the control and 
CFS/ME groups, these were found to be similar. (C) Using the raw data from the flow 
cytometry results, total cell counts of NK cells were deduced. These measurements are 
plotted using bar graphs, CD56
bright
CD16
-
NK cells are more reduced in the CFS/ME 
(black bars) group in comparison to the controls (white bars). *Denotes statistical 
significant results (P≤ 0.05). Data presented as means ± SEM. 
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3.4.3. Profile of CD4+T cells Subsets and Protein Expressions 
After 72 hours of culture Th1 and Th2 cytokine secretions were considerably different 
between groups, however, Th17 cytokines remained unchanged. In particular IL-10, 
IFN-γ and TNF-α production was significantly elevated in the CFS/ME group compared 
to the control group (Figure 13). Other cytokines IL-2 and IL-6 although increased in 
the CFS/ME population were not statistically different between groups (Figure 13). IL-
17A was similarly not significantly different between the two groups. FOXP3 secretion 
by Tregs was significantly higher in the CFS/ME group compared to healthy 
participants (Figure 14). Incidentally, Treg cell counts were also higher in the CFS/ME 
group compared to the healthy population (0.77±0.10 vs. 0.24±0.02). Lymphocyte 
expression of VPACR2 was significantly higher in the CFS/ME patients compared to 
the control group (Figure 15).  
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Figure 13: Examination of the expression levels of CD4
+
T cell Related Cytokines in 
CFS/ME following mitogenic stimulation. CD4+T cells that is, Th1, Th2 and Th17, 
cytokine levels in CFS/ME (black bars) and control participants (white bars) measured 
after stimulation with PHA. The concentrations of cytokines were measured in pg/mL. 
Both anti-inflammatory (IL-10) and pro-inflammatory (IFN-g, TNF-a) cytokines were 
increased in the CFS/ME group following mitogenic stimulation. *Statistically 
significant results at p<0.05. Data presented as log of mean concentration ± SEM. 
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Figure 14: FOXP3 expression and CD4
+
CD25
+
T cells in CFS/ME. The percentage of 
CD4+T cells expressing CD4
+
CD25
+
FOXP3
+
 markers are represented in the bar graph. 
Tregs of interest in this study were those positive for FOXP3 and CD4
+
CD25
+ 
in 
CFS/ME (black bars) and control (white bars) participants. *Represents statistically 
significant results at p<0.05. Data presented as log of mean concentration ± SEM. 
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Figure 15: VPAC2R immune cells in CFS/ME.  VPAC2R expression on the CD4
+
T 
cells was assessed in CFS/ME (black bars) and controls (white bars). The data presented 
here are based on percentage of cells positive for CD4 and VPAC2R. *Represents 
statistically significant results at p<0.05. Data presented as mean ± SEM. 
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3.5. Discussion 
This is the first study to show significantly higher levels of VPACR2 receptors, 
CD4
+
CD25
+
Tregs and FoxP3
+
Treg expression in CFS/ME patients compared to healthy 
controls. In addition, CFS/ME patients had significantly higher levels of anti-
inflammatory cytokine IL-10 and pro-inflammatory cytokines IFN-γ and TNF-α. This 
profile reflects significant and important immunological dysregulation that could 
explain some of the clinical symptoms, for example the ongoing sickness that patients 
experience with CFS/ME. 
 
This is the first study to provide a thorough investigation of the CD4
+
T cell profile in 
CFS/ME patients through the assessment of cytokine secretion and regulatory protein 
levels in particular VPACR2 receptors and FoxP3 expression. Cytokines are soluble 
proteins with either anti-inflammatory or pro-inflammatory effects. Equivocal cytokine 
expression patterns in CFS/ME patients have been reported without a definite 
identification as to which cytokines may be specifically linked to CFS/ME. Possible 
explanations for the inconsistencies in cytokine distribution across studies are the 
heterogeneous nature of the disorder and differences in analytical methods used. 
However, newer and more sensitive assays have been developed since the conflicting 
results were reported (Broderick et al., 2010). It has been suggested that the mechanism 
underlying CFS/ME may involve a shift in cytokine production leading to either a 
predominant Th1 or Th2 cytokine profile (Skowera et al., 2004, Swanink et al., 1996, 
Nakamura et al., 2010). In the adaptive immune system, CD4
+
T cells subsets, Th1, Th2, 
Th17 and regulatory T cells (Tregs) are the main regulators of cytokine secretion and 
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the inflammatory immune response. A bimodal Th1/Th2 response was observed in the 
present study. A predominant Th1 and Th17 immune response has been linked to the 
development or presence of an autoimmune disease whereas increases in Th2 cytokines 
suggest the presence of other systemic disorders (Drulovic et al., 2009, Nevala et al., 
2009). Th1 cells secrete cytokines IFN-γ and IL-2 while Th2 cells secrete cytokines IL-
4 and IL-10 (Zhu and Paul, 2008) and Th17 secrete pro-inflammatory IL-17a, IL-17f 
and IL-22 (Paust et al., 2009, Pene et al., 2008). Recent data on cytokine networks in 
CFS/ME show a predominant Th2/anti-inflammatory profile in CFS/ME with a 
weakened Th1 profile (Broderick et al., 2010).  
 
This study supports the presence of a possible imbalance in Th1/Th2 response in 
CFS/ME characterised by a significant increase in IL-10 together with significant 
increases in IFN-γ and TNF-α. Such increases in IL-10 are suggestive of a persistent 
chronic infectious state and may be associated with a dampening of the NK and CD8
+
T 
cell immune response (White et al., 2007). Others have shown that IL-10RA is 
differentially expressed in CFS/ME patients, highlighting a potential compromise in IL-
10 function or its receptor in CFS/ME patients (Kaushik et al., 2005, Kerr, 2008). 
Nonetheless, increased levels of IL-10, IFN-γ and TNF-α indicate the presence of fungal, 
bacterial or viral infection (Couper et al., 2008). Incidentally in HIV elevation in IL-10, 
IFN-γ and TNF-α denote the presence of a chronic infection and this correlated with 
viral load (Norris et al., 2006). Similarly in CFS/ME such alterations in these cytokines 
may also suggest an increase in viral load and the occurrence of flu-like symptoms. An 
increase in IL-10 also may contribute to decreased cytotoxic activity observed in the 
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NK and CD8
+
T cells (den Haan et al., 2007, Szkaradkiewicz et al., 2010). The increase 
in pro-inflammatory cytokines such as TNF-α, may also depict the presence of an 
inflamed gut or irritable bowel syndrome in some CFS/ME patients (Scully et al., 
2010). Inflammation in the gut can alter the central nervous system (Goehler et al., 
2007, Lakhan and Kirchgessner, 2010) and affects various physiological mechanisms 
including neuropeptides. 
 
The changes in both the Th1 and Th2 responses may suggest changes in the function of 
VN receptor VPACR2 which is a key promoter and stimulator of anti-inflammatory 
cytokines such as IL-10 (Delgado et al., 1999b). It is important to note that VNs, VIP 
and PACAP have never been assessed in CFS/ME previously. These important 
neuropeptides increase IL-10 gene expression via the cAMP response element DNA 
binding complex pathway, therefore changes in VNs such as elevations in VPACR2 
may suggest an increase in IL-10 (Pozo et al., 2000). Further, an increase in TNF-α and 
IFN-γ suggests an inability of the heightened VPACR2 to suppress TNF-α and IFN-γ 
secretion as these neuropeptides are noted to suppress pro-inflammatory cytokines 
while favouring anti-inflammatory cytokine secretions (Pozo and Delgado, 2004). 
Additionally, increases in VPACR2 potentially suggest changes in cAMP associated 
with the inflammatory immune response in CFS/ME. Although our study did not assess 
the levels of cAMP present in CFS/ME patients, VIP binding to its receptor, in this case 
VPACR2, is known to stimulate the presence of FoxP3
+
 which assists in regulating the 
T cell response. Thus it is consistent that heightened levels of VPACR2 will translate 
into heightened FoxP3 expression. FoxP3
+
 Tregs also secrete IL-10 which maintains the 
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expression of FoxP3 in Tregs (Gonzalez-Rey and Delgado, 2007). The increased 
expression of IL-10 and the relatively higher expression of FoxP3 together with 
significant increases in CD4
+
CD25
+
Tregs suppressive activity suggest a requirement to 
counter a significant pro-inflammatory response in these patients. While levels of viral 
antigens were not measured in this study, these observations may suggest a plausible 
prevalence in viral antigens, adjuvants or autoantibodies in the peripheral circulation of 
CFS/ME patients (Nancy and Shoenfeld, 2008, Buskila et al., 2008). 
 
Natural Killer cytotoxic activity in CFS/ME has received much attention (Klimas et al., 
1990; Masuda et al., 1994; Maher et al., 2005; Roberson et al., 2005; Siegel et al., 
2006; Brenu et al., 2010) while only one study has examined CD8
+
T cell cytotoxic 
activity. Most studies found significant decreases in NK activity and one study found 
decreased CD8
+
T cell cytotoxic activity in a CFS/ME population compared with a 
control group. These findings are confirmed in our study. In a previous study (Brenu et 
al., 2010) as well as this study in a larger population, we have found that NK cytotoxic 
activity and CD56
bright
 NK phenotypes are decreased in CFS/ME patients. These 
atypical cytotoxic responses may be linked to compromised granule-mediated cell death 
pathways involving apoptotic mediators, perforin and granzymes. Perforin forms pore-
like structures to facilitate the entry of granzymes into the target cell (Scott et al., 2008), 
and granzymes activate several apoptosis pathways that ensure effective killing of the 
target cell (Chowdhury and Lieberman, 2008). Perforin and granzymes have been 
shown to be decreased in both NK and CD8
+
T cells in CFS/ME (Maher et al., 2005, 
Saiki et al., 2008). In contrast both granzyme A and granzyme K were significantly 
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reduced while perforin levels were elevated in both the NK and CD8
+
T cells of 
CFS/ME patients. Reduced cytotoxic activity may therefore be an important component 
of the immune dysregulation seen in CFS/ME.  
 
 
3.6. Conclusions 
These results illustrate a severely compromised immunomodulation mechanism in 
CFS/ME where attempts to regulate or restore immune homeostasis appear to be 
impaired. These findings suggest that certain immunological biomarkers as 
demonstrated in this study may be unique to CFS/ME. To date no routinely available 
clinical immunological markers have been identified that characterise CFS/ME, 
resulting in poor recognition and management of patients. The immunological 
abnormalities identified in our study can potentially fill this void as potential 
biomarkers and assist clinicians and patients in diagnosis and management of this 
severely debilitating condition. These biomarkers may include NK phenotypes, NK 
activity, CD8
+
T cell activity, IL-10, IFN-γ TNFα, FoxP3 and VPACR2. These markers 
that seem to be unique to CFS/ME patients could assist in identifying them as a distinct 
population, enabling more appropriate clinical management and better targeted 
scientific investigations into the underlying pathomechanisms of the disease.  
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S.L., Tajouri L., Ramos S.B., Marshall-Gradisnik S. 2011. Longitudinal Investigation of 
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4.1. Abstract 
Objective: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is an 
etiologically unexplained disorder characterised by irregularities in various aspects of 
the immunological function. Presently, it is unknown whether these immunological 
changes remain consistent over time. This study investigates Natural Killer (NK) cell 
cytotoxic activity, NK cell subsets (CD56
bright
CD16
-
 and CD56
dim
CD16
+
) and cytokines, 
over the course of a12 month period in patients with CFS/ME.  
Methods: Participants for the study included CFS/ME patients (n=50) assessed using 
the 1994 Centre for Disease Prevention and Control (CDC) definition and non-fatigued 
control (n=27). Participants were assessed at baseline (T1), 6 (T2) and 12 months (T3). 
Flow cytometric protocols were used to assess NK subsets and NK cytotoxic activity. 
Cytokine secretions were measured following stimulation of peripheral blood 
mononuclear cells. 
Results: NK cytotoxic activity was significantly decreased in the CFS/ME patients at 
T1, T2 and T3 compared to the non-fatigued group. Additionally, in comparison to the 
non-fatigued controls, the CFS/ME group had significantly lower numbers of 
CD56
bright
CD16
-
 NK cells at both T1 and T2. Interestingly, following mitogenic 
stimulation, cytokine secretion revealed significant increases in IL-10, IFN-γ and TNF-
α at T1 in the CFS/ME group. A significant decrease was observed at T2 in the 
CFS/ME group for IL-10 and IL-17A while at T3, IL-2 was increased in the CFS/ME 
group in comparison to the non- fatigued controls. Overall cytotoxic activity was 
significantly decreased at T3 compared to T1 and T2. CD56
bright
CD16
-
 NK cells were 
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much lower at T2 compared to the T1 and T3. IL-10 and IL-17A secretion was elevated 
at T2 in comparison to the T1 and T3.  
Conclusion: These results confirm decreases in immune function in CFS/ME patients, 
suggesting an increased susceptibility to viral and other infections. Furthermore NK 
cytotoxic activity may be a suitable biomarker for diagnosing CFS/ME as it was 
consistently decreased during the course of the 12 month study. 
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4.2. Introduction 
Immune responses to infection and inflammation are important aspects of physiological 
homeostasis. This involves constant co-ordinated responses from and between the 
innate and adaptive immune systems (Wasowska, Clark and Kupper, 2005). Cells of the 
innate immune system in particular Natural Killer (NK) cells are important mediators of 
targeted cell killing of tumor, transformed and virus infected cells (Marcenaro et al., 
2011b). NK cells are recruited by interferons and chemoattractive chemokines including 
CCL22, CX3CL1 and CXCL8 (Gong and Clark-Lewis, 1995, Loetscher et al., 1996, 
Bochner et al., 1999, Imai et al., 1998). At sites of infection, stochastic expression of 
NK receptors with the release of granzymes and perforin via mitogenic pathways 
ensures efficient elimination of unwanted cells (Delgado et al., 2010, Marcenaro et al., 
2011a, Marras et al., 2011, Vivier et al., 2004).  
 
As a diseases with unknown pathomechanism and lacking specific diagnostic markers, 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) has been associated 
with diminished immune function (Lorusso et al., 2009). CFS/ME is characterised by 
severe fatigue with apparent flu-like symptoms that either fluctuate or deteriorate and 
persist for many months to years (Fukuda et al., 1994, Wallman et al., 2005). To date 
cytokines, lymphocyte subsets and cytotoxic activity, have been examined in patients 
with CFS/ME using serum, plasma or blood samples. The findings from these 
investigations demonstrate equivocal quantities in lymphocyte numbers and cytokines 
but interestingly consistent decrease in NK cytotoxic activity (Tirelli et al., 1994, Barker 
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et al., 1994, Masuda et al., 1994, Racciatti et al., 2004, Stewart et al., 2003, Brenu et al., 
2010). 
  
A decrease in NK cytotoxic activity is thus a recurring finding in CFS/ME research 
(Fletcher et al., 2010, Brenu et al., 2010, Ojo-Amaize et al., 1994, Barker et al., 1994, 
Maher et al., 2005, Masuda et al., 1994) and remains a hallmark of the disease. 
Additionally, equivocal changes in NK cell subsets, CD56
dim
CD16
+
 and 
CD56
bright
CD16
-
 NK cells have been shown to occur (Brenu et al., 2010, Brenu et al., 
2011). Abnormalities in cellular levels of either CD56
dim
CD16
+
 NK or CD56
bright
CD16
- 
NK cells can affect cytokine production and subsequent clearance of pathogens. Despite 
these striking alterations there are no follow up studies reporting on the profiling of both 
NK cells subsets and activity during an extended course of CFS/ME. Perturbations in 
cytokine production favouring either an anti-inflammatory or pro-inflammatory 
cytokine profile may be prevalent in some CFS/ME patients (Skowera et al., 2004, 
Swanink et al., 1996, Metzger et al., 2008). CFS/ME is a chronic disease with a 
relatively long duration, persisting for more than 6 months, however, it is not reported 
yet whether alterations in cytokines occur and persist over time in adults with CFS/ME. 
 
At this stage the diagnosis of CFS/ME is based on self-reported clinical symptoms. The 
difficulty in establishing a stringent medical diagnosis for CFS/ME may be related to 
the lack of data in monitoring the stability of immune markers during the course of the 
disease. Almost all studies to date investigating immune function in CFS/ME including 
cell activity, lymphocyte subsets and cytokines in CFS/ME adults were only restricted 
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to single time point examination, providing insufficient information on the changes in 
these makers as the disease progresses. Additionally, there are many factors that can 
affect the differences in data reported. As CFS/ME is heterogeneous and multi-factorial, 
CFS/ME patients may experience periods of high, medium or low severity in symptoms 
which may be related to the levels of cytokines and immune function.  
 
Therefore, the purpose of this study is to examine the validity and stability of immune 
parameters previously known to be compromised in CFS/ME and to determine most 
importantly whether these observations are consistent during the course of the disease. 
Assessment and evaluation of these markers potentially enables both the determination 
and knowledge of their stability profile over the course of the disease. This is the first 
longitudinal study assessing NK cytotoxic activity, NK subsets and CD4
+
T cell cytokine 
distribution over a period of 12 months in adults suffering from CFS/ME.   
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4.3. Method 
4.3.1. Recruitment 
Participants for this study were comprised of CFS/ME patients and non-fatigued 
controls recruited from an existing cohort in Queensland and New South Wales, 
Australia (Brenu et al., 2011). Prior to inclusion all participants completed a consent 
form and a questionnaire. The description of these participants is provided in Table 1. 
The CFS/ME group met the 1994 CDC criteria for CFS/ME and the control group 
consisted of non-fatigued volunteers. The non-fatigued controls were recruited from 
similar locations as the CFS/ME cohort. In both groups, individuals with known 
autoimmune disorders, psychosis, epilepsy, diabetes and cardiac related disorders prior 
to the onset of CFS/ME like symptoms were excluded from the study. These exclusions 
were also applied to the control group.  
 
4.3.2. Data Collection 
Samples were collected at baseline (T1), after 6 months (T2) and after 12 months (T3). 
Blood collections were performed at three testing sites as it was not always feasible for 
participants to travel to the main testing site. Participants were recruited in 2009 and 
enlisted for the study in December 2009. The first collection was performed in 
December 2009. The second sampling point took place in June 2010 and the third in 
December 2010. Clinical data were collected through self-administered questionnaires 
at baseline (T1) and T3.  
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4.3.3. Sample Preparation and Routine Measurements 
Non-fasting morning blood samples were collected from the antecubital vein of all 
participants into lithium heparin (12mL) and EDTA (25mL) tubes. Regular full blood 
count (Coulter Counter, Beckman Coulter) assessments were performed ahead of 
immunological assessments. All analyses and experiments were performed immediately 
following blood collection. On a given day blood samples were collected from a 
maximum of 10 participants each day. These participants comprised of a mixture of 
CFS/ME patients and healthy controls, however, as there were more CFS/ME patients 
compared to healthy controls, in some cases the samples comprised only CFS/ME 
patients. 
 
4.3.4. NK cytotoxic activity 
Natural Killer cytotoxic activity was examined as previously described (Aubry et al., 
1999, Brenu et al., 2010, Brenu et al., 2011). In brief, NK lymphocytes were isolated 
from blood samples using density gradient centrifugation and labelled with 0.4% PKH-
2T2 (Sigma, St Louis, MO). Following which NK cells were incubated with K562 cells, 
for 4 hours at 37°C in 95% air, 5% CO2 at an effector to target ratio of 25 (NK cells):1 
(K562). An E:T ratio of 25:1 was chosen as we have previously found this ratio to be 
the most optimal condition for assessing cytotoxic activity. In previous studies this ratio 
has been used (Brenu et al., 2010, Brenu et al., 2011). After four hours of incubation 
NK lysis of K562 cells was calculated as previously described (Aubry et al., 1999) to 
determine the ability of NK cells to induce tumor cell death or apoptosis via FACS-
Calibur flow cytometry (BD Bioscience, San Jose, CA), using Annexin V-FITC and 7-
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AAD reagents (BD Pharmingen, San Diego, CA). The NK assay was performed within 
2-4 hours upon receipt of all blood samples for that particular day hence each sample 
was treated the same. Each sample was performed in duplicates and a control sample 
was included in each run. 
 
4.3.5. NK subsets 
The frequency of NK cell subsets was evaluated as previously described (Brenu et al., 
2010, Brenu et al., 2011). Briefly, a negative selection system using RosetteSep Human 
Natural Killer Cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC) was 
used to segregate NK lymphocytes from whole blood. Preferentially isolated NK cells 
were then labelled with CD56-FITC and CD16-PE monoclonal antibodies (BD 
Pharmingen, San Jose, CA). In a forward scatter and side scatter plot the lymphocyte 
gate was set on NK cells. Subset profile was measured in a PE versus FITC plot. 
  
4.3.6. T cell specific cytokine distribution 
Isolated PBMCs were cultured at 1x10
6 
cells/mL with or without 1µg of 
phytohemagluttinin mitogenic stimulation for 72 hours. Cellular supernatants were 
collected following incubation and stored at -80
0
C for later assessment. Th1, Th2 and 
Th17 cytokine concentrations were determined using the cytometric bead array (CBA) 
kit (BD Pharmingen, San Jose, CA) (Brenu et al., 2011, Dickson and Finlayson, 2009). 
The cytokines that were measured include IL-2, IL-4, IL-6, IL-10, tumour necrosis 
factor (TNF)-α, interferon (INF)-γ and IL-17A. The CBA kit includes a standard that is 
diluted at different concentrations as per manufacturer‟s instructions to produce a 
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standard curve for each cytokine to be measured. This was included in the cytokine 
assessment. During each run of the CBA analysis control samples were included and 
each set of samples analysed on a given day consisted of both CFS/ME patients and 
non-fatigued control cell supernatants.  
 
4.3.7. Statistical Analysis 
Statistical analysis was performed using SPSS software (18.0; SPSS Inc, Chicago). . 
The experimental data represented in this study are reported as means plus/minus 
standard error of the mean (±SEM) while all the clinical date are reported as means 
plus/minus standard deviation (±SD). Comparative assessments among participants 
(CFS/ME and control subjects) were performed with the analysis of variance test 
(ANOVA) and repeated measures. For the repeated measures assessment time was the 
within-subjects factor and group was the between subject factor. Instances where 
Mauchly‟s test indicated that sphericity assumption was breached, the Huynh-Feldt 
correction was applied. Bonferroni method was used as post-hoc analysis to assess 
changes in the data. Time effects and group effects on the variables measured were 
assessed using eta squared, where eta squared (η2) is the ratio of the sum of squares of 
the variance to the sum of squares of the total variance (η2=SS variance effect/SS total). To 
determine within subject stability. Pearson and Spearman‟s rank correlations were 
determined between the three time points. P-values less than or equal to 0.05 were 
considered statistically significant. 
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4.3.8. Ethical Clearance and Participant Selection 
Approval for this study was granted after review by the Bond University Human 
Research Ethics Committee (R0852A). 
 
4.4. Results 
4.4.1. Participants 
Data for baseline, 6 months and 12 months were available for 86 participants (65 
CFS/ME patients and 25 non-fatigued controls). The mean age for the CFS/ME patients 
was 47.2±11.5 years and 45.2±9.3 years for the non-fatigued controls. 75.4% of 
CFS/ME patients and 66.7% of the non-fatigued controls were female and the mean 
BMI in both groups was 24.5±5.0 for the CFS/ME patients and 24.5±4.3 for the non-
fatigued controls. The CFS/ME patients had been suffering from fatigue for a mean of 
16.4±12.5 years and their mean score on the Fatigue Severity Scale (FSS) was 55.5±9.1 
(the lowest possible score of the FSS was 7 and highest is 63) (Krupp et al., 1989). Only 
19.4% of patients indicated that they were still able to carry out normal activities. 
Clinical baseline characteristics are reported in Table 6. 
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Table 6: Baseline clinical characteristics of chronic fatigue syndrome patients 
(cases) and non-fatigued controls. 
 Cases 
(n=65) 
Controls 
(n=21) 
Age, mean in years (SD) 47.2 (11.5) 45.2 (9.3) 
Female (%) 75.4 66.7 
BMI kg/m
2 
(SD) 24.4 (4.9) 25.3 (5.5) 
Smoked in the past 2 years (%) 4.7 4.8 
Symptom (%)   
Weakness >24 hours after exercise 93.8 9.5 
Unrefreshing sleep 93.8 19.0 
Impaired concentration 90.8 4.8 
Muscle pain 81.5 14.3 
Joint pain 70.8 9.5 
Headaches 67.7 9.5 
Lymph glands 43.1 0 
Sore throat 46.2 8.0 
Diagnosed with depression or anxiety 64.6 19.0 
 
4.4.2. Longitudinal assessment of NK cytotoxic activity 
Natural Killer cytotoxic activity, the ability of the NK cells to effectively cause 
apoptosis of K562 cells was significantly reduced (p< 0.05) in CFS/ME patients 
compared to the control group. Significant changes between the groups were noticed at 
the different time points, i.e. at T1 (p<0.001), T2 (p<0.001) and T3 (p<0.001) (Figure 
16A). Regardless of the time point cytotoxic activity remained significantly decreased 
(p<0.001). Time effects had no interaction with the group (p=0.495). There were 
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significant time effects in cytotoxic activity from T1 to T3 (p=0.023) and from T2 to T3 
(p=0.016) (Figure 16B).  
 
Figure 16: NK cytotoxic activity was decreased at all time points in the CFS/ME 
patients.  (A) Cytotoxic activity presented as % lysis of K562 cells by NK cells assessed 
overtime at T1, T2 and T3 in the CFS/ME patients (black bars) and control (white bars) 
participants. (B) Cluster analysis showing the overall cytotoxic activity in the whole 
participant group. *Indicates statistical significant results relative to controls. Statistics 
are presented as mean ± SEM. 
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4.4.3. Differential Distribution of NK Cells Between Groups 
 
The NK subsets were classified as CD56
dim
CD16
+
 and CD56
bright
CD16
-
 NK cells. 
CD56
bright
CD16
-
 NK cells were significantly lower at T1 (p=0.020) and T2 (p<0.001) in 
CFS/ME patients compared to non-fatigued controls (Figure 17A). Significant time 
effects were observed for CD56
bright
CD16
-
NK cell levels (p=0.003) in the overall group.  
Additionally, there was a significant interaction between time and group (p=0.015). 
Pairwise comparison revealed significant changes in the overall group from the T1 to 
T2 period (p=0.037) and from T1 to T3 (p=0.014) (Figure 17B). CD56
dim
CD16
+
NK 
cells remained unchanged throughout the study for both groups.  
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Figure 17: CD56
bright
CD16
-
NK Subset distribution in the CFS/ME group. Percentage of 
NK cells stained positive for CD56
bright
CD16
-
 was significantly low in the CFS/ME 
group at the T1 and at T2. The white bars represent control data while the black bars 
represent CFS/ME data. (B) Cluster analysis showing the overall CD56
bright
CD16
-
 NK 
cells in the whole participant group. Data are presented in the form of log of the total 
events collected via flow cytometry ± SEM. *Signifies statistical significant results 
relative to controls.  
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4.4.4. T Cell Related Cytokine Distribution 
Following mitogenic stimulation, production significant differences in cytokine 
distribution were observed at T1, T2 and T3. At T1, IL-10 (p=0.051), IFN-γ (p=0.003) 
and TNF-α (p=0.002) were significantly increased in the CFS/ME patients compared to 
the non-fatigued controls (Figure 18B, D, E). IL-10 (p=0.026) and IL-17A (p=0.002) 
were significantly decreased at T2 (Figure 18B, C) and only IL-2 (p=0.005) was 
significantly increased at T3 (Figure 18A). There was no significant difference in the 
remaining cytokines. 
 
Irrespective of the group, overall production of some cytokines was significantly 
different from one time point to another. IL-2 was increased from T1 to T2 (p<0.001) 
and from T1 to T3 (p<0.001) (Figure 4A). IL-17A was increased from T1 to T2 
(p=0.009) but declined fron T2 to T3 (p=0.022) (Figure 4D). Secretion of IL-6 was 
decreased fromt T1 to T2 (p=0.001) and T1 to T3 (p=0.001) (Figure 19B). IL-10 
proressively declined from T1 to T3 (p<0.001) and T2 to T3 (p <0.001) (Figure 19C). 
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Figure 18: Between group differences in cytokine production overtime. The secretion 
of IL-2 (A) was significantly increased in the CFS/ME patients at the T3, (B) IL-10 
increased at the T1 and dropped significantly at the T2 in the CFS/ME group. (C) IL-
17A was reduced at the T1 while (D) IFN-γ and (E) TNF-α were increased significantly 
only at the T1. The CFS/ME data are signified by the black bars and non-fatigued 
controls the white bars. *Symbolizes statistically significant results were considered 
where p≤0.05. The results are expressed as the mean concentration at each time point ± 
SEM. 
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Figure 19: Overall Cytokine Secretion with Respect to Time. (A) Cytokine production 
within group was significantly different in IL-2 with high levels noticed at T1 compared 
to the T2 and T3. (B) A similar pattern was noticed in IL-2. (C) IL-10 was however 
significantly decreased at T3 compared to the T1 or at T2. (D) IL-17A tended to be 
higher at T2 within group. Data are presented in the form of log of the total events 
collected via flow cytometery ± SEM. *Designates statistical significant results relative 
to controls. 
B C 
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4.4.5. Parameter stability 
In this study the stability of the immune parameters over time was assessed using 
Pearson and Spearman‟s correlation analysis, where significance was set at P less than 
or equal to 0.05. The results were highly significant for NK activity data, a positive 
correlation was perceived at all time points for NK activity (T1-T2; p=0.003, T1-T3; 
p=0.032). Although, CD56
bright
CD16
-
NK cells were not significantly decreased at T3 
the correlation between time points was significant (T1-T2; p<0.0001, T1-T3; 
p<0.0001, T2-T3; p<0.0001). Using eta squared, significant main effects (η2=0.44) were 
noticed for NK activity. Of note, cytokines were not correlated at any time point.  
However decreases in IFN-γ, TNF-α and IL-10 were correlated at T1.  
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4.5. Discussion 
Our investigation is the first study to demonstrate that NK cytotoxic activity remains 
consistently decreased in CFS/ME patients during the course of the disease. However, 
other immune parameters, especially cytokine secretions fluctuate at different time 
points and therefore demonstrate inconsistencies in their distribution pattern during the 
course of the disease.  The purpose of this investigation was to identify immune markers 
that can be possibly used as biomarkers for CFS/ME in a longitudinal manner. 
 
Primarily, this longitudinal study has illustrated that NK cytotoxic activity is potentially 
useful as biomarkers for CFS/ME, since it was the most stable in the CFS/ME patients 
over the 12 months period of the study. Decreases in cytotoxic activity occur in 
CFS/ME, in some cases this is associated with differential expression in the levels of 
cytotoxic molecules (Klimas et al., 1990, Klimas and Koneru, 2007, Brenu et al., 2010, 
Robertson et al., 2005). These cytotoxic proteins and their genes including perforin 
(PRF1), granzyme A (GZMA),  granzyme B (GZMB) and granzyme K (GZMK) have 
been shown to be either increased or decreased in CFS/ME (Brenu et al., 2011, Maher 
et al., 2005, Saiki et al., 2008). For example, the perforin gene (PRF1) may increase in 
some cases of CFS/ME while intracellular perforin protein may be decreased in other 
CFS/ME patients (Brenu et al., 2011). Such profound differences in protein and mRNA 
can reduce the effectiveness of NK cells to induce lysis/cytotoxic activity of viral 
infected cells. Hence, defective cytotoxic activity in CF/ME patients may be due to 
perturbations in the expression of cytotoxic factors resulting in reductions in cytotoxic 
proteins required for effective lysis of viral and microbial particles. Importantly, NK 
 142 | P a g e  
 
cells have both activating and inhibitory receptors, successful killing of target cells 
occurs through integrated signalling by activating and inhibitory receptors, and co-
receptors. Inhibitory receptors are activated through the recognition of MHC class I 
proteins and this inhibits NK cytoxic activity (Biassoni, 2009, Biassoni et al., 2001). 
Activating receptors are important for eliminating tumours, and other microbes through 
intracellular signal transduction mechanisms that connect them to immunodominant 
tyrosine based activation motif (ITAMS) adaptor proteins (Moretta et al., 2001, 
Biassoni, 2009, Biassoni et al., 2001). Certain viruses can affect NK receptor signalling 
thus reducing cytoxic activity. For example, the cytomegalovirus viral genes can 
regulate NK inhibitory receptor expression preventing the induction of activating 
receptors (Reyburn et al., 1997). An increase in viral load occurs during the course of 
CFS/ME, may trigger defective cytotoxic receptor activations hence resulting in 
malfunctioning of NK cytotoxic activity. The overall decrease in cytotoxic activity at 
T3 is not explicitly known.  
 
The exact consequence of alterations in CD5
6bright
CD16
-
 NK cells in CFS/ME is not 
fully known, however, patterns of CD56
bright
CD16
-
 NK cells were affected by seasonal 
changes which may affect NK cytokine production. Incidentally gene expression of 
IFNG which is an important NK cytokine was significantly decreased in the NK cells of 
CFS/ME patients (Brenu et al., 2011), which may be related to the decrease in 
CD56
bright
CD16
-
 NK cells. Decreases in CD56
bright
CD16
-
 NK cells have been observed 
in coronary heart disease, allergic rhinitis and juvenile rheumatoid arthritis while in 
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diseases such as Chronic Obstructive Pulmonary Disease (COPD) CD56
bright
CD16
-
 NK 
cells have been reported to be increased (Scordamaglia et al., 2008, Hak et al., 2007).  
 
Interleukin 2, a pro-inflammatory cytokine produced by Th1 cells (Zhu and Paul, 2008) 
is required for naïve CD4
+
T cell differentiation into Th2 and regulatory T cells (Tregs) 
in the presence of IL-4 and transforming growth factor beta (TGF-β) respectively (Zhu 
and Paul, 2008). Binding of IL-2 to its high affinity receptor IL-2R induces the 
proliferation of T cells and memory CD4
+
 and CD8
+
T cells (Thornton et al., 2004, 
Williams et al., 2006, Yamane et al., 2005). It is also has important roles in generating 
effector functions for B cells, CD56
bright
NK and CD8
+
T cells (Fehniger et al., 2003). IL-
2 regulates Treg cells and interestingly, CD4
+
CD25
+
Foxp3
+
Treg cells, have been 
reported to be significantly increased in the CFS/ME patients in comparison to non-
fatigued controls (Brenu et al., 2011). An increase in IL-2 may suggest a shift towards 
Th1/ pro-inflammatory immune response in CFS/ME patients. 
 
Anti-inflammatory IL-10 exerts inhibitory effects on cytokine secretion and acts as an 
inhibitor to pro-inflammatory cytokine secretion by multiple cells including Th1 cells 
(IFN-γ), macrophages/monocytes (IL-1, IL-T2, IL-8, IL-12 and TNF-) and NK cells 
(IFN-γ and TNF-α) (Commins et al., 2010). A decrease in IL-10 favours an increase in 
pro-inflammatory responses and this may increase the prevalence of Th1 like cytokines. 
IL-17A is expressed by Th17 cells, it recruits and activates neutrophils, stimulates the 
generation of pro-inflammatory cytokines, chemokines and increases antimicrobial gene 
expression (Weaver et al., 2007, Fossiez et al., 1996, Liang et al., 2006, Ouyang et al., 
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2008). IL-17A is an important immunoregulator during microbial infections as it 
activates immune cells to secrete pro-inflammatory factors. A decrease in IL-17A may 
contribute to the prevalence of infections. A possible explanation for the observed 
changes in the secretion of this cytokine may be related to TGF-β which at optimal 
levels directly promotes IL-17A generation while reducing IL-2 (Cejas et al., 2010). 
Thus, in the CFS/ME patients, TGF-β may be decreased causing an increase in IL-2. 
Therefore, cytokine release in CFS/ME patients undergoes shifts during the course of 
the disease where patients may present with either an amplified or depressed anti-
inflammatory or pro-inflammatory cytokine profile. These alterations in cytokine 
secretion may occur during the course of the disease and at different times causing 
either a shift towards a predominant Th1 or Th2 immune response in CFS/ME (Brenu et 
al., 2011, Broderick et al., 2010, Fletcher et al., 2009, Skowera et al., 2004, Swanink et 
al., 1996). This makes it difficult to establish a unique CFS/ME-like inflammatory 
cytokine profile. The observed pattern of cytokine distribution among our CFS/ME 
patients is consistent with equivocal findings in the literature (Patarca et al., 1994, Linde 
et al., 1992, Lloyd et al., 1992, Peakman et al., 1997, Gold et al., 1990). In adolescents 
with CFS/ME cytokine secretions have been observed to be correlated with seasonal 
variations (ter Wolbeek et al., 2007). Therefore, CFS/ME may be associated with 
oscillations in pro and anti-inflammatory cytokines, supporting the heterogeneity and 
multifactorial nature of the disease and the diversity in symptom presentations. 
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4.6. Conclusion 
In conclusion, altered regulation of immunological function, in particular reduced 
cytotoxic activity, is a key component of CFS/ME. This longitudinal study has 
identified NK cytotoxic activity and possibly CD56
bright
CD16
-
 NK cells as potential 
biomarkers for diagnosing CFS/ME. The observation of immune dysregulation made in 
this study in relation to CFS/ME patients have been observed in various immunological 
diseases. This suggests the need for further investigations into the underlining disrupted 
mechanism of decreases in cytotoxic activity. It is important to note that these cytokine 
profiles were measured following mitogenic stimulation of PBMCs, serum 
measurements of cytokines may display different results. Further studies are therefore 
required to investigate whether changes in cytokine secretions from activated PBMCs 
and/ or serum levels are associated with severity and progression of the complex clinical 
presentations in CFS/ME pathology. 
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5. Project Three: Cytotoxic Lymphocyte MicroRNAs as Potential 
Biomarkers for Chronic Fatigue Syndrome /Myalgic 
Encephalomyelitis Patients 
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Cytotoxic Lymphocyte MicroRNAs as Potential Biomarkers for Chronic Fatigue 
Syndrome Patients/Myalgic Encephalomyelitis. Journal of Translational Medicine, 2012 
May 7. [Epub ahead of print] 
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5.1. Abstract 
Background: Immune dysfunction associated with disease often has a molecular basis. A 
novel group of molecules known as microRNAs (miRNAs) have been associated with 
suppression of translational processes involved in cellular development and proliferation, 
protein secretion, apoptosis, immune function and inflammatory processes. MicroRNAs 
may be implicated in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), 
where immune function is impaired. The objective of this study was to determine the 
association between miRNAs in cytotoxic cells and CFS/ME.  
Methods: Natural Killer (NK) and CD8+T cells were preferentially isolated from 
peripheral blood mononuclear cells from all participants (CFS/ME, n=28; mean 
age=41.8±9.6 years and controls, n=28; mean age=45.3±11.7 years), via negative cell 
enrichment. Following total RNA extraction and subsequent synthesis of cDNA, reverse 
transcriptase-quantitative polymerase chain reaction (RT-qPCR) was used to determine the 
expression levels of nineteen miRNAs.  
Results: There was a significant reduction in the expression levels of miR-21, in both the 
NK and CD8+T cells in the CFS/ME sufferers. Additionally, the expression of miR-17-5p, 
miR-10a, miR-103, miR-152, miR-146a, miR-106, miR-223 and miR-191 was significantly 
decreased in NK cells of CFS/ME patients in comparison to the non-fatigued controls.  
Limitations: The results from these investigations are not yet transferable into the clinical 
setting, further validatory studies are now required. 
Conclusions: Collectively these miRNAs have been associated with apoptosis, cell cycle, 
development and immune function. Changes in miRNAs in cytotoxic cells may reduce the 
functional capacity of these cells and disrupt effective cytotoxic activity along with other 
immune function in CFS/ME patients. 
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5.2. Introduction 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a multi-symptom, 
multi-factorial and heterogeneous disorder. CFS/ME  affects about 1-4% of individuals 
worldwide and is characterised by deficits in short term memory and concentration, 
tender lymph nodes, muscle pain, severe headaches, sleep disturbances, profound 
fatigue and postexertional malaise (Fukuda et al., 1994). Immune markers have been 
identified including decreased cytotoxic activity (Klimas et al., 1990, Maher et al., 
2005, Brenu et al., 2010). Differential expressions of genes involved in immunological, 
neurological and metabolic processes have also been implicated in CFS/ME (Kerr, 
2008, Lin and Hsu, 2009, Saiki et al., 2008, Kaushik et al., 2005, Kerr et al., 2008a, 
Kerr et al., 2008b). A number of these genes encode transcription factors known to 
regulate immune function such as cytotoxicity, cytokine secretion and apoptosis and 
have been shown to be decreased in CFS/ME patients (Brenu et al., 2012, Faria and 
Weiner, 2006, Schaefer et al., 2007, Matsuoka and Jeang, 2005).  
 
Other regulatory molecules have been identified that may have characteristics similar to 
transcription factors, these molecules are known as microRNAs (miRNAs). It is 
predicted that the human genome may encode over 1,000 miRNAs (Griffiths-Jones, 
2010). MicroRNAs are highly conserved non-coding RNA molecules 18-24 nucleotides 
in length that preferentially target 3‟ untranslated regions of their target mRNAs (Sun et 
al., 2010). MicroRNAs are endogenously expressed and transcribed into a primary 
miRNA from introns of protein-/non-coding sequences of exclusive miRNA genes or 
host genes (Sun et al., 2010). The pri-miRNA formed is processed into a pre-miRNA 
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and integrated into an RNA-Induced Silencing Complex (RISC) (Hammond et al., 
2000). The miRNA-RISC either cleavages complementary mRNA molecules or inhibits 
protein translation resulting in the decrease of de novo synthesis of the corresponding 
protein (Behm-Ansmant et al., 2006). The interactions between miRNAs and mRNAs 
are important in maintaining coherent physiological processes such as immune function.  
 
MicroRNAs are required during development, maturation, proliferation, antigen 
recognition, apoptosis induction and cytokine secretion of immune cells (Tili et al., 
2007, O'Connell et al., 2007, Taganov et al., 2006, Liston et al., 2010a). Dysregulation 
in the expression of miRNAs may adversely affect immune homeostasis. For example, 
deficiencies in miR-155 encourage a shift towards T helper 2 (Th2) anti-inflammatory 
immune responses (Rodriguez et al., 2007, Thai et al., 2007), while in the absence of 
miR-101 autoreactive T cell mediated autoimmunity occurs (Yu et al., 2007). 
MicroRNAs are also essential for modulating immune responses to bacterial and viral 
infection. Alterations in these miRNAs may significantly affect immune reactions such 
as cytotoxic activity which are known to be compromised in CFS/ME. 
 
The purpose of this study was to assess the possible role of miRNAs in cytotoxic cells 
of the innate (NK cells) and adaptive (CD8
+
T cells) immune system in CFS/ME 
patients. We hypothesised that as miRNAs can either increase or decrease the 
expression of various genes, they may also be involved in the regulation of cytotoxic 
cells in CFS/ME patients. To the best of our knowledge this is the first study to explore 
the role of miRNAs in cytotoxic cells of CFS/ME patients.  
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5.3. Method 
5.3.1. Subject Recruitment 
This study was approved by the Bond University Human Research Ethics Committee 
(R0852A). Participants (n=56) for the study were recruited from a database of patients 
from the South East Queensland region of Australia. The inclusion criteria for CFS/ME 
(n=28; age=42.0±9.4 years) was based on the Centers for Disease Control and 
Prevention (CDC) 1994 case definition while the non-fatigued healthy control (n=28; 
age=45.0±14.0 years) were participants with no medical history or symptoms of 
prolonged fatigue or illness of any kind (Fukuda et al., 1994).  
 
5.3.2. Sample Collection and Cell Isolation 
Venous blood samples (40mL) from all participants were collected into EDTA tubes 
and analysed within three hours of collection. Peripheral blood mononuclear cells were 
isolated from 20mL of whole blood for each cell type using Ficoll-hypaque (GE 
Healthcare, Uppsala, Sweden). Enrichment of NK or CD8
+
T cells was performed using 
NK and CD8
+
T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer‟s instructions. Enriched NK or CD8+T cell purity was 
examined on the FACSCalibur flow cytometer (BD Bioscience, San Diego, CA) after 
staining with CD16/CD56 or CD8/CD3 monoclonal antibodies (BD Bioscience, San 
Diego, CA). Flow cytometry and haemocytometer assessment were used to determine 
the purity of the cells isolated for miRNA expression analysis. The recovery of isolated 
cells was calculated based on the observation that NK and CD8
+
T cells represent 2% 
and 5% of peripheral blood lymphocytes respectively (Dorfman and Raulet, 1998, 
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Banerjee et al., 2005) hence; there are more CD8
+
T cells in circulation compared to NK 
cells. Thus recovery was defined as the ratio of percentage of the total number of cells 
(i.e. NK or CD8
+
T cells) isolated to the percentage of cells (ie. NK or CD8
+
T cells) 
present in the volume of blood collected. Enriched cells were snap frozen in liquid 
nitrogen and stored at -80°C until further assessment.  
 
5.3.3. RNA Extraction and cDNA Synthesis of NK and CD8+T Cells 
Total RNA (containing miRNA) was extracted from isolated NK and CD8
+
T cells using 
the miRNeasy isolation kit (Qiagen, Hilden, Germany) according to manufacturer‟s 
instructions. Concentration and purity of RNA was determined using the NanoDrop 
3300 (Thermo Scientific, Waltham, MA). Synthesis of cDNA from 250ng of miRNA 
was performed using the NCode™ miRNA First-Strand cDNA Synthesis Kit 
(Invitrogen, Carlsbad, CA) according to the manufacturer‟s instructions. Synthesized 
cDNA were diluted 1:20 and stored at -20
o
C prior to RT-qPCR.   
 
5.3.4. RT-qPCR 
A panel of 19 miRNAs expressed in NK and CD8
+
T cells, was selected based on their 
involvement in immune cell function (Table 7). Six small non-coding RNA genes 
(SNORD25, SCARNA17, SNORA73A, RNU5A, RNU1A and RNU6B) (Qiagen, Hilden, 
Germany) were assessed using GeNorm to determine their usability as reference genes 
(Etschmann et al., 2006). RNU1A was found to be the most stable and therefore served 
as the endogenous reference control for all miRNAs assessed in this study. RT-qPCR 
was performed in a CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). 
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The final reaction volume (10µL) included 1× iQ SYBR-Green Supermix (Bio-Rad, 
Hercules, CA), 200nM of each primer and 4µL of diluted cDNA. Primer pairs consisted 
of a miRNA-specific forward primer (Zhang et al., 2009) and the universal RT primer 
(Invitrogen, Carlsbad, CA). The RT-qPCR conditions were 95°C for 3 minutes, 
followed by 45 cycles of 95°C for 10s, 57°C for 30s and generation of melt curves at 
65°C to 95°C for the detection of secondary amplicons (Mestdagh et al., 2009). All 
reactions were performed in triplicate with each reaction plate containing an equal 
number of CFS/ME and non-fatigued controls, a calibrator control derived from a pool 
of all cDNA samples and a no template control (NTC). PCR amplification efficiencies 
(85-100%) for each primer pair was calculated using a 4-log serial dilution of the 
calibrator sample and efficiency correction was applied to the data during analysis. 
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Table 7: Summary of miRNA investigated, including their targeted messenger RNAs 
and function. 
Gene mRNA Targets Function 
miR-10a BCL2L2, BCL6, 
E2F3 
Induction of cell survival; 
inhibition of transcription 
necessary for germinal centre 
formation; cell cycle regulation  
Apoptosis  
miR-16 BCL2, CDK6 Anti-apoptotic; regulation of cell 
cycle 
miR-15b CDK6, BCL2, ARL2 Anti-apoptotic; cell cycle 
progression; regulation of STAT3 
miR-107 PTEN Regulates AKT-mTOR signalling; 
tumor suppression  
miR-128b APAF1, BAG2 Anti-apoptotic 
miR-146a NFKB1 Inflammation; cell differentiation; 
apoptosis 
miR-191 IL2RA, BCL214 Regulation of apoptosis 
miR-21 TLR4, PITX2, 
EGR2 
Activation of NFκB; regulation of 
gene expression; regulation of 
embryo development 
Cell 
proliferation 
miR-223 E2F1,NFIA, 
MEF2C 
Regulation of cell proliferation; 
regulation of cell cycle genes; 
activation of transcription and 
replication 
miR-17-5p MAPK9, RBL2, 
TNFRSF21, 
TGFBR2 
Phosphorylation of transcription 
factors; chromatin Maintenance; 
activation of immune factors 
miR-150 C-MYB, NOTCH3, 
EIF4B 
Activation of transcription factor; 
regulation of receptor function 
miR-103 ARL2, DICER, 
TGIF2 
Formation of RISC complex; 
repression of transcription 
Immune 
functions 
miR-106b STAT3 Transcription activation 
miR-126 ITGA6 Cell adhesion 
miR-142-
3p 
IL6ST Signal transduction 
miR-146-
5p 
EGFR Phosphorylation of proteins 
miR-152 HLA-G, DNMT1, 
EIF4G3 
Antigen presentation; methylation 
miR-181 EGR1, HOXA11, 
TCL1, BCL215 
Regulation of transcription; 
phosphorylation  
Let 7a E2F2,  Activation of transcription 
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5.3.5. Data and Statistical Analysis 
The PCR data were analysed using the CFX Manager v1.6 (Bio-Rad, Hercules, CA). 
Baseline subtractions and threshold settings above background were applied to all data. 
The calibrator sample was used to normalize inter-assay variations, with the threshold 
coefficient of variance (CV) for intra-assay and inter-assay replicates <1% and <5% 
respectively. Following efficiency correction normalized expression (Cq) was 
calculated with miRNA expression normalized to RNU1A levels and the calibrator 
control. Expression values were log2 transformed and the median expression value for 
the non-fatigued group was set to zero. Data was analysed using the software packages 
SPSS 18 for Windows (SPSS Inc., Chicago, IL) and GraphPad Prism 5 (GraphPad 
Software, San Diego, CA). For miRNA analysis unpaired groups of values were 
compared according to the non-parametric Mann-Whitney test. Statistical significance 
was set at P ≤ 0.05. ANOVA was used in analysing the results in Table 1 where results 
with P ≤ 0.05 were classified as significant. 
 
5.4. Results 
5.4.1. Attributes of Participants 
Participants from this study were randomly selected from a cohort of participants with 
known decreases in NK and CD8
+
T cell cytotoxic activity (Brenu et al., 2011). Full 
blood counts were performed prior to cell isolation and gene expression. There were no 
significant changes in white blood cell counts between CFS/ME patients and controls, 
however, mean platelet volume was significantly different between the two groups 
(Table 8). 
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Table 8: Characteristics of CFS/ME and Non-fatigued Control Participants  
Parameters Control (n=30) CFS/ME (n=30) *p-values 
Sex: Female 22 23  
         Male 8 7  
Mean Age  45.3±11.7 41.8±9.6 0.11 
Height (cm) 167.47±13.2 167.9±8.9 0.16 
Weight (lbs) 169.8±140.7 159.8±46.5 0.11 
White Blood Cells 6.16 ± 0.25 5.17 ± 0.19 0.17 
Lymphocyte (%) 35.02 ± 1.37 38.18 ± 0.10 0.10 
Monocytes (%) 5.72 ± 0.30 6.00 ± 0.33 0.56 
Granulocyte (%) 59.28 ± 1.48 54.99 ± 1.52 0.07 
Lymphocyte (x10
3
/µL) 2.07 ± 0.11 2.12 ± 0.08 0.75 
Monocytes (x10
3
/µL) 0.32 ± 0.02 0.33 ± 0.02 0.67 
Granulocyte (x10
3
/µL) 3.71 ± 0.22 3.21 ± 0.17 0.09 
Red Blood Cells 
(x10
6
/µL) 4.56 ± 0.04 4.36 ± 0.05 0.01* 
Haemoglobin (g/L) 136.30 ± 1.41 131.70 ± 1.52  0.05* 
Haematocrit (%) 41.57 ± 0.59 38.77 ± 0.50 0.00* 
MCV 84.78 ± 1.61 88.44 ± 0.73 0.05* 
MCH 33.74 ± 1.91 30.36 ± 0.23 0.09 
MCHC 321.65 ± 10.30 341.29 ± 1.35 0.07 
RDW 13.94 ± 10.91 12.58 ± 0.14 0.06 
PLT 238.30 ± 10.40 237.93 ± 8.19 0.98 
MPV 7.02 ± 0.08 7.24 ± 0.12 0.18 
 
  
 *significance set at p ≤ 0.05 
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5.4.2. Cell Purity and Recovery 
High levels of purity (>93%) were observed following isolation and enrichment. The 
rate of recovery was measured as a percentage of the cells isolated following 
enrichment to the expected number of NK or CD8
+
T cells present in the volume of 
venous blood collected (Figure 20). The rate of recovery was higher for the NK (>90%) 
cells in comparison to the CD8
+
T cells (>83%) (Figure 20). 
 
 
Figure 20: The purity of NK and CD8
+
T cells. Minimal contamination from other 
cells types was observed as represented by the graphs. The white bars denote the non-
fatigue control group (n=30) while the black bars depict the CFS/ME group (n=30). 
Results are presented here as means ± SEM. 
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5.4.3. RT-qPCR Results 
The choice of a stable reference gene is critical for accurate gene experiment analysis, 
therefore a number of the reference genes were examined to determine the best possible 
gene to use. Expression of non-coding RNAs varied in both the NK and the CD8
+
T cells 
(Figure 21). In both the NK and CD8
+
T cells despite the slight discrepancies in 
expression, there were no significant differences between the two groups on measures 
of expression of the reference genes. RNU1A was determined to be the most stable 
reference gene for both cell types; in addition its relative abundance was most similar to 
the average abundance of the miRNAs investigated. Stability of reference genes were 
determined using the M values. M values refer to the average pair wise deviations of 
one reference gene to other reference genes. This deviation relates to the differences in 
the log2-transformed expression standard deviation of one gene to another. Therefore 
the stability of reference gene decreases at high M values compared to low M values. 
The M values for four snRNAs were much lower in both the NK and CD8
+
T cells.  
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Figure 21: Expression profile of non-coding snRNAs in NK cells and CD8
+
T cells. The 
figure represents all the snRNAs tested for use as a stable reference gene. GeNorm 
threshold value (1.5) is indicated with a dashed line. 
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The expression levels of 19 miRNAs were compared between CFS/ME and non-
fatigued controls. Overall, NK cells had the most downregulated miRNAs in the 
CFS/ME population compared to the non-fatigued controls. Of the miRNAs selected, 
eight have regulatory roles involving apoptosis, and of these, four (miR-10a, miR-146a, 
miR-191 and miR-223) were found to be significantly decreased (Figure 22A) in the NK 
cells while none were significantly decreased in the CD8
+
T cells (Figure 22B). 
Similarly of the six miRNAs involved in cell proliferation that were investigated, four 
(miR-17-5p, miR-21, miR-106 and miR-152) were significantly reduced in the NK cells 
(Figure 23A). A two-fold decrease in miR-21 was also observed in the CD8
+
T cells of in 
the CFS/ME group (Figure 23B). Of the remaining five miRNAs with broad function in 
immunity, only miR-103 was significantly decreased in NK cells (Figure 24A and 24B). 
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Figure 22: Expression profile of miRNAs involved in apoptosis. Relative 
expression data presented as boxplots for miRNAs involved in cell proliferation in A) 
NK cells and B) CD8+T cells. Boxes indicate the interquartile range (25%-75%) with 
the horizontal bar within each box indicating the median. The whiskers show the 
minimum and maximum values.*P < 0.05 vs. non-fatigued control. 
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Figure 23: Relative expression data presented as boxplots for miRNAs involved in cell 
proliferation in A) NK cells and B) CD8+T cells. Boxes indicate the interquartile range 
(25%-75%) with the horizontal bar within each box indicating the median. The whiskers 
show the minimum and maximum values.*P < 0.05 vs. non-fatigued control. 
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Figure 24: Relative expression data presented as boxplots for miRNAs involved in 
immune function in A) NK cells and B) CD8
+
T cells. Boxes indicate the interquartile 
range (25%-75%) with the horizontal bar within each box indicating the median. The 
whiskers show the minimum and maximum values.*P < 0.05 vs. non-fatigued control. 
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5.5. Discussion 
We examined the expression of miRNAs and contribution of miRNAs to the immune 
profile of cytotoxic cells, that is NK and CD8
+
T cells, in CFS/ME patients. Non-coding 
RNA molecules affect physiological processes and certain pathological conditions. Our 
patient groups had similar cell numbers signifying that CFS/ME is not associated with 
changes in cell numbers. Similarly, there were no significant differences in the number 
of cells isolated from each group. However, mean platelet volume was reduced in the 
non-fatigued control in comparison to the CFS/ME patients; this may be due to 
individual characteristics and the heterogeneous nature of CFS/ME. Mean platelet 
volume has been reported elsewhere to be decreased in CFS/ME patients and this was 
not associated with heightened platelet activation or a hypercoagulable state (Kennedy 
et al., 2006). This study has shown significant down-regulation in the expression of 
miRNAs in CFS/ME population in comparison to a non-fatigued control group. These 
findings implicate miRNAs in the pathogenesis of CFS/ME, possibly relating to the 
cytotoxic function of NK and CD8
+
T cells which has consistently been shown to be 
decreased in patients with CFS/ME (Brenu et al., 2010, Klimas et al., 1990, Maher et 
al., 2005, Fletcher et al., 2010). If cytotoxic activity of NK cells is deemed a possible 
biomarker for CFS/ME (Fletcher et al., 2010), then it is imperative to determine all 
components of this process that may be compromised.  
 
Natural Killer and CD8
+
T cells are important apoptosis inducers, therefore, a down 
regulation in miR-10a, miR-146a, miR-223 and miR-191 may affect the efficiency of 
these cells to induce apoptosis of target cells (Subramanian and Steer, 2010). These 
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miRNAs promote apoptosis by targeting the 3‟UTR region of BCL2, CDK6 and BAX, 
thus inhibiting their expression at the post-transcriptional level and potentially leading 
to increased programmed cell death (Nishi et al., 2010). Although the action of these 
miRNAs in cytotoxic cells is not explicitly known, the genes targeted by these miRNAs 
(Table 2) may suggest an involvement in the cytotoxic activity of NK cells (Xia et al., 
2009, Satzger et al., 2010). Hence a decrease in their expression may reduce the 
induction of cell death and potentially affect the commitment of these cells to trigger 
apoptosis of viral infected cells in CFS/ME. Interestingly, miR-146a is modulated by 
NFκB and suppresses the expression of Toll-like receptor signalling related proteins 
TRAF6 and IRAK1 in immune cells (Taganov et al., 2006, Kawai and Akira, 2007, 
Shen et al., 2008, Hurst et al., 2009). This results in a decrease in TNF-α and helps to 
maintain inflammatory tolerance promoting cell survival and preventing the occurrence 
of hyperactive immune system (Nahid et al., 2009). In our CFS/ME patients TNF-α 
secretion by PBMCs after mitogenic stimulation was significantly increased at the time 
these measurements were performed (Brenu et al., 2011). NFκB also regulates the 
expression of pro-inflammatory cytokines TNF-α, IFN-γ, IL-1β, IL-2 and IL-12 
(Nakasa et al., 2008), hence a decrease in miR-146a may be associated with decreases 
in NF-κB thus influencing cytokine expression. Incidentally, significant decreases in 
IFN-G were observed in the NK cells from our CFS/ME cohort compared to the non-
fatigued controls (Brenu et al., 2011). This suggests a possible decrease in IFN-G 
induced cytotoxic activity in CFS/ME patients.  
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Additionally, miR-191 facilitates p53 function by targeting inhibitors of p53 such as 
Mdm4 (Wynendaele et al., 2010), hence low levels of miR-191 may affect cell cycle 
events related to p53 regulation in CFS/ME patients. Using the microrna.org 
(http://www.microrna.org) database we also found potential target sites for miR-191, 
these include BCL214 and IL2RA. A direct association of miRNAs and cytotoxic 
activity may be associated with miR-152 which targets inhibitory human leukocyte 
antigen–G (Zhu et al., 2010). CFS/ME patients have reduced cytotoxic cell function and 
miR-152 may be implicated in this pathway. Importantly, miR-223 has been shown to 
target the 3‟UTR region of the GZMB mRNA in mice (Fehniger et al., 2011). Although 
it is not known what other miRNAs target granzymes, in our previous study a reduction 
in GZMA and GZMK  was observed in the CFS/ME group in comparison to the non-
fatigued controls (Brenu et al., 2011). Granzyme function and regulation are perhaps 
associated with the presence of certain miRNAs at the 3‟UTR regions of these 
granzyme genes.  
 
The miRNAs, miR-21, miR-106, miR-152 and miR-17-5p promote cell proliferation 
(Chung et al., 2010, Pan et al., 2011, Subramanian and Steer, 2010). They inhibit 
apoptosis by negatively regulating apoptotic tumour suppressor related genes PDCD4, 
PTEN, TMPI and RECK (Li et al., 2009, Asangani et al., 2008). The observation of 
decreases in these miRNAs is counter-intuitive as similar findings were observed in the 
apoptotic promoters. This presupposes that these miRNAs may be involved in other 
aspects of immune function in CFS/ME. Similarly, these miRNAs also regulate certain 
cytokines produced by NK cells. For example miR-21 down regulates IL-12 which 
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inhibits cytotoxic activity (Mehrotra et al., 1993), thus a down regulation in miR-21 
results in an over-expression of IL-12 which may severely dampen cytotoxic activity in 
NK cells. miR-21 is important during the development and differentiation of effector 
CD8
+
T cells (Salaun et al., 2011a), although the purpose of this increase is unclear. 
During pathogen invasion or immune insults CD8
+
T cells and NK cells may be primed 
by miR-21 and this may facilitate the cytotoxic activity of these cells as they both 
showed a similar decrease in miR-21. miR-103 was significantly decreased in the NK 
cells of CFS/ME patients.  It may have a role in the creation of the RISC (Tan et al., 
2011).  
 
Parallels can be drawn between the findings in this study and our previous work. In 
particular, miR-146a and miR-21 regulate FOXP3 and Treg function (Rouas et al., 
2009), which was observed to be compromised in our previous study (Brenu et al., 
2011). Similarly, decreases in the expression of miR-152 and miR-21 may be 
responsible for the reduced cytotoxicity of NK and CD8
+
T cells respectively in 
CFS/ME patients (Brenu et al. 2011). Heightened levels of miR-152 may promote 
effective NK cytolytic activity while miR-21 is vital for the delineation of CD8
+
T cells 
in to effector cells (Salaun et al., 2011; Zhu et al., 2010).  
 
The above mentioned miRNAs may serve as potential biomarkers for diagnosing and 
identifying CFS/ME patients. The methodology described in this paper may be tedious 
in clinical settings, however, identification of miRNA biomarkers using plasma or 
serum may be more useful. Analysis of circulating miRNAs in plasma and serum can 
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serve as biomarkers for cancer and other autoimmune diseases (Chen et al., 2008). 
Identification of miRNAs as biomarkers for CFS/ME may increase our understanding of 
the disease presentation and establish better diagnostic strategies for these patients.   
 
5.6. Conclusion 
In summary, miRNAs may play a role in immunological changes associated with 
CFS/ME. This study has identified miRNAs that may be used as potential biomarkers 
for CFS/ME, specifically, miR-146a, miR-223 and miR-21. Although, the current 
literature on the influences of these miRNAs on NK and CD8
+
T cell related lytic 
proteins, receptors and cytotoxic activity is limited, the presence of similar expression 
levels of miRNAs in both cells suggests a common pathway of the miRNAs in these 
cells.  Cells that are regulated by these miRNAs could be important in understanding the 
mechanism of CFS/ME. Further studies are required to determine the exact genes 
regulated by these miRNAs in cytotoxic cells and their longitudinal expression patterns. 
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6. Final Discussion and Conclusion 
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This project has identified NK cytotoxic activity and NK phenotypes as potential 
biomarkers for CFS/ME. Additionally, this project has also for the first time identified 
novel immune parameters involved in the dysregulated immunological pathway in 
CFS/ME. These parameters include FOXP3, VPACR2 and miRNA and the relevance of 
these findings to CFS/ME is discussed below. 
 
The establishment of decisive biomarkers for CFS/ME facilitates proper diagnosis and 
alleviates patient distress and financial burdens. Generally, biomarkers are key cellular 
or molecular events that are used as indicators of a biological state such as a specific 
disease. They can be measured in human body fluids as an indicator of normal 
biological functions, pathogenic processes and pharmacological responses to therapeutic 
intervention using available technologies (Naylor, 2003). For a biomarker to be useful 
they have to display certain important characteristics which include determination of the 
duration of a disease, recognition of possible pathways related to the disease, detect 
variability and modifications, decrease incidences of misclassification, are highly 
reliable, valid and repeatable (Mayeux, 2004). This study has identified a number of 
parameters with properties that make them potential biomarkers for CFS/ME diagnosis. 
 
The results from this project illustrate significant decreases in cytotoxic activity, NK 
phenotypes, GZMA, GZMK, IFNG mRNA and miRNA genes with significant increases 
in PRF1 mRNA, FOXP3 and VPAC2R proteins in CFS/ME patients compared to non-
fatigued controls. Similarly in CFS/ME patients, compared to the non-fatigued controls, 
cytokine levels were inconsistent with no exact pattern yet discernible. Most gene 
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studies on CFS/ME have focused substantially on mRNA expression with little focus on 
small non-coding miRNAs. Despite the limited knowledge on miRNAs, a number of 
molecules have been implicated to be important immune and physiological functions; 
therefore they may have a role in CFS/ME. 
 
Overall, the results emanating from this study strongly support an inept immune system 
in CFS/ME exemplified by decreases in cytotoxic activity, granzyme gene expressions 
(GZMA and GZMK), NK phenotypes and miRNAs with increases in perforin gene 
expression (PRF1), FOXP3, VPAC2R and differential expression of cytokines. The 
immune markers investigated were selected based on their salient role in innate and 
adaptive immune function. The heterogeneity and persistence of CFS/ME over many 
years or even decades with differing levels of severity, necessitates an inquiry into the 
condition of immune compromises during the course of the disease. Moreover, as this 
project explores biomarkers for CFS/ME it is obligatory to establish the pattern and 
stability of these markers over time before we can classify them as clinically useful 
markers for CFS/ME. Therefore a number of these immune parameters, specifically, 
cytotoxic activity, NK phenotypes and cytokines, were assessed over a period of 12 
months.  
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6.1. Impaired Cytotoxic Activity in CFS/ME 
The observation of a decrease in cytotoxic activity has been previously reported (Klimas 
et al. 1990; Fletcher et al. 2010; Maher et al. 2005). Recently, in cross-sectional studies 
cytotoxicity has been identified as an important marker in CFS/ME (Fletcher et al., 
2010). The significance of the present findings is that these cytotoxic changes were 
confirmed at different time points in the course of the disease, which has not been 
previously shown. Thus, in the present study, NK lysis activity remained consistently 
decreased throughout the duration of the study, i.e. at baseline, 6 and 12 months. This 
not only confirms an involvement of cytotoxic activity in CFS/ME but also 
demonstrates that this persists overtime. Although, the causal factor eliciting these 
changes is not fully known, a few propositions can be put forward. These include 
decreases in cytolytic molecules mRNA and protein levels (Maher et al. 2005, Saiki et 
al., 2008). At baseline cytotoxic activity was measured in conjunction with granzyme 
and perforin. The mRNA expression levels of granzyme A (GZMA) and granzyme K 
(GZMK) were significantly decreased while perforin (PRF1) was increased in the 
CFS/ME patients compared to non-fatigued controls (Brenu et al. 2011). Perforin and 
granzymes are important lytic proteins required for the granule dependant cytotoxic 
activity pathway (Dustin and Long, 2010). Perforin protein has been suggested to act as 
a medium to facilitate the entry of granzymes into the target cells where granzymes 
induce apoptosis by inducing the release of anti-apoptotic BCL2, caspase activation or 
double and single stranded DNA nicks (Cullen et al., 2010).  
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This is the first study to observe a decrease in GZMK gene expression in CFS/ME 
patients. At the protein level, both GZMA and GZMK act independently of caspases 
and induce the accumulation of reactive oxygen species (ROS) in the mitochondria 
(Beresford et al., 1999). GZMA shares homology with GZMK, they are tryptases and are 
both found co-located at chromosome 5q11 (Bovenschen et al., 2009, Hua et al., 2009, 
Jenkins et al., 2008). GZMA acts by activating the caspase-independent programmed 
cell death pathway, using the substrate enzyme pro-interleukin 1β which activates pro-
inflammatory IL-1 (Irmler et al., 1995). The exact role of GZMK is not fully known, 
nonetheless it is thought that in the absence of GZMA, GZMK is able to salvage the 
caspase-independent programmed cell death pathway and where they are both 
decreased, it may suggest failure to effectively remove pathogens (Pardo et al., 2009). 
Additionally, GZMA and PRF1 are polymorphic, thus, phenotypic differences within 
the gene may affect their effectiveness to induce effectual pathogen lysis (Girnita et al., 
2009, Padovan et al., 2011). Cytokines such as IL-2 regulate the expression of GZMA 
and PRF1. Differential expression in these cytokines may affect the expression of these 
genes and consequently cytolysis in all NK phenotypes (Janas et al., 2005). 
Transcriptional and post-transcriptional processes contribute to differential expression 
in GZMA, GZMK and PRF1 for example activation of T cell receptor and co-
stimulation from cytokines are fundamental mechanisms for inducing the expression of 
these molecules (Ruike et al., 2007). Similarly, signal transduction pathways involving 
the interaction between cytolytic genes and transcription factors initiate the expression 
of these molecules and their transcripts (Chowdhury and Lieberman, 2008). This 
suggests that the aberrant expression of these molecules in CFS/ME patients entails 
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other molecular networks that are probably dysregulated in CFS/ME. As mentioned 
previously mRNA expression is not necessarily representative of protein expression. 
However, in the occurrence of differential expression of GZMA, GZMK or PRF1 
cytotoxic activity can be severely compromised.  
 
The decrease in GZMA and GZMK gene expression was not correlated with a decrease 
in PRF1 and this is consistent with the observation that perforin and granzymes genes 
may work through different pathways (de Saint Basile et al., 2010). These results may 
translate into decreases in granzyme proteins however, as mRNA expressions are not 
wholly indicative of protein levels this may not apply in the case of PRF1. Perforin 
proteins have been shown to be significantly decreased in some cases of CFS/ME 
(Maher et al. 2005).  
 
A decrease in cytotoxic activity corroborated with an increase in PRF1, which may 
reflect inadequacies in other regulatory mechanisms such as transcription factors that 
control the expression of these lytic genes. These transcription factors may be 
disproportionately expressed, thus translating into differential expression of these genes. 
In certain melanomas, elevated levels of PRF1 have been reported and these were 
associated with deficits in cytotoxic activity (Guillot et al., 2005). CD2 has recently 
been shown to play a pivotal role in the reduced NK cytotoxic activity noticed in NK 
cells of CFS/ME patients. Importantly, CD2 acts as a co-stimulatory molecule and 
stimulates NK cells. This activates the src-family kinases leading to the production of 
inositol triphosphates and efficient target killing (Cheent and Khakoo, 2009). Other 
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possible contributors to the reduced cytotoxic activity may be related to cytotoxic 
receptors such as the killer cell immunoglobulin-like receptors (KIRs). In some 
CFS/ME patients, there is evidence indicating an increase in KIR3DS1 with indications 
for a loss in HLA-Bw4Ile80 binding motif for the KIR3DL1 and KIR3DS1 receptors 
(Pasi et al., 2011).  A high incidence of inhibitory KIR receptors in combination with a 
deficiency in binding motifs may oppose efficient cytolysis and increase disease 
prevalence (Blackwell et al., 2009). Generally, HLA-B and its clusters tend to have 
protective effects that suppress infections. Similarly, a decrease in cytokines such as IL-
18 can affect perforin and granzyme production and effective lysis (Hyodo et al., 1999). 
 
Natural Killer cytotoxic activity was not affected by seasonal variations in CFS/ME 
patients as it remained consistent over time confirming that NK cytotoxic activity is a 
hallmark of CFS/ME patients. However, there may be a strong association between 
cytotoxic activity and miRNA expression pattern as these molecules were shown to be 
decreased in the cytotoxic cells (as detailed in Chapter 5). MicroRNAs regulate the 
transcription of genes and it is highly plausible, that most of the genes they modulate 
are responsible for NK and CD8
+
T cell lysis of pathogens. A down regulation makes 
these cells redundant in the overall immune function of CFS/ME individuals. 
 
The observation that the reduced cytotoxic activity remains stable over time makes it a 
useful biomarker for CFS/ME and thus advocates its use for diagnosing CFS/ME. The 
use of cytotoxic activity may encourage early detection of CFS/ME. Incidentally 
cytotoxic activity may be the hallmark of CFS/ME and its inefficiency ultimately 
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generates other immune function deficits as noted in this study. Additionally, using 
cytotoxic function as a primer for diagnosing CFS/ME may assist in differentiating 
subtypes of CFS/ME patients. CFS/ME patients have been previously subgrouped based 
on their symptoms and severity of illness. Subtyping of patients under these conditions 
when applied to genomic studies has successfully identified both universal and 
distinctive physiological pathways that are associated with these subtypes of CFS/ME 
patients (Kerr et al., 2008). Subtypes of CFS/ME patients may exist in the studied 
population and this may be related to cytotoxic activity. Additionally, in-depth 
clustering analysis of miRNAs may be associated with disease severity and cytotoxic 
activity.   
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6.2. NK Phenotypes 
NK phenotypic studies demonstrated significantly lower levels of 
CD56
bright
CD16
negative
NK cells in CFS/ME patients compared to the non-fatigue 
controls. CD56
dim
CD16
positive
NK cells remained unchanged in both CFS/ME and non-
fatigued controls. The CD56
bright
CD16
negative
NK cells are highly proliferative, less 
cytotoxic and produce significant amounts of cytokines, IL-10, IL-13, IFN-γ, TNF-α 
and GM-CSF compared to the CD56
dim
CD16
positive
NK cells (Cooper et al., 2001). The 
CD56
dim
CD16
positive
NK cells are more cytotoxic and secrete less cytokines (Cooper et 
al., 2001). It would be expected that a decrease in cytotoxic activity may transpire from 
reductions in the main cytotoxic NK cells, that is, CD56
dim
CD16
positive
NK cells. 
However, this was not the case in this cohort of CFS/ME patients. Considering the 
function of CD56
dim
CD16
positive
 and The CD56brightCD16negativeNK cells, reduced levels 
of CD56
bright
CD16
negative
NK cells are detrimental to efficient innate immune function. 
CD56
bright
CD16
negative
NK cells activate dendritic cells and monocytes to respond to 
pathogen invasion (Vitale et al., 2004, Dalbeth et al., 2004). Additionally, the adhesion 
molecule CD2 is strongly expressed on CD56
bright
CD16
negative 
NK cells and facilitates 
the migration of these NK cells into the secondary lymphoid tissues (Cooper et al., 
2001, Poli et al., 2009). Perhaps in CFS/ME CD2 expression is decreased and this may 
be related to a limited number of CD56
bright
CD16
negative 
NK cells in these sites.  
 
Another possible explanation for the decrease in CD56
bright
CD16
negative 
NK cells may be 
related to the notion of an increase in lymphocyte apoptosis among some CFS/ME 
patients (Kennedy et al., 2004). This is uncertain as CD56
bright
CD16
negative 
NK cells are 
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more resistant to apoptosis owing to their ability to resist reactive oxygen species 
(Harlin et al., 2007). Reductions in CD56
bright
CD16
negative 
NK cells may reflect the low 
expression of IFN-γ in the NK cells of the CFS/ME patients. IFN-γ produced by NK 
cells plays a pivotal role in T cell activation by promoting Th1-like immune responses, 
generation of cytotoxic and memory T cells, while suppressing inflammation and 
infection by suppressing Th17 cytokines (Agaugue et al., 2008, Mailliard et al., 2003, 
Martin-Fontecha et al., 2004, Robbins et al., 2007, Lo et al., 2008). 
 
Immune cell phenotyping to date in general has not been the most reliable marker for 
differentiating patients with CFS/ME from patients without the condition. This may 
have occurred due to the lack of exclusivity within the lymphocyte phenotypes. Most of 
the markers used in delineating lymphocyte phenotypes are partially expressed on most 
of these cells. Selection techniques that preferentially distinguish lymphocyte 
populations as used in this study may be the most optimal method of determining the 
exact phenotype within the major lymphocyte subsets that show inequality in their 
levels. Currently, this implies a potentially costly biomarker, therefore, administering it 
in the clinical setting may be difficult. These findings also open avenues for targeting 
new treatment options where the aim might be to develop pharmaceutical targets that 
are cell specific. 
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6.3. Impaired Distribution of immune regulators 
The FOXP3 and VPACR2 protein expressions were increased in the CFS/ME patients 
in comparison to the non-fatigued controls. Profound increases in FOXP3 are 
suggestive of amplifications in the suppressive activities of regulatory T cells. This 
implicates possible increases in both anti- and pro-inflammatory immune reactions in 
CFS/ME patients. Levels of FOXP3 are correlated with the suppressive function of 
Tregs. Hence, it is possible that FOXP3 increased in an attempt to decrease potential 
incidences of over expressed pro-inflammatory reactions in the immune system of 
CFS/ME patients. At baseline an increase in IL-10 occurred in conjunction with an 
increase in FOXP3. This to some extent is indicative of heightened immune activation 
in CFS/ME. Heightened levels of FOXP3 have been used as markers for certain 
diseases with compromised immune function such as HIV where FOXP3 levels were 
increased. This was correlated with disease severity (Suchard et al., 2010). 
Additionally, these increases in FOXP3 may be related to compromises to receptors that 
reduce the suppression. Presently, it is not known which types of Tregs were increased 
in the CFS/ME patients. It is possible that these were adaptive Tregs, differentiated 
from conventional Tregs due to the presence of high levels of antigens in the circulation 
(Sakaguchi et al., 2008). Deficiencies in FOXP3 typically suggest an autoimmune 
disease while heightened levels of FOXP3 have been observed in a number of human 
carcinomas (Wang et al., 2009). An increase in the levels of FOXP3 may be detrimental 
as this can severely decrease viral elimination by overly suppressing important anti-
inflammatory immune responses required for pathogen clearance (Belkaid, 2008).   
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Heightened levels of FOXP3 reduces IL-17 as the available number of cells, i.e. the 
Th17 cells, are reduced in the presence of high levels of FOXP3 (Ziegler and Buckner, 
2009). This may explain the observed reduced levels of IL-17 cytokines at 12 months. 
High levels of FOXP3 can also inhibit the activation of CD4
+
T and CD8
+
T cells, which 
consequently decreases CD8
+
T cell cytotoxicity (Xu et al., 2009, Guo et al., 2010).  
FOXP3 over-expression also reduces the following cytokines IL-2, IL-4, IL-17 and 
IFN-γ (Zhu and Paul 2008). Elevations in FOXP3 Tregs confers a hypo-active immune 
state (Yun et al., 2010) and in our CFS/ME patients this possibly affects all other known 
immune functions modalities including NK cell and CD8
+
T cell cytotoxic activity (Hinz 
et al., 2007). Whilst TGF-β was not measured in this study, elevations in FOXP3 may 
suggest an increase in TGF-β which subsequently inhibits the activity of NK cells by 
repressing the action of IFN-γ, TNF-α and GMCSF, and also reducing the action of 
cytotoxic receptors NKp30 and NKG2D (Marie et al., 2006, Bellone et al., 1995, 
Castriconi et al., 2003). These may therefore have additional effects that contribute to 
the decrease in cytotoxic activity. 
 
In Treg cells, the RNase Dicer is an important enzyme that determines the type of 
phenotype that is produced, and deletion of Dicer results in a more aggressive 
phenotype (Liston et al., 2008). This suggests an important role of miRNAs in 
regulating Treg development and function. Regulation of FOXP3 expression may be 
associated with miR-21 and miR-31 which confer agonistic and antagonistic function on 
FOXP3 respectively (Redouane et al., 2009). Importantly, miR-146a is most abundant 
in Tregs and regulates the functional capacity of Tregs required to control Th1 related 
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responses including production of IFN-γ by dampening STAT1. Hence miR-146a is an 
important molecule ensuring effective Treg suppressor function (Lu et al., 2010). In this 
study, a down-regulation of miR-146a was observed in NK cells and this may likely 
affect the function of these cells in CFS/ME. The exacerbated expression of FOXP3 
expression in CFS/ME may not necessarily correlate with excessive suppression. 
 
Additionally, a compromise in VN function may be a hallmark of CFS/ME. VNs during 
aberrant immune regulation are able to decrease TNF-α, IL-6 and increase Il-10. In the 
current project, the increase in IL-10 and VPAC2R may be due to the action of VNs to 
reducing the pro-inflammatory state occurring as a result of an increase in TNF-α and 
IFN-γ. However since a decrease in TNF-α and IFN-γ did not occur it is likely that this 
mechanism is compromised in CFS/ME, that is the anti-inflammatory reaction from IL-
10 and receptor activations are not enough to inhibit over-reactive pro-inflammatory 
reactions (Abad et al., 2001). VPAC receptor activation stimulates downstream second 
messenger systems including adenosine and the PKA pathways, the result of which is 
the production of cAMP. Activation of a high number of VPAC receptors may increase 
adenosine and consequently intracellular cAMP which weakens cytotoxic activity 
(Hoskin et al., 2008). VPACR regulation is related to the normal circadian function and 
changes in their expression may perturb the circadian rhythm (Pretzmann et al., 2008), 
possibly explaining the sleep disturbances among CFS/ME patients. However elevation 
in VPAC2R may not necessarily mean an increase in VIP as in some cardiomyopathies 
increases in VPAC2R mRNA was not associated with an increase in VIP (Dvorakova et 
al., 2006). The exact role of high VPAC2R is currently not known and most measures 
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of VPAC2R were performed on brain samples hence it is very difficult to understand 
how these may have contributed to the immune profile in CFS/ME patients. 
Overexpression of VPAC2R may decrease cytotoxic activity in particular FasL directed 
cytotoxicity by inhibiting the expression of FasL on CD8
+
T cells (Delgado and Ganea, 
2000a). Similarly, VIP inhibits IL-12 and this acts to decrease cytotoxicity of NK and T 
cells (Delgado et al., 1999c).  
 
Heightened immune activation is present in CFS/ME and in an attempt to modulate 
these abnormal reactions, the immune system inadvertently increases known 
mechanisms of suppression. In CFS/ME patients these suppressive reactions persist for 
a longer duration as the immune system is not able to effectively clear these heightened 
immune reactions. However, the converse may be true where discrepancies in the pro-
inflammatory mechanisms alter the immune system. Moreover, high antigen load due to 
pathogen prevalence may account for these observations. Persistent viral or microbial 
antigen load initially activates the pro-inflammatory reactions. These reactions are 
dampened by the anti-inflammatory reactions and at the same time anti-inflammatory 
reactions are activated to restore immune balance. However this overstrains other 
immune activities thus allowing pathogens to persist and avoid elimination. Therefore, 
further studies are required to elucidate and validate the exact role of VPAC2R in 
CFS/ME patients. 
 
Longitudinal assessment of cytokine secretion has previously been measured in a cohort 
of adolescents with severe cases of fatigue. Similar to the results presented here, the 
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cytokine distribution was not consistent over time and also varied at the three different 
time points at which they were measured (ter Wolbeek et al., 2007). The pattern of 
cytokine distribution followed an initial increase in the production of cytokines at the 
initial time point, in the fatigued adolescent this was followed by a drop in cytokine 
levels at 6 months and an increase at 12 months (ter Wolbeek et al., 2007). Similar to 
our findings, anti-inflammatory cytokine IL-10 was significantly increased in the 
fatigued patients compared to the controls at baseline (Brenu et al., 2011, ter Wolbeek 
et al., 2007). Additionally, a cohort of CFS/ME patients within the ter Wolbeek et al. 
(2007) study were shown to have an anti-inflammatory bias in cytokine secretion where 
CFS/ME patients had significantly lower levels of TNF-α and IFN-γ in comparison to 
the fatigued and the non-fatigued controls (ter Wolbeek et al., 2007). This is in contrast 
to the findings from this project where IFN-γ and TNF-α were increased in the CFS/ME 
group relative to the controls (Brenu et al. 2011). The pattern of cytokine secretions was 
attributed to seasonal variations (ter Wolbeek et al., 2007). In the present project 
variations in cytokine distribution were noticed between the two subject populations for 
the duration of the study. The differences in findings between the ter Wolbeek et al. 
(2007) study and this project can be explained by the stimulant used. In our study the 
cells were stimulated with PHA which induces mitogenesis, while in the ter Wolbeek 
(2007) study cells were stimulated with LPS to produce inflammation. Additionally, the 
cytokines at baseline may have increased because of other cell types such as the Treg 
cells. Although cytokine secretions from the Treg cells were not measured, the elevated 
levels of anti-inflammatory IL-10 can be explained by a substantial increase in the 
levels of FOXP3. 
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The fluctuations in cytokine levels suggest that they may not be the best biomarkers for 
CFS/ME. Nonetheless, this may be an indicator for other aspects of the disease such as 
disease progression and disease severity. Per chance cytokine fluctuations correspond to 
disease severity as the patient gets better or worse the cytokine distribution changes in 
that order (Bozza et al., 2005, Cheung et al., 2002, Gardlund et al., 1995, Jacob et al., 
2003, van Deuren et al., 1995). This further suggests that cytokine skewness either 
towards a predominant pro- or anti-inflammatory secretion does not necessarily exist in 
CFS/ME; however, this may potentially reflect the severity of the disease. In our present 
study disease severity was not investigated and this may be a topic for further studies.  
 
Th1/Th2/Th17 cytokine studies were not confined preferentially to CD4
+
T cells but to 
PBMCs, it is possible that production of cytokines by other cells may have contributed 
to the cytokine milieu in the CFS/ME patients this study. NK cells in particular secrete 
high levels of IFN-γ which can increase Th1 immune response and thus cause them to 
secrete both IFN-γ and TNF-α (Martin-Fontecha et al., 2004). They can also regulate 
Th1 immune response by producing IL-10 to decrease Th1 immune reactions (Deniz et 
al., 2008), while causing an increase in Tregs through the production of TGF-β 
(Horwitz et al., 1999, Horwitz et al., 1997). Over-expression of FOXP3 can lower 
cytotoxic activity (Trzonkowski et al., 2006) while an increase in Th17 cells may 
increase lysis through the secretion of IL-21 (Liu et al., 2009). 
 
Natural Killer cell interaction with other immune cells (in particular T cells) is 
dependent on a number of co-stimulatory molecules. Alterations in the expression of 
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these molecules are known to affect T cell function (Sharpe, 2009). For example, 
binding of CD80, CD86, CD70, Ox40 ligand and 2B4 on the NK cells to CD28, CD27, 
Ox40 and CD48 on the T cells translates into effective cytotoxic and memory T cells, 
expansion and proliferation of T cells (Hanna and Mandelboim, 2007). Hence, further 
studies are now required to determine the association of cytokines and disease severity 
in CFS/ME patients. 
 
Moreover, these attributes may relate to the advancement in the disorder. Fluctuations 
in CFS/ME over time presuppose that a unique cytokine profile exists at the initial 
stages of the disease and with the advancement or progression in symptoms these 
become obscured. Hence, cytokines may be useful during early detection of CFS/ME 
and in this way they may contribute to the biomarker panel for CFS/ME. However, 
FOXP3 and VPAC2R are likely candidates for generating CFS/ME biomarkers. These 
parameters in general provide information on the pro- and anti-inflammatory reactions 
in the immune system and are therefore important in regulating cytokine distribution 
patterns. The lack of alignment between FOXP3, VPACR and cytokine pattern in 
CFS/ME presupposes distinct pathways in maintaining and activating these proteins. 
Further validity test are required to confirm these parameters.  
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6.4. The Profile of miRNAs in CFS/ME 
MicroRNAs have only recently been discovered and therefore their exact role in all cell 
types has not yet been characterised (Sun et al., 2010). In this project miRNA gene 
expression was investigated in NK and CD8
+
T cells. Although, the data presented here 
suggests a role for these molecules in immune function especially in cytotoxic cells, the 
exact genes targeted by these miRNAs are yet to be fully determined. Little is known 
currently about these miRNAs in relation to the cells that were measured, but they have 
been examined in cancer and cardiovascular diseases and therefore we have suggested 
similar roles in NK and CD8
+
T cells (Lu et al., 2008). The results from this study 
suggest that miRNAs could be used as biomarkers for diagnosing CFS/ME. As these 
molecules are more stable than mRNA, their role in CFS/ME may be important for 
diagnosis. MicroRNAs could be responsible for the decreases in cytotoxic activity 
noticed in cytotoxic cells.  
 
The observation of a decrease in miRNA levels on CFS/ME patients compared to 
controls may alter their effects on particular genes and possibly promote either a hyper 
or hypo state in immune function by targeting particular genes (Pauley and Chan, 2008). 
The importance of these miRNAs relates to their functional connotations where most of 
them regulated cellular apoptosis, cell proliferation and varying immune related 
pathways. Therefore, an inadvertent decrease in their optimal levels affects their 
function, alters gene expression and possibly affects the regulatory effects of the protein 
they target.  
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Importantly, the observed roles of some of these miRNAs in the regulation of apoptosis 
suggest an essential role of miRNAs in the activation and control of cytotoxic activity. 
For example, miR-223 which showed marked reductions in CFS/ME patients compared 
to non-fatigued controls, targets and regulates the expression of GZMB which is a 
necessary factor in the granule induced exocytosis pathway (Fehniger et al., 2011). In 
the present study GZMB was not measured, however, decreases in the expression of 
GZMA and GZMK were observed (Brenu et al., 2011). It is plausible to infer that miR-
223 possibly also regulated these granzyme genes and this may account for their 
diminished expression. Per chance, a down regulation in miR-223 negatively affects the 
expression pattern of GZMA and GZMK and this may also manifest in the form of 
diminished cytotoxic activity. Notably these patterns of expression in miR-223 and 
GZMA and GZMK were similar in both the NK and CD8
+
T cells indicating that 
cytotoxic activity within these cells entails analogous pathways that are regulated by 
miRNAs. MiR-152 may be important for NK cell cytolysis as increased levels of miR-
152 is beneficial to NK cytolytic activity (Zhu et al., 2010). Nonetheless, phenotypic 
differences within the cells may also account for the lack of efficient cytotoxicity in the 
CFS/ME cohort.  
 
Lymphocyte differentiation, proliferation and expansion are also regulated by miRNAs 
(Belver et al., 2011). For example, miR-21 modulates the differentiation of CD8
+
T cells 
in to the various subsets, thus inefficient cytolysis might ensue from the type of CD8
+
T 
cells present in the circulation (Salaun et al., 2011b). Low expression of miR-21 
possibly contributes to the generation of CD8
+
T cells with less cytotoxic properties or 
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poor memory CD8
+
T cells. CD56
bright
CD16
negative
NK cell decreases in CFS/ME may to 
some extent ensue from the diminished expression in miRNAs that regulate the 
differentiation of NK cells and possibly transcription factors responsible for NK 
delineation.  
  
Activation of the T cell receptor in CD8
+
T cells is an important component of the 
cytotoxic mechanism, however, this also stimulates miR-21 which regulates TCR 
signalling by targeting the RASGRP1 (Sonkoly and Pivarcsi, 2009, Wu et al., 2007b). 
MiR-21 is also induced in other inflammatory diseases (Takagi et al., 2010). If miR-21 
is essential for regulating TCR activities their down-regulation may affect many T cell 
activities such as pathogen recognition, cytokine secretion and cytolysis which are 
dysregulated in CFS/ME. Importantly, miR-21 regulates cytokine production such as 
IL-12 which is responsible for Th1 immune responses (Lu et al., 2009b). In addition, 
miR-21 is activated by NFκB, however it can act to decrease or dampen the NFκB by 
targeting PDCD4, which dampens the activity of NFκB and the induction of pro-
inflammatory responses (Shin et al., 2011, Sheedy et al., 2010). Other miRNAs, 
including miR21, miR-15b, miR-146a and miR-223 have an involvement in the NFκB 
signalling pathway (Ma et al., 2011). Although, it is not known whether NFκB has an 
effect in CFS/ME, their role in pathogen recognition is imperative for immune function. 
They regulate many immune related molecules including chemokines and cytokines 
(Ma et al., 2011). Activation of the NFκB signalling pathway is dependent on the type 
of stimulus present (Miyamoto, 2011). The observation that miR-15b, miR-21 and miR-
223 are down-regulated could suggest an impaired NFκB signalling in these cells. 
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Cytokine distribution in the present study was differentially expressed with no singular 
pattern over time that may be specific for CFS/ME. Despite these shortcomings, 
atypical NFκB signalling either directly or downstream from this pathway as a 
consequence of low miRNA expression may produce perturbations in the inflammatory 
pathways. Anti and pro-inflammatory signalling can be mediated by miRNAs given that 
these molecules regulate a vast majority of genes and their function may be different in 
each cell type. For example, the action of miR-21 on certain genes such as PDCD4 and 
IL-12p35, STAT3 and TLR4, regulates both anti and pro-inflammatory pathways 
necessary to maintain homeostasis (Kumarswamy et al., 2011). Although the present 
findings are limited to NK and CD8
+
T cells, given that miRNAs regulate a plethora of 
immune genes they may be differentially expressed in other immune cells. 
Suggestively, miRNAs may be implicated in the immune compromises in the CFS/ME 
patients. Correspondingly, miR-21 directly regulates FOXP3 expression in regulatory T 
cells (Rouas et al., 2009). These extensive properties of miR-21 in immune function 
strongly suggest a role of this miRNA in most of the altered immune activities in 
CFS/ME. Decreases in miR-21 expression may affect the differential expression of 
cytokines, cytotoxic activity and possibly facilitate the over–expression of FOXP3 via 
other pathways. Thus, miR-21 could be a candidate for a biomarker for CFS/ME. 
 
Additionally, differential expression of miRNAs may exist in other cell types in 
CFS/ME patients and this may prospectively explain the differential cytokine 
distribution and heightened FOXP3 and VPAC2R expression noticed at baseline. 
Importantly, miR-525-5p has been noted to target and down-regulate VPAC1 gene in 
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monocytes (Cocco et al., 2011). As expressions of most miRNAs were decreased in our 
CFS/ME patients, it can be postulated that a similar trend may occur in other immune 
cells and this may prompt an increase in VPACR1 in CFS/ME. Given that miRNAs are 
stable molecules they may also remain stable over time. Here the present study provides 
only baseline data on the miRNAs, however, stability of miRNAs over time can be 
inferred from the maintenance of reduced cytotoxic activity.  
 
Although, only recently discovered, miRNAs are emerging as putative biomarkers in a 
number of neuroimmune disorders and cancers (Duroux-Richard et al., 2011, Yu et al., 
2011). These non-protein coding molecules can be identified both in the intracellular 
and extracellular environment and in both instances they have shown to be reliable 
biomarkers. Importantly, in lung cancer miR-1254 and miR-574-5p have been identified 
as indicators for early onset of non-small cell lung cancer (Foss et al., 2011). Similarly, 
detection of differential expression of miRNAs at different stages of prostate cancer has 
been useful in determining disease progression (Long et al., 2011).  In breast cancer 
over expression of miR-10b and miR-34a in association with a reduced expression of 
miR-195 and let 7a has helped to distinguish between cancer patients and non-cancerous 
tumours (Andorfer et al., 2011, Weigel and Dowsett, 2011). Identifiers for detecting 
hepatocellular carcinoma include miR-21, miR-221, miR-222 and miR-155 (Yoon et al., 
2011). Hence, miRNAs are useful markers for the detection of various cancers. In other 
diseases such as autoimmune Sjogren‟s syndrome, miR-768-39 and miR-574 are 
candidates for diagnosing this disease (Alevizos et al., 2011). Equally, miRNAs are 
relevant in neurological disorders such as Alzheimer‟s disease where at least eight of 
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these miRNAs (miR-9, miR-132, miR-146b, miR-145, miR-29a, miR-129b, miR-423 and 
miR-98) have been identified as candidates for differentiating patients with or without 
Alzheimer‟s disease (Cogswell et al., 2008). Not only have they been identified in 
neurological disease but a vast majority of research has also focused on the role of 
miRNAs in cardiovascular disorders. Studies have identified biomarkers that may be 
associated with myocardial infarction and heart failure (Meder et al., 2010). 
 
MicroRNAs may be recommended as biomarkers for CFS/ME given the present data. 
This is mainly related to the stability of these molecules.  MicroRNAs are found in the 
blood plasma and serum samples and unlike the mRNA these miRNAs are stable and 
highly resistant to RNases (Mitchell et al., 2008, Chen et al., 2008). Uncovering of 
these molecules in the extracellular environment may be a faster and more effective way 
of determining their targets. Moreover, the correlation between miRNAs and different 
stages of cancer or onset of a particular disease may potentially be useful in determining 
and defining subclasses of CFS/ME. In principle, a general trend of reduced miRNA 
expression permits the establishment of miRNA finger printing which may be useful in 
generating a complex of biomarkers with regulatory effect that are specific in CFS/ME. 
Furthermore, significant reductions in similar miRNAs in both cell populations, i.e. NK 
and CD8
+
T cells, signify the existence of analogous pathways that are targets of these 
miRNAs. MicroRNAs may be a more robust approach to biomarker development for 
CFS/ME in view of the fact that CFS/ME is a disorder with a heterogeneous 
presentation. Additionally, miRNA expression patterns may be related to the time 
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course of the disease, perhaps miRNA progressively decreases in expression 
significantly as the disease often persists over decades.  
 
Identification of the exact genes that these miRNAs regulate in NK and CD8
+
T cells 
may help explain the reduced cytotoxic activity in CFS/ME patients.  
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6.5. Limitations 
The study design of the present project has a number of shortcomings. The patient 
group comprised CFS/ME patients who had CFS/ME for many years. Conceivably, a 
subject group that was recently diagnosed with CFS/ME may have been more ideal in 
determining the time course and mechanism of CFS/ME. Although, cytokine 
measurements have demonstrated abnormal levels of Th cytokines in CFS/ME patients 
these were performed on PBMCs, hence they are still not specific and do not 
preferentially provide information on CD4
+
T cell cytokines. Thus, the cytokine 
secretions are representative of the total cytokines secreted by not only T cells but also 
by other PBMCs. Further studies are required to investigate whether the changes and 
elevated levels of FOXP3 noticed in this study are related to receptors such as inhibitory 
CTLA-4. The cytokines examined in the CFS/ME project were based on activated cells 
and this is not representative of the cytokines present in the circulation on the day of 
sample collection. Analysis of cytokines in unstimulated samples may have provided a 
more clear indication of the inflammatory immune profile in CFS/ME. The project did 
not provide information on the cell counts of the different phenotypes of lymphocytes 
investigated. In CFS/ME, the levels of lymphocyte subsets are inconsistent and are 
therefore poor markers for CFS/ME. Additionally, although the miRNA studies suggest 
a role of miRNAs in CFS/ME, it is still not known which genes are targeted specifically 
by these miRNAs. Knowledge of the immune related genes modulated by these 
miRNAs may be important for diagnostic purposes. All the CFS/ME participants in this 
study were taking different medications at the time of the project and medications were 
not part of the exclusionary criteria for this project. Hence, it is likely that some of the 
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immune changes noted in this project may have being influenced by medications or 
supplements taken by the patients.  
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6.6. Further Research 
Following these important findings, further research is now required to examine the 
immunological parameters investigated in this study, in other chronic disorders that 
present with persistent fatigue (such as rheumatoid arthritis or multiple sclerosis) to 
determine if the markers are specific for CFS/ME. Similarly, gene expression of 
miRNAs necessitates longitudinal assessment to determine whether these are stable 
markers for CFS/ME and also the role of these markers in other immune cell types. This 
study focused on only VIP related receptors, however, PACAP receptor PAC1 has been 
associated with many diseases and it may be important to ascertain whether or not 
CFS/ME is related to compromise in all VN receptors. Severity and type of onset 
(gradual or sudden) were not investigated in this research, these may be important 
components of the disease that determine immune presentation, especially cytokine 
distribution as previously highlighted. Lastly, CFS/ME patients are known to take an 
array of medications and supplements in the quest to attain full health. Most of these 
medications have side effects that may affect immune related activities, thus a study 
examining CFS/ME on or off medications may also be necessary. CFS/ME patients 
present with a wide spectrum of symptoms that are identified in many diseases. 
Although, an increase in FOXP3 was noted it is still not known whether this translates 
into increase in suppressive actions by Tregs, thus a further in depth examination may 
disclose the type of phenotype of FOXP3 that is highly expressed in these patients. The 
results have provided salient information on the status of CFS/ME patients that can 
assist in the development of important biomarkers. However, transference of these 
results in to useable biomarkers may be difficult as the techniques and reagents used are 
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costly and time consuming. For example, most of the gene studies were performed on 
isolated cells, and the techniques involved in these isolations are time consuming and 
expensive. Therefore miRNA biomarkers for CFS/ME can only be useful where whole 
blood samples, plasma or serum are used without further isolation of cells. This 
necessitates further investigations into the role of circulating miRNAs in CFS/ME. 
Similarly much work is now required to specifically focus on the status of CD4
+
T cells 
in CFS/ME. The present investigations related to CD4
+
T cells cytokine profiles were 
performed PBMCs, it will be important for future studies to exclusively focus on 
isolated CD4
+
T cells to determine their role in regulating the Th immune complex. 
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6.7. Conclusion 
Diagnosis of CFS/ME based on well established laboratory procedures may not be out 
of reach as our data have highlighted a number of specific immunological markers that 
could be used as biomarkers for CFS/ME. Previous research suggests that CFS/ME is 
characterised by decreases in cytotoxic activity, granzyme A, B and perforin with 
differential expression of genes involved in immune, cellular, metabolic and 
neurological function. However, inconsistencies have been shown across research on 
measures of cytokines and lymphocyte subsets.  
 
The present study adds to the available scientific knowledge on CFS/ME. The results 
accumulated from this research ultimately indicate the importance of longitudinal 
assessment of immune cell markers in CFS/ME. This study has shown for the first time 
consistent decreases in cytotoxic activity and NK phenotypes over a period of 12 
months. This is also the foremost study to report a decrease in granzyme K and an 
increase in perforin in cytotoxic cells of patients with CFS/ME. Similarly, this study has 
illustrated compromises to the VN mechanism characterised by significant increases in 
VPAC2R and FOXP3 expression over time in CFS/ME. Further, the observations of 
inconsistencies in cytokine distribution in CFS/ME patients, observed in other studies 
were confirmed in this study, even though the previous studies measured only at one 
point. This is also the first study to advocate for a role of miRNAs in the reduced 
activity of cytotoxic cells and consequently immune function owing to the decreases in 
miRNA expression in cytotoxic cells, CD8
+
T and NK, of CFS/ME patients. The above 
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data demonstrates that immunological impairments are an important component of the 
mechanism of CFS/ME.  
 
Importantly, this study has further identified novel immunological pathways that may 
be important in understanding the dysfunctional immune presentations in CFS/ME. 
These pathways are in relation to FOXP3 and VPACR2, important suppressors of pro-
inflammatory episodes. Similarly, the observation of reduced miRNA expression in 
CFS/ME suggests a role of these molecules in dysregulated expression of genes related 
to various aspects of immune function. Lastly, the consistency in certain immunological 
parameters over time has not yet been reported in CFS/ME and this further verifies the 
notion of immune compromise. However, further validatory studies are now required to 
establish a suite of biomarkers that can be tested in the clinical setting. 
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8. Appendix 
A. Chronic Fatigue Syndrome Questionnaire adapted from the Centre for Disease 
Prevention and Control. (Fukkudah et al. 1994) 
Participant Name: __________________________________ 
 
Contact Details 
Phone Number: _____________________________ 
Email Address:  _____________________________ 
 
1. Age ____ years 
2. Weight____ kg/lb 
3. Height ____ cm 
4. Sex _________ 
Please circle the appropriate answer. 
5. Have you felt generally “unwell” for more than 6 months? 
a. Yes 
b. No 
6. Do you have severe fatigue of that has persisted for 6 months or longer? 
a. Yes 
b. No. 
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7. Can you still do most or all of the physical and mental activities that you did 
before you began feeling unwell? 
a. Yes 
b. No 
8. Has your illness had a major impact on work, social, and/or educational 
activities, to the extent that you have had to make adjustments in your lifestyle 
in an effort to avoid relapsing or becoming more ill?  
a. Yes 
b. No 
9. Have you had at least four (4) of the following eight (8) symptoms for 6 months 
or longer? Circle which 4. 
 Weakness and exhaustion, lasting more than 24 hours, following mental or 
physical activity 
 Unrefreshing sleep  
 Substantial impairment of short-term memory or concentration  
 Muscle pain  
 Pain in the joints, without swelling or redness  
 Headaches of a new type, pattern or severity  
 Tender armpit and/or neck lymph nodes  
 Sore throat 
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10. Did your feelings of unwellness begin suddenly, within a period of hours or a 
couple of days? 
a. Yes 
b. No 
11. Have you ever been diagnosed with one or more of the following conditions? 
Please circle which ones. 
 Fibromyalgia  
 Multiple chemical sensitivity or environmental illness  
 Irritable bowel syndrome  
 Orthostatic intolerance in any form, including fainting, vasovagal syncope, 
neurally mediated hypotension or postural orthostatic tachycardia syndrome  
 Chiari 1 malformation  
 Depression  
 Anxiety disorder 
 Autoimmune disorder 
 Anaemia 
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12. In the next section please rate your symptoms on a 100 point scale, with 0= no 
pain or problem and 100= severe pain. Please rate these symptoms during your 
periods before the onset of illness, 6 month period of illness, your worst period 
during those six months or more and also rate the symptoms for how you are 
experiencing them today.  
 Symptoms Pre-
date 
illness 
6 or more 
months 
Rating during 
the worst 
period 
Rating 
today 
a.  Fatigue     
b.  
Post-exertional 
malaise lasting more 
than 24 hours 
    
c.  Sore throat     
d.  
Tender neck or 
axillary lymph nodes 
    
e.  Muscle pain     
f.  
Multiple joint pain 
without swelling or 
redness 
    
g.  
Headaches of a new 
type, pattern or 
severity 
    
h.  Unrefreshing sleep     
i.  
Impairments in short 
term memory or 
concentration 
    
 
13. Circle which of the following type(s) of cognitive difficulties you experience  
a. Slowness of thought  
b. Absent-mindedness  
c. Confusion/disorientation  
d. Difficulty reasoning things out  
e. Forgetting what you are trying to say  
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f. Difficulty finding the right word  
g. Difficulty following things  
h. Difficulty understanding  
i. Slow to react  
j. Poor hand to eye coordination  
k. New trouble with math  
l. Concern with driving  
m. Other:__________________________________________  
 
 
 
14. Circle which one(s) of the following mood difficulties you experience  
a. Anxiety/tension  
b. Easily irritated  
c. Depression  
d. Mood swings  
e. Other: _________________________________ 
15. Do you smoke or have you smoked in the past two years? 
a. Yes 
b. No 
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16. Please specify the medications you are currently taking. 
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________ 
 
 
